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Abstract 
Introduction: Ataxia-telangiectasia (A-T) is an autosomal, recessive disorder that is caused by 
mutations in the ataxia-telangiectasia mutated (ATM) gene. The gene product, ATM, is a 350 
kDa serine/threonine protein kinase with a large number of substrates in various pathways. 
Patients suffering from A-T display a high incidence of insulin resistance or type 2 diabetes 
mellitus (T2DM) and are more susceptible to ischaemic heart disease. Although it is known that 
the ATM protein is expressed in the heart and that structural and functional changes are 
observed in the hearts of ATM knock-out mice, very little research has been done on ATM and 
its role in insulin signalling in the cardiovascular context. 
This project aimed to identify and characterise an obese, insulin resistant animal model in which 
myocardial ATM expression is altered; to use this model to determine the effect of ATM 
manipulation on myocardial function and response to ischaemia/reperfusion injury (IRI); and to 
determine the effect of ATM manipulation on insulin signalling networks. 
Methodology: Male Wistar rats received a high caloric diet (HCD) or standard rat chow 
(control) for 16 weeks after which biometric data was collected. ATM was manipulated in 
perfusion studies prior to ischaemia using insulin (activator) and KU-60019 (inhibitor). Hearts 
perfused using the Langendorff balloon model were subjected to global ischaemia followed by 
reperfusion and Western blots were performed to evaluate insulin signalling intermediates. 
Hearts were also perfused using the working mode and subjected to regional ischaemia. 
Following reperfusion, infarct size (IFS) was determined. Aortic ring isometric tension studies 
were performed to determine the effect of KU-60019 on vasodilation. 
Results: The HCD resulted in significantly increased body mass, visceral fat mass, glucose 
levels, insulin levels and HOMA-IR index compared to the control diet and ATM expression was 
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reduced in the HCD hearts. Cardiac function and IFS were comparable in the control and HCD 
hearts. In control hearts, insulin administration activated the insulin signalling network prior to 
ischaemia and cardiac function was improved during reperfusion. Insulin had no effect on the 
insulin signalling network or cardiac function in the insulin resistant HCD hearts. High 
concentrations of insulin increased IFS in both the control and HCD hearts.  
ATM inhibition improved cardiac function in control and HCD hearts during early reperfusion but 
had no effect on cardiac function during later reperfusion. ATM phosphorylation was increased 
by insulin and decreased by KU-60019 in control hearts, but could not be manipulated in HCD 
hearts. Insulin-stimulated PKB/Akt activation is not ATM-dependent in the heart. However, ATM 
inhibition appears to down-regulate insulin signalling via PI3K, PTEN and GSK-3β. ATM 
inhibition caused NO-dependent vasodilation in control hearts, suggesting a role for ATM in 
vasoconstriction. 
Conclusion: ATM is a complex signalling regulator with numerous substrates.  In our study, we 
found that acute cardiac ATM inhibition did not result in significant cardiac dysfunction or 
complete abrogation of insulin signalling. However, we found that ATM possibly plays a 
significant role in vasoconstriction. More research needs to be done to fully understand the 
cardiac role of ATM in insulin signalling. 
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Opsomming 
Inleiding: Ataxia-telangiectasia (A-T) is ‘n autosomale, resesiewe siekte wat deur mutasies in 
die ATM geen veroorsaak word. Die geenproduk, ATM, is ‘n 350 kDa serien/treonien 
proteϊenkinase met ‘n groot aantal substrate wat in verskeie molekulêre paaie aktief is. Daar is ŉ 
hoë insidensie van insulienweerstandigheid en tipe 2 diabetes mellitus onder A-T pasiënte en 
hulle ontwikkel ook meer iskemiese hartsiektes. Alhoewel dit bekend is dat ATM in die hart 
uitgedruk word en dat struktruele en funksionele veranderinge gesien kan word in die harte van 
muise wat nie die ATM geen het nie, is daar baie min bekend oor ATM se rol in insulien-
seintransduksie in die hart. 
Hierdie projek het beoog om ‘n vetsugtige, insulienweerstandige rotmodel te identifiseer waarin 
ATM vlakke verander is; om te bepaal hoe die hart reageer op iskemie/herperfusie wanneer 
ATM gemanipuleer word, en om te bepaal hoe ATM manipulasie insulien-seintransduksie 
beϊnvloed. 
Metodiek: Manlike Wistar rotte wat vir 16 weke ‘n hoë-kalorie dieet (HCD) of standaard rotkos 
(kontrole) gevoer is, is gebruik. ATM uitdrukking en/of aktivering is in die harte gemanipuleer 
deur hulle voor iskemie met insulien (aktiveerder) of KU-60019 (inhibitor) te perfuseer. Harte is 
met die Langendorff ballonmodel aan globale iskemie blootgestel en na herperfusie is proteϊene 
van die insulien-seintransduksiepaaie met behulp van die Western-klad tegniek ge-analiseer. 
Harte is ook deur middel van die werkharttegniek aan streeksiskemie/herperfusie blootgestel 
waarna infarktgrootte bepaal is. Isometriese spanningsondersoeke is op aortaringe uitgevoer 
om die effek van KU-60019 op verslapping te bepaal. 
Resultate: HCD diere het beduidende hoër liggaamsmassas en visserale vet massas; hoër 
glukosevlakke en insulienvlakke; ‘n verhoogde HOMA-IR indeks en laer ATM vlakke gehad as 
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die kontrole diere. Miokardiale funksie en infarktgroottes het nie verskil tussen kontrole en HCD 
harte nie. Insulien kon insulien-seintransduksie voor iskemie in kontrole harte stimuleer en het 
hartfunksie tydens herperfusie verbeter. Daarteenoor het insulien geen effek op hartfunksie of 
insulien-seintransduksie in die HCD harte gehad nie. In beide die kontrole en HCD harte het 
hoë konsentrasies insulien infarkte vergroot. 
In kontrole en HCD harte het ATM inhibisie hartfunksie vroeg tydens herperfusie verbeter, maar 
het geen effek op hartfunksie later in herperfusie getoon nie. Alhoewel ATM fosforilering deur 
insulien verhoog is en deur KU-60019 verlaag is in kontrole harte, was daar geen verandering in 
ATM fosforilering in HCD harte nie. Insulien-gestimuleerde aktivering van PKB/Akt was nie 
afhanklik van ATM aktivering in die hart nie. ATM inhibisie het wel gelei tot onderdrukking van 
insulien-seintransduksie deur effekte op PI3K, PTEN en GSK-3β. ATM inhibisie het ook 
verslapping in aortaringe op ŉ stikstofoksied-afhanklike manier veroorsaak wat ‘n aanduiding is 
dat ATM betrokke is by vasokonstriksie. 
Gevolgtrekkings: Deur ‘n groot aantal substrate te beïnvloed, speel ATM ‘n belangrike rol in 
die regulering van seintranduksiepaaie. Ons het bevind dat akute inhibisie van ATM in die hart 
nie ‘n beduidende negatiewe effek op hartfunksie gehad het of insulien-seintransduksie 
onderdruk het nie. Ons het wel bevind dat ATM moontlik ‘n beduidende rol speel in 
vasokonstriksie. Verdere studies is nodig om die kardiovaskulêre rol van ATM in insulien-
seintransduksie ten volle te verstaan. 
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Chapter 1: Introduction 
1.1 General Introduction 
Cardiovascular disease (CVD) is the leading cause of death globally, with approximately 31% of 
all deaths being attributed to CVD in 2012 as reported by the World Health Organization (WHO, 
Fact Sheet 317). In the same year, diabetes was ranked as the eighth leading cause of death in 
the world (WHO, Fact Sheet 310). Additionally, it is estimated that 387 million people were living 
with diabetes in 2014 and that 77% of these people are living in low- and middle-income 
countries (International Diabetes Federation, 2014). Alarmingly, the incidence of both CVD and 
diabetes is on the rise. This places a tremendous financial burden on governments, both for the 
treatment and management of these conditions and for the loss in productivity in individuals 
affected by CVD and diabetes. 
Diabetes is a major contributing factor to the development of CVD, with 50% of diabetic 
individuals eventually dying of CVD (Morrish et al., 2001). Although a number of molecular 
mechanisms have been proposed to explain how diabetes can lead to CVD (reviewed in Bugger 
and Abel, 2014), new insights are continuously coming to light. 
Ataxia-telangiectasia mutated (ATM) is a protein kinase well known for its nuclear role in the 
response to double-stranded deoxyribonucleic acid (DNA) breaks. In recent years, it has 
become apparent that ATM also plays important metabolic roles outside of the nucleus and that 
defective ATM signalling can lead to a clinical picture resembling that of the metabolic 
syndrome. 
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1.2 Problem Identification 
Although it is known that ATM is expressed in the heart, very little scientific literature is available 
on ATM in the cardiovascular pathology context. It is as yet unknown how ATM participates in 
signalling networks in the heart. Additionally, the effect of the insulin resistant state on the 
expression or activation of ATM in the myocardium is unknown as well as the contribution of 
altered ATM signalling in the development of cardiovascular pathology associated with insulin 
resistance. The main purpose of this study was, therefore, to investigate the role of ATM in the 
myocardium, specifically in the insulin resistant state. We hypothesise that ATM plays a 
currently unrecognised role in the development of the cardiovascular pathology associated with 
the insulin resistant state. 
1.3 Aims and Objectives 
The aims of the study were as follows: 
 To determine the myocardial expression of ATM in different rat models. 
Objective 1: Select the most suitable model to study the effects of the protein on 
cardiovascular function. 
Objective 2: Determine the whole-body glucose homeostasis in the chosen model as 
well as the myocardial insulin resistance. 
 To determine the effects of manipulation of the expression or activation of ATM on 
myocardial function and resistance to IRI. 
Objective 1: Manipulate the expression and/or activation of ATM with insulin/chloroquine 
and the inhibitor KU-60019 using the ex vivo working heart perfusion model and 
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measure myocardial function and the ability of the hearts to recover contractile function 
after a period of regional ischaemia followed by reperfusion. 
Objective 2: Use the same interventions but measure the IFS induced by regional 
ischaemia in hearts perfused using the ex vivo working heart model. 
 To determine the effects of manipulation of the expression or activation of ATM on relevant 
myocardial signalling networks following IRI. 
 Objective 1: Use the same interventions as in the previous aim in Langendorff ex vivo 
perfused hearts using the balloon model and subject the hearts to global ischaemia 
followed by reperfusion. 
Objective 2: Determine the expression and activation of signalling intermediates of the 
insulin network.  
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Chapter 2: Literature Review 
2.1 Insulin Signalling 
2.1.1 The history and structure of insulin 
Insulin has been one of the most intensely studied proteins and has led to great technical 
advances in science. It was the first protein ever to be sequenced and has served as a model 
protein to help study the structure, properties and characteristics of other proteins. The term 
"insuline" (derived from the Latin insula, meaning island) was first used in 1909 by Jean De 
Meyer to describe "the internal secretion of the pancreas" (De Meyer, 1909). It was not until 13 
years later that insulin was successfully purified by Frederick G. Banting and Charles H. Best 
(Banting et al., 1922). Frederick Sanger and colleagues were responsible for determining the 
protein sequence of the B and A chains of insulin in 1951 and 1953 respectively (Sanger and 
Thompson, 1953a,b; Sanger and Tuppy, 1951a,b), and in 1955 the primary protein structure of 
insulin was elucidated (Figure 2.1) (Ryle et al., 1955). Another decade later, scientists were able 
to successfully synthesise insulin for therapeutic use. Today, no other peptide or protein is more 
in use as a therapy than insulin and millions of people globally are dependent on insulin for the 
treatment of diabetes (Mayer et al., 2007). 
 
Figure 2.1: The primary protein structure of insulin as it appeared in Ryle et al., 1955. 
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Insulin is a peptide hormone secreted by the β-cells of the islands of Langerhans in the 
pancreas. Insulin consists of two polypeptide chains held together by two disulphide bonds. 
Chain A consists of 21 amino acid residues while chain B is longer, consisting of 30 amino acid 
residues.  
2.1.2 Normal insulin signalling 
Although plasma glucose levels rise and fall during the day due to meal ingestion, fasting and 
exercise, it is important that the levels are maintained in a narrow range as both hypo- and 
hyperglycaemia have severe consequences. Insulin is one of the very important hormones 
responsible for maintaining glucose homeostasis. Tissues that are responsive to insulin include 
skeletal and cardiac muscle, adipose tissue and the liver. Insulin is described to have both an 
excitatory and an inhibitory action in these tissues as it increases the uptake of glucose in 
muscle and fat tissue, and decreases glucose production and release by the liver (Saltiel and 
Kahn, 2001; Sonksen and Sonksen, 2000). After food is ingested, the resulting rise in plasma 
glucose will trigger the release of insulin from the β-cells in the pancreas, causing a three- to 
fourfold increase in insulin levels within 60 minutes. In fact, an increase in plasma glucose levels 
as small as 10 mg/dL (0.55 mmol/L) will result in the secretion of insulin (Shrayyef and Gerich, 
2010). Insulin secretion may also be stimulated by increased amino acids and free fatty acids 
(FFA). By binding to receptors in its target tissues, insulin activates a cascade of signalling 
events that results in the glucose to either be immediately stored as glycogen or undergo 
oxidative or non-oxidative glycolysis. 
Insulin never enters the cells. It simply binds to the alpha subunit of the transmembrane insulin 
receptor (IR) tyrosine kinase to initiate the signalling cascade inside the cell. The IR is activated 
through trans-autophosphorylation, after which it recruits and phosphorylates any one of six 
members of the insulin receptor substrate (IRS) family. This results in activation of either the 
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metabolic phosphatidylinositol 3-kinase (PI3K)-protein kinase B (PKB)/Akt pathway or the 
mitogenic Ras-mitogen-activated protein kinase (MAPK) pathway (Taniguchi et al., 2006). The 
IRS family are scaffolding proteins that recruit and dock downstream proteins (White, 1998). Of 
the six known IRS isoforms, IRS-1 and IRS-2 are the most widely distributed and the most 
important. Both IR and IRS are activated by tyrosine phosphorylation, but inhibited by serine 
phosphorylation. A third pathway, the CAP-Cbl-TC10 pathway, is also activated in response to 
insulin stimulation following IR activation (Figure 2.2). 
The PI3K-PKB/Akt pathway 
The PI3K-PKB/Akt pathway is a highly conserved pathway (Hemmings and Restuccia, 2012). 
The class 1A PI3K is a heterodimer, consisting of a 110 kDa (p110) catalytic subunit and an 85 
kDa (p85) regulatory subunit (Carpenter et al., 1990). Once IRS-1 is activated, the 
phosphorylated tyrosine residues create sites that can associate with proteins containing Src 
Homology 2 (SH2) domains. PI3K is activated via the p85 regulatory subunit that contains SH2 
domains that can dock to tyrosine phosphorylated IRS-1. The catalytic subunit converts the 
membrane bound lipid, phosphatidylinositol (3,4)-bis-phosphate (PIP2), to phosphatidylinositol 
(3,4,5)-tris-phosphate (PIP3), which in turn recruits both PKB/Akt and 3-phosphoinositide-
dependent protein kinase-1 (PDK1) to the plasma membrane, allowing PKB/Akt to be 
phosphorylated in the kinase domain, at threonine 308, by PDK1 (Alessi et al., 1997; Hemmings 
and Restuccia, 2012). This association is mediated by the plecstrin homology domains of 
proteins which allow them to associate with specific phosphorylated inositide lipids in specific 
membrane structures. The conversion of PIP2 to PIP3 is negatively regulated by the tumour 
suppressor, phosphatase and tensin homolog (PTEN) (Maehama and Dixon, 1998). Full 
activation of PKB/Akt is only achieved after phosphorylation in the regulatory domain, at serine 
473, possibly mediated by mammalian target of rapamycin complex 2 (mTORC2), DNA-
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dependent protein kinase (DNA-PK) or ATM (Bozulic and Hemmings, 2009; Sarbassov et al., 
2005; Viniegra et al., 2005). 
Activated PKB/Akt contributes to a number of processes, including cell survival, cell growth, 
proliferation, angiogenesis, cell migration and metabolism (Manning and Cantley, 2007). By 
negatively regulating pro-apoptotic proteins such as BAD and deactivating pro-apoptotic 
transcription factors such as FOXO and p53, PKB/Akt promotes cell survival (Datta et al., 1997; 
Tran et al., 2003). Cell growth is achieved by the activation of Mammalian target of rapamycin 
complex-1 (mTORC1) and the downstream effects of p70S6K and 4EBP1/eIF-4E (Laplante and 
Sabatini, 2012). PKB/Akt phosphorylates tuberous sclerosis complex (TSC) 2 on multiple sites, 
which destabilizes the TSC1/TSC2 complex which usually inhibits mTORC1 (Inoki et al., 2002). 
Additionally, PKB/Akt has also been shown to phosphorylate proline-rich Akt substrate of 40 
kDa (PRAS40) causing PRAS40 to dissociate from mTORC1 and lifting the inhibitory effect on 
mTORC1 (Wiza et al., 2012). The activation of mTORC1 also results in cell proliferation through 
the translation of proteins involved in cell-cycle progression (Manning and Cantley, 2007). 
Glycogen synthase kinase-3 (GSK-3) phosphorylates proteins responsible for cell-cycle 
progression which results in proteasomal degradation of these proteins and thus, inhibition of 
cell-cycle progression. Therefore, by phosphorylating and inactivating GSK-3, PKB/Akt 
contributes to cell-cycle progression and proliferation (Diehl et al., 1998). Angiogenesis, as well 
as vasodilation and vascular remodelling is the result of nitric oxide (NO) being released after 
PKB/Akt phosphorylates and activates endothelial NO synthase (eNOS) (Dimmeler et al., 1999; 
Morbidelli et al., 2003). PKB/Akt additionally affects angiogenesis by increasing the production 
of hypoxia inducible factor-1 (HIF-1), a transcription factor that leads to the expression of 
vascular endothelial growth factor (VEGF), which is responsible for angiogenesis (Lee et al., 
2007). 
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Metabolically, PKB/Akt plays an important role in glucose uptake in adipose tissue and muscle 
and in the inhibition of glucose production by the liver in response to insulin. Glucose transporter 
type-4 (GLUT4) levels at the plasma membrane rise at least 10-fold in response to insulin 
(Welsh et al., 2005). In muscle, PKB/Akt has been shown to phosphorylate the Akt substrate of 
160 kDa (AS160) on multiple sites, causing it to stimulate GLUT4 translocation to the cell 
membrane and glucose to be taken up by the cells (Manning and Cantley, 2007; Sakamoto and 
Holman, 2008). Both GSK-3α and -β are phosphorylated and thus, inactivated, by PKB/Akt, 
causing an increased conversion of glucose to glycogen by glycogen synthase (GS) in muscle 
and liver (Cross et al., 1995). Plasma glucose levels are further reduced by PKB/Akt by 
increasing the rate of glycolysis, the process by which glucose is broken down to pyruvate 
(Elstrom et al., 2004). 
The CAP/Cbl/TC10 pathway 
Although the PI3K-PKB/Akt pathway is required for GLUT4 translocation, it is not sufficient on 
its own (Chiang et al., 2001). Once the IR is activated, the adaptor protein, APS, binds to the IR 
and recruits CAP, which in turn recruits the proto-oncogene, Cbl to the IR and a CAP/Cbl 
complex is formed. Upon phosphorylation of Cbl, the CAP/Cbl complex is released from the IR 
and gets translocated to lipid rafts. Lipid rafts are areas in the plasma membrane that are 
enriched in cholesterol and specific lipids and proteins such as sphingolipids, lipid-modified 
signalling proteins, glycosylphosphotidylinositol-anchored proteins and glycolipids (Pike, 2009). 
Once at the lipid raft, Cbl recruits the Crkll-C3G complex and C3G activates TC10, leading to 
GLUT4 translocation and the subsequent uptake of glucose in response to insulin stimulation 
(Chiang et al., 2001; Tomasovic et al., 2012). The CAP/Cbl/TC10 pathway takes place in 
parallel to the PI3K-PKB/Akt pathway, but is PI3K-independent (See Figure 2.2). 
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The MAPK pathway 
The MAPK pathway is a signalling cascade that amplifies an extracellular signal and achieves 
proliferation, differentiation and development (Seger and Krebs, 1995). The signalling pathway 
consists of a MAPK kinase kinase (MAP3K), MAPK kinase (MAP2K) and a MAPK, and each of 
these phosphorylates and activates the next protein in the signalling pathway (i.e. MAP3K 
phosphorylates and activates MAP2K, which then phosphorylates and activates MAPK). In 
response to insulin stimulation, and the consequent activation of the IR, son-of-sevenless (SOS) 
is recruited to the IR and activates a small GTPase, namely Ras (Geiβler et al., 2013). Ras 
leads to the sequential activation of Raf (a MAP3K), MEK1/2 (a MAP2K) and ERK1/2, the 
MAPK (Kim and Choi, 2010). The MAPK pathway results in cell proliferation, cell-cycle 
regulation, differentiation, cell migration and cell survival in response to insulin (Peyssonnaux 
and Eychène, 2012). 
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Figure 2.2: Binding of insulin to the insulin receptor results in the activation of three different pathways, namely the PI3K-PKB/Akt pathway, the 
CAP-Cbl-TC10 pathway and the MAPK pathway. These pathways result in a range of different processes such as angiogenesis, cell growth, cell 
survival, cell proliferation, glycogen synthesis and glucose uptake. 
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2.1.3 The development of insulin resistance 
Insulin resistance is defined as a decreased ability of cells to respond to insulin (Nieto-Vazqiez 
et al., 2008). To compensate for this effect, the pancreas secretes more insulin, leading to 
hyperinsulinemia. However, this can only be tolerated for a short period of time, after which it 
leads to β-cell failure and ultimately, T2DM (White, 2003). Insulin resistance has a complicated 
aetiology in which a number of different pathways have been shown to play a role. 
Obesity and insulin resistance 
Thirteen percent of the global population, accounting for 600 million people, were obese in 2014 
according to the WHO (WHO, Fact Sheet 311). Obesity is considered the most common 
contributor to the development of insulin resistance in humans (Johnson and Olefsky, 2013). An 
individual is classified as obese when their body mass index, calculated as weight in kilograms 
divided by height in meters squared (kg/m2) is higher than 30 kg/m2. Obesity is the result of 
surplus energy being stored as fat when more energy is consumed in food than what is needed 
and used (Bray, 2004). Adipose tissue, made up of fat cells, is recognized as a metabolic and 
endocrine organ. During obesity, the function of adipose tissue is altered, resulting in increased 
release of fatty acids, hormones and pro-inflammatory cytokines (Weisberg et al., 2003). 
Obese individuals are considered to experience chronic low-level inflammation as macrophages 
infiltrate adipose tissue and pro-inflammatory cytokine levels increase in the obese state 
(Tzanavari et al., 2010). One of the pro-inflammatory cytokines that is elevated during obesity, is 
tumour necrosis factor-alpha (TNF-α), which is over-expressed in adipose tissue (Hotamisligil et 
al., 1993). Elevated TNF-α levels have been shown to be consistent with the degree of obesity 
as well as hyperinsulinemia (Hotamisligil et al., 1995). Upon treatment with TNF-α, reduced 
insulin-stimulated autophosphorylation of IR was observed, as well as reduced tyrosine 
phosphorylation and increased serine phosphorylation of IRS-1 in adipocytes (Hotamisligil et al., 
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1996). Improved insulin sensitivity was found to be associated with decreased TNF-α levels that 
accompanied weight loss in obese individuals (Hotamisligil et al., 1995). Although the insulin 
resistant effect of cytokines released from adipose tissue is predominantly local, the cytokines 
could cause a systemic effect in muscle and liver when their levels rise, causing them to leak 
out from the adipose tissue (Osborn and Olefsky, 2012). It is noted that it is only visceral 
adipose tissue, and not subcutaneous adipose tissue, that display the increased inflammation 
and macrophage infiltration and the accompanying negative effect on metabolism (Johnson and 
Olefsky, 2013). 
In addition to an increase in pro-inflammatory cytokines during obesity, increased plasma FFA 
concentrations are also observed and have been implicated in the development of insulin 
resistance (Nielsen et al., 2004). In fact, insulin resistance that developed in high-fat diet fed 
rats was found to be due to FFAs in circulation rather than increased TNF-α levels (Jiao et al., 
2008). Free fatty acids are bound to albumin in the plasma and this is how triacylglycerol (TAG), 
which is usually stored in adipose tissue, is transported to other sites for utilization (Karpe et al., 
2011). The main source of FFAs is the abdominal subcutaneous adipose tissue, while a small 
portion of FFAs is released by visceral fat (Karpe et al., 2011; Vatier et al., 2012). High levels of 
FFAs were first described to contribute to abnormal carbohydrate metabolism and to lead to the 
development of insulin resistance in 1963 (Randle et al., 1963). In what is now termed the 
Randle cycle, Randle and colleagues (1963) explained that dynamic interactions exist between 
substrates and that glucose and fatty acids compete with each other to be oxidized in muscle 
and adipose tissue. They thus proposed that high FFA levels are able to inhibit glucose 
oxidation. Fatty acid oxidation increases the mitochondrial acetyl-coenzyme A (CoA)/CoA and 
nicotinamide adenine dinucleotide (NADH) /NAD+ ratios. The increased ratios lead to the 
inhibition of pyruvate dehydrogenase in order to reduce the production of acetyl-CoA. 
Furthermore, accumulation of citrate in the cytosol inhibits 6-phosphofructo-1-kinase which 
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increases glucose-6-phosphate, eventually leading to hexokinase inhibition (summarised in Hue 
and Taegtmeyer, 2009). It has now been shown that high FFA concentrations reduce glucose 
uptake by reducing glycogen synthesis and carbohydrate oxidation, by stimulating 
glycogenolysis and also by increasing hepatic gluconeogenesis, all leading to hyperglycaemia 
(Boden et al., 1994; Staehr et al., 2003). Insulin sensitivity is improved through weight loss and 
exercise and this effect is mediated by reduced FFA mobilization and uptake (Schenk et al., 
2009). Conversely, others have shown that insulin resistance can develop in the absence of 
elevated FFA and that high FFA levels are not necessarily associated with insulin resistance, 
and it is suggested that more dynamic studies are needed to elucidate the relationship between 
FFA and insulin resistance (Karpe et al., 2011). 
A role for GSK-3 in the development of insulin resistance has also been proposed. Although 
GSK-3 protein levels have been shown to be increased during T2DM, limited studies are 
available on the regulation of GSK-3 in insulin resistance (Lee and Kim, 2007; Nikoulina et al., 
2002). Mice genetically prone to the development of diet-induced obesity and diabetes 
(C57BL/6J mouse strain), had increased GSK-3 activity levels in adipose tissue compared to 
mice resistant to diet-induced obesity and diabetes (Eldar-Finkelman et al., 1999). Basally 
active GSK-3 can contribute to the development of insulin resistance as it is able to oppose the 
action of insulin by inhibiting glucose uptake and glycogen synthesis as well as inhibiting IRS-1, 
and thus, the insulin signalling pathway (Liberman and Eldar-Finkelman, 2005). 
Ectopic fat accumulation 
Besides the role of circulating FFAs, ectopic fat accumulation has also been implicated in the 
development of insulin resistance. Ectopic fat is the result of storage of triglycerides in insulin 
responsive tissues other than adipose tissue, such as muscle and the liver (Snel et al., 2012). 
These lipids accumulate when the supply is bigger than the capacity of the liver and muscle to 
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oxidize the lipids. Partial oxidation of FFA results in accumulation of metabolites such as long-
chain acyl-CoA, diacylglycerol and ceramides that are able to activate protein kinase C, IKB-
kinase-β and c-Jun N-terminal kinase (JNK). These proteins phosphorylate serine residues in 
IRS-1, causing inhibition and ultimately, insulin resistance (reviewed in Morino et al., 2006). 
Endoplasmic reticulum stress and activation of the unfolded protein response 
The endoplasmic reticulum (ER), together with the attached ribosomes, are responsible for 
protein and lipid synthesis and the consequent folding of the newly synthesized proteins (Alberts 
et al., 2002). When problems with the folding of proteins arise, the unfolded protein response 
(UPR) is launched. The aims of the UPR are to reduce the rate at which mRNA is translated, to 
enlarge the folding capacity of the ER and to degrade incorrectly folded proteins (Scheuner and 
Kaufman, 2008). Activation of the UPR has been shown to contribute to insulin resistance via a 
number of different mechanisms, but a central theme appears to be the alteration of lipid 
balance through accumulation of lipid intermediates (reviewed in Samuel and Shulman, 2012). 
Oxidative stress and insulin resistance 
Oxidants are free oxygen or nitrogen radicals that are natural by-products of aerobic metabolism 
that play significant beneficial physiological roles by acting as second messengers in signalling 
cascades. However, when the production of oxidants exceeds the antioxidant capacity of the 
cell, oxidative stress ensues (Sies, 1997). Hyperglycaemia is able to induce both mitochondrial 
and ER dysfunction, causing an increase in oxidative stress (Fiorentino et al., 2013). Other 
causes of increased levels of reactive molecules include inflammatory cytokines, 
hyperinsulinemia and high levels of FFA (Evans et al., 2005). Oxidative stress, in turn activates 
stress-sensitive molecules such as JNK, PKC, TNF-α and Iκβ kinase B (IKKβ), all of which have 
been shown to inhibit insulin signalling by inactivating the IR and/or IRS-1 (Evans et al., 2005). 
Several studies have shown that treating diabetic or insulin resistant patients with antioxidants 
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such as vitamin C, vitamin E or α-lipoic acid improved insulin sensitivity (Caballero, 1993; 
Hirashima et al., 2000; Jacob et al., 1999). 
2.1.4 The development of diabetes 
Insulin resistance is linked to a number of different conditions such as T2DM, hypertension, 
dyslipidemia, non-alcoholic fatty liver disease, blood coagulation problems and fibrinolysis 
(Bray, 2004). Insulin resistance can ensue for a long time before the eventual development of 
T2DM, and during this time blood glucose levels could be maintained in the normal range 
through compensatory mechanisms such as hyperinsulinemia (Kahn, 2003). Eventually, the β-
cells of the pancreas can no longer maintain the increased insulin production required to 
overcome insulin resistance. The resulting hyperglycaemia and high FFA levels lead to 
oxidative stress, which is detrimental to β-cell function and structure (Cerf, 2013; Gastaldelli, 
2011). T2DM is widely thought to be caused by a combination of insulin resistance and 
pancreatic β-cell dysfunction. The cardiorenal metabolic syndrome, which is comprised of a 
number of metabolic abnormalities, is said to drive the T2DM epidemic. These metabolic 
abnormalities include the following: a HCD accompanied by a sedentary lifestyle that leads to 
obesity; hyperglycaemia due to insulin resistance; pre-hypertension caused by increased 
vascular tone; dyslipidemia due to a rise in pro-inflammatory cytokines; kidney dysfunction due 
to decreased glomerular filtration and microalbuminuria (Mandavia et al., 2013; Sowers et al., 
2011). Individuals have an increased risk for the development of T2DM if they display impaired 
glucose tolerance and/or fasting glucose levels, have hypertension, high triglyceride levels and 
low high-density lipoprotein-cholesterol (dyslipidemia) levels. Additional factors include having a 
close relative with T2DM (genetics) or previously having gestational diabetes during pregnancy. 
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2.2 The heart and insulin resistance 
2.2.1 The metabolism of the heart 
The heart has a higher metabolic demand per gram than any other organ in the body. It utilizes 
adenosine triphosphate (ATP) as energy source to fuel basal metabolism, contraction and ionic 
homeostasis (Lopaschuk et al., 2010). If ATP synthesis were to cease, cardiac ATP stores 
would be depleted within approximately 15 seconds. In order to maintain adequate ATP levels, 
the rates at which ATP is produced and used must thus be closely regulated. Because of the 
high ATP demand, the heart is capable of using a number of different substrates to generate 
enough ATP. These substrates include fatty acids, carbohydrates, lactate, ketone bodies and 
amino acids (Weiss and Maslov, 2004). The heart is able to alternate between the choice of 
substrates and adapt rapidly during exercise, ischaemia and fasting when the supply of 
substrates or need for ATP is changed (Stanley et al., 2005). Under non-ischaemic conditions, 
over 95% of the heart’s energy is produced through the oxidation of fatty acids and 
carbohydrates (Lopaschuk et al., 2010). Below is a simplified overview of the use of fatty acids 
and carbohydrates as substrates as these are the predominant substrates used for energy 
production in the heart. A schematic representation of myocardial metabolism can be seen in 
Figure 2.3. 
Fatty acid metabolism 
The β-oxidation of fatty acids generates the most ATP molecules and fatty acids are thus the 
predominant substrate used by cardiac cells, producing 50-70% of the ATP in the adult heart 
(Lopaschuk et al., 2010; Weiss and Maslov, 2004). The fatty acids are either taken up from the 
plasma or they are released by the breakdown of stored TAG that is already present in the 
cardiomyocyte (Stanley et al., 1997). Once fatty acids, bound to fatty acid binding proteins, 
enter the cytosol of cardiomyocytes, they are esterified into long-chain fatty acyl CoA by fatty 
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acyl-CoA synthetase. The fatty acyl-CoA is transported into the mitochondria with the help of 
carrier proteins and once in the mitochondria, they enter the β-oxidation cycle. During each 
cycle, acyl-CoA becomes two carbons shorter and acetyl-CoA, flavin adenine dinucleotide 
(FADH2) and NADH are produced (Lopaschuk et al., 2010). The reducing agents, FADH2 and 
NADH, take part in the electron transport chain while acetyl-CoA enters the Krebs cycle (also 
known as the citric acid cycle or tricarboxylic acid cycle) and both of these processes result in 
the generation of ATP. 
Carbohydrate metabolism 
Glucose uptake is dependent on the glucose transmembrane gradient as well as the presence 
of glucose transporters at the plasma membrane (Stanley et al., 1997). Besides the insulin 
responsive transporter, GLUT4, GLUT1 has also been shown to be present in the myocardium 
and to be responsible for a significant amount of basal glucose uptake in the heart (Abel, 2004). 
During exercise and stresses such as ischaemia and hypoxia, GLUT4 translocation can be 
stimulated by AMP–activated protein kinase (AMPK) (Coven et al., 2003; Russel et al., 1999). 
During glycolysis, which takes place in the cytosol, each glucose molecule is converted into two 
molecules each of pyruvate, ATP and NADH (Mathews et al., 2000). Pyruvate is further 
metabolised in the mitochondria by decarboxylation to form acetyl-CoA. The acetyl-CoA derived 
from carbohydrates is subsequently fed into the Krebs cycle similar to the acetyl-CoA derived 
from fatty acid β-oxidation, in order to produce ATP. 
Although fatty acid oxidation produces more ATP molecules than carbohydrate metabolism, 
glucose is a more oxygen-efficient energy source for producing ATP than fatty acids 
(Fukushima et al., 2015; Lopaschuk et al., 2010). It has also been shown that cardiac efficiency 
decreases with an increased utilization of fatty acids as substrate as opposed to glucose as is 
the case during obesity, insulin resistance, diabetes and reperfusion after an ischaemic period 
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(Lopaschuk et al., 2010). The efficiency of the heart is determined by comparing the myocardial 
oxygen consumption with the work performed by the left ventricle (Bing and Michal, 1959). 
 
Figure 2.3: Schematic representation of the substrate metabolism of the heart. Free fatty acids, taken up 
from the plasma or released from TAG, is converted to acyl-CoA before entering the mitochondria where 
they undergo β-oxidation. This results in the release of acetyl-CoA, NADH and FADH2. The acetyl-CoA 
enters the Krebs cycle which also results in the release of NADH and FADH2. These reducing agents 
then enter the electron transport chain for the generation of ATP. Glucose is taken up by cardiomyocytes 
via the GLUT transporter family and converted to glucose-6-phosphate, which can either be stored as 
glycogen or enter glycolysis. Glycolysis produces both ATP and pyruvate. Pyruvate is converted into 
acetyl-CoA, which follows the same fate as acetyl-CoA produced from fatty acid metabolism. 
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2.2.2 Mechanisms that lead to cardiovascular disease 
Cardiovascular disease is an umbrella term used to describe conditions affecting the heart and 
vascular system. These conditions include hypertensive heart disease, stroke, arrhythmias, 
coronary artery disease, myocardial infarction, rheumatic heart disease, cardiomyopathy, atrial 
fibrillation, congenital heart disease, endocarditis, aortic aneurysms, peripheral artery disease, 
venous thrombosis and cardiac failure (Wattanapitayakul and Bauer, 2001). A number of 
underlying mechanisms have been defined and these vary depending on the condition in 
question. Only a few mechanisms that are relevant to this study will be discussed in more detail 
below. 
Substrate usage and cardiovascular disease 
Cardiac substrate usage is tightly controlled and the choice of substrate is dependent on their 
supply, need for energy production, hormones and transcription factors. Metabolic abnormalities 
such as obesity, and the accompanying high fatty acid levels, insulin resistance, 
hyperinsulinemia and hyperglycaemia interfere with the normal functioning of the heart and can, 
therefore, lead to cardiac dysfunction. Hypertensive and ischaemic heart disease are more 
prevalent in diabetic patients compared to healthy individuals and diabetic cardiomyopathy 
(DC), which is not associated with hypertension or coronary artery disease, is also a hallmark of 
diabetes (Mandavia et al., 2013). In fact, the presence of T2DM can increase the likelihood of 
having CVD up to fivefold (Dagogo-Jack and Santiago, 1997). 
A potential mechanism for the development of CVD during T2DM is the increased reliance on 
fatty acids as substrate during diabetes. Due to the increased oxidation of fatty acids as 
opposed to glucose, there is a greater oxygen cost for ATP production, which leaves the heart 
at risk of energy depletion during periods of limited oxygen supply or when workload is 
increased (McNulty, 2006). Hafstad and colleagues also demonstrated that isolated hearts from 
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diabetic db/db mice increasingly oxidized fatty acids and showed decreased glucose oxidation 
compared to non-diabetic db/+ hearts. Additionally, contractile dysfunction, exhibited as reduced 
peak aortic systolic pressure (SP), cardiac output and work, was also observed in diabetic 
hearts. Surprisingly, they found that the diabetic db/db hearts were, in fact, responsive to large 
insulin doses and that insulin increased PKB/Akt phosphorylation, glucose uptake, and glucose 
oxidation and decreased fatty acid oxidation in these hearts. Insulin had no effect on contractile 
function in either the diabetic or non-diabetic hearts (Hafstad et al., 2006). 
Although it is well known that obesity, insulin resistance and diabetes contribute to the 
development of CVD, it is becoming evident that the heart is able to tolerate insulin resistance. It 
is suggested in several studies that hearts of T2DM individuals may have very little to no loss of 
insulin sensitivity compared to hearts of non-diabetic individuals (Jagasia et al., 2001; Utriainen 
et al., 1998). Nevertheless, defective systemic insulin signalling, that is comprised of 
hyperinsulinemia, hyperglycaemia and insulin resistance, gives rise to oxidative stress which is 
thought to be the basis of the metabolic dysfunction that leads to DC (Aksakal et al., 2011). It is 
proposed that insulin resistance in the heart and the lack of metabolic flexibility are the main 
contributing factors to metabolic cardiomyopathy (Mandavia et al., 2013). 
Diabetic cardiomyopathy 
Diabetic cardiomyopathy was first described in 1972 by Rubler et al. (1972). They noted 
myocardial changes while performing autopsies on diabetic patients that could not be explained 
by hypertension, coronary artery complications, valvular or neuromuscular disease, alcoholism, 
uraemia or renal disease, and concluded that it must be a form of cardiomyopathy associated 
with diabetes that had not been described previously (Rubler et al., 1972). Only abnormal 
muscle function is implicated in DC, which is the initial manifestation of heart disease associated 
with diabetes (Mandavia et al., 2013). Early in DC, diastolic dysfunction and ventricular 
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hypertrophy are observed, while systolic dysfunction becomes evident later in the condition. A 
number of mechanisms, causing structural and signalling alterations have been described in 
DC. 
Increased left ventricular mass and wall thickness are seen in individuals with T2DM compared 
to non-diabetic individuals (Eguchi et al., 2008; Somaratne et al., 2011). Leptin, which is 
released by adipose tissue, was shown to increase endothelin-1, which in turn stimulated the 
production of reactive oxygen species (ROS) and led to hypertrophy in cultured neonatal rat 
cardiomyocytes (Xu et al., 2004). Another cytokine over-expressed during diabetes, both by 
adipose tissue and the heart, is resistin. Resistin was shown to contribute to the development of 
hypertrophy in neonatal cardiomyocytes via the activation of ERK and p38 in the MAPK 
pathway as well as IRS-1 serine phosphorylation (Kim et al., 2008). Diastolic dysfunction is the 
result of intra-myocardial lipid accumulation during diabetes, obesity, insulin resistance and 
impaired glucose tolerance. This lipid accumulation is termed cardiac steatosis, is independent 
from circulating triglyceride levels and exceeds the oxidative capacity of the mitochondria 
(McGavock et al., 2007). Cardiac steatosis leads to the production of lipotoxic intermediates that 
cause apoptosis through the increased production of ROS (Zhou et al., 2000). Interstitial and 
perivascular fibrosis is seen in DC, with significantly increased collagen type III in diabetic 
patients compared to healthy individuals (Shimizu et al., 1993). 
As mentioned earlier, diastolic dysfunction is observed early in DC. Diastolic dysfunction could 
occur due to increased lipid accumulation in the heart or alterations in the calcium homeostasis 
(Boudina and Abel, 2010). Since mitochondria play a central role in metabolism, and diabetes is 
known to alter metabolism, it is no surprise that mitochondrial dysfunction is present and plays a 
role in the pathogenesis of DC. Potential mechanisms that contribute to the mitochondrial 
dysfunction in the hearts of diabetic patients include mitochondrial uncoupling and altered 
energy metabolism, oxidative stress, defective handling of calcium by mitochondria, 
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mitochondrial-induced cell death and increased mitochondrial biogenesis without improved 
mitochondrial respiration or ATP production (reviewed in Duncan, 2011). Compromised 
mitochondrial function during diabetes can thus lead to contractile dysfunction and contribute to 
the development of DC. 
Although all the mechanisms involved in the development of DC have not yet been elucidated, it 
is clear that DC is associated with structural, functional and metabolic changes that lead to 
cardiac dysfunction and heart failure that is independent of coronary artery disease or 
hypertension (Boudina and Abel, 2010). 
Endothelial dysfunction and atherosclerosis 
Nitric oxide synthase converts L-arginine into L-citrulline in endothelial cells, which is associated 
with the production of NO. Vascular effects of NO include vasodilation, decreased migration and 
growth of vascular smooth muscle cells, aggregation of platelets and thrombosis, inflammation 
and monocyte and macrophage adhesion (Caballero, 2003). During diabetes, both a reduction 
in the production of NO by endothelial cells and a reduced response to NO in vascular smooth 
muscle cells are observed (Williams et al., 1996). Endothelial dysfunction develops when there 
is a loss of balance between vasoconstrictors and vasodilators, promoters and inhibitors of 
growth, pro- and anti-atherogenic factors and pro- and anti-coagulant factors (Quyyumi, 1998). 
Endothelial dysfunction has been associated with obesity and insulin resistance and is 
considered to be a key element in the development of atherosclerosis (Steinberg et al., 1996). 
Obesity, and the resulting high plasma FFA levels, leads to increased FFA levels in the liver. 
The delivery of high FFA levels to the liver, accompanied by hepatic insulin resistance and 
hyperinsulinemia, results in increased production and secretion of very low density lipoproteins 
(VLDL) by the liver (reviewed in Julius, 2003; Lewis, 1997). Once in circulation, VLDL are 
converted to low density lipoproteins (LDL), and high LDL concentrations are associated with an 
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increased risk for the development of CVD and, specifically, atherosclerosis (McLeod et al., 
2004). When oxidized, LDL is phagocytosed by macrophages, forming foam-cells that hinder 
the degradation of oxidized LDL and perpetuates the high LDL levels (Shashkin et al., 2005; 
Sowers and Lester, 1999). The accumulation of foam cells in the tunica intima of blood vessels 
is the hallmark first step in the progression to atherosclerotic lesions (Yu et al., 2013). 
Oxidative stress 
Superoxide, hydrogen peroxide, hydroxyl radical and NO are all forms of ROS that are involved 
in the cardiovascular system (Molavi and Mehta, 2004). These free radicals can be produced 
via nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, xanthine oxidase, NOS or 
uncoupling of the electron transport chain. A role for ROS in cardiac damage was first identified 
through IRI and myocardial infarction, where acute periods of reduced perfusion and oxygen 
deprivation are followed by perfusion and oxygen restoration. This leads to alterations in 
myocardial metabolism, the production of ROS and cell death. It is interesting to note that more 
ROS is produced and more ROS-related damage occurs during reperfusion than during the 
ischaemic or hypoxic state. It is now known that ROS not only contributes to cardiovascular 
complications during acute ischaemic or hypoxic periods, but also in the progression of chronic 
CVD states (Wattanapitayakul and Bauer, 2001). 
Oxidative stress has been found to be associated with reduced left ventricular function and 
ventricular remodelling and it is suggested that the amount of free radicals produced is 
correlated with the severity of the heart failure (Belch et al., 1991; Mallat et al., 1998). A role for 
oxidative stress has also been described in the development of cardiac hypertrophy (reviewed 
in Maulik and Kumar, 2011). When superoxide interacts with NO, peroxynitrite is formed. 
Peroxynitrite is cytotoxic, and can result in lipid peroxidation, protein oxidation, activation of 
matrix metalloproteinases (MMPs) that are implicated in chamber remodelling, and alterations in 
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excitation-contraction coupling, leading to impaired contractility (Katori et al., 2006; Pacher et 
al., 2005). 
2.3 Mammalian heart perfusion as a tool to study cardiovascular disease 
Ethical considerations, difficulties in obtaining tissue and the inability to control and limit 
confounding factors limit the use of human subjects in cardiovascular research. Although it is 
not without shortcomings, the use of animal models has significantly contributed to our 
understanding of normal and pathogenic biological structures and functions, including the 
cardiovascular system. Myocardial perfusion of rodent or small mammalian hearts is a 
particularly useful technique to study and investigate myocardial functioning in the healthy or 
diseased state or in response to various pharmaceutical substances. 
2.3.1 The principles of myocardial perfusion 
Langendorff perfused heart model 
The isolated perfused mammalian heart technique was initially developed in 1895 by Oskar 
Langendorff, based on the isolated frog heart perfusion method (Langendorff, 1895). In this 
method, named Langendorff or retrograde perfusion, oxygenated perfusate is administered via 
a cannula inserted into the ascending aorta. This forces the aortic valves to close and the 
perfusate enters the coronary ostia, causing the coronary vasculature of the heart to be 
perfused. The perfusate then drains into the right atrium via the coronary sinus and flows out of 
the heart (Figure 2.4a) (Liao et al., 2012; Sutherland and Hearse, 2000). The Langendorff 
perfused heart continues beating, however, it is not considered a working heart as the heart 
chambers are not being filled and the perfusate is not ejected by the heart (Liao et al., 2012). 
Langendorff perfusion experiments can make use of constant pressure or constant flow and can 
be used to investigate the effect of pharmaceutical compounds on myocardial function, electrical 
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conduction, reactivity of the vasculature, vascular endothelial and smooth muscle function, 
myocardial ischaemia, stunning and preconditioning (Liao et al., 2012). Modifications to the 
Langendorff method include the insertion of an inflatable balloon into the left ventricle to 
measure isovolumic pressures (Gottlieb et al., 1904) and the use of constant flow to determine 
changes in pressure during perfusion which signifies vascular resistance (Katz et al., 1939). 
Working heart perfusion model 
Another modification to the perfusion technique, developed by Neely et al. (1967), enables the 
perfused heart to have pump action and, thus, to perform mechanical work. This is now known 
as the working heart or ejecting heart perfusion technique and is a more physiologically relevant 
perfusion technique compared to the Langendorff technique. In the working heart model, 
perfusate is administered to the left atrium via the cannulated left pulmonary veins. The 
perfusate is then transferred to the left ventricle and ejected out the cannulated aorta by the 
beating heart (Figure 2.4b). The heart works against constant preload and afterload hydrostatic 
pressure (Liao et al., 2012). This method is preferred for studies investigating substrate usage 
and metabolic parameters under physiological conditions and the use of a microconductance 
catheter enables the measurement of the pressure-volume relationship (Liao et al., 2012). 
The most commonly used perfusate is Krebs-Henseleit buffer (KHB), which is a crystalloid 
bicarbonate buffer. Although fatty acids are the preferred metabolic substrate of the heart under 
normal physiological conditions, glucose is mostly used as substrate in perfusion experiments 
due to the low solubility of fatty acids and the frothing that occurs as a result of the oxygenation 
of a fatty acid-containing perfusate (Liao et al., 2012). The perfusate is oxygenated with a 95% 
O2 / 5% CO2 gas mixture. 
In spite of some limitations to the technique, such as the absence of neuronal and humoral 
influences, the perfusate being cell-free and a high coronary flow (CF) (Skrzypiek-Spring et al., 
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2007), the many advantages make the mammalian isolated heart perfusion technique a useful 
tool in the study of the cardiovascular system. Advantages of the technique include its simplicity 
and relatively low cost, high reproducibility, a large number of measurable parameters and the 
accuracy at which parameters can be measured (Skrzypiek-Spring et al., 2007). The ability to 
study the effects of global or regional ischaemia and reperfusion injury using ex vivo perfusion 
experiments makes it a powerful tool in cardiovascular research as the experiments can 
continue in spite of heart pump failure or lethal arrhythmias, which would otherwise kill the 
animal in in vivo studies (Sutherland and Hearse, 2000). 
 
Figure 2.4: Schematic representation of the basic elements of the A) Langendorff perfusion method and 
B) working heart perfusion method. 
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2.3.2 Myocardial ischaemia/reperfusion injury 
Myocardial ischaemia 
When the supply of blood (or perfusate) to the heart is restricted, a lack in both oxygen and 
nutrients is experienced, while metabolites accumulate as they cannot be removed. This is 
referred to as myocardial ischaemia. In perfusion experiments, global myocardial ischaemia is 
induced when the total perfusion supply to the heart is interrupted, while regional ischaemia is 
induced by ligation of the left descending coronary artery, thereby interrupting perfusion to that 
part of the myocardium supplied by this artery (Sutherland and Hearse, 2000). In the body, 
myocardial ischaemia is predominantly caused by coronary artery diseases such as 
atherosclerosis. 
Ischaemia can result in myocardial injury and dysfunction, which is also observed at the 
molecular level (Ytrehus, 2006). The severity of ischaemia determines the myocardial metabolic 
response. In response to a mild decrease in blood flow (20-60%), the heart has reduced oxygen 
consumption and FFA oxidation, and increased anaerobic glycolysis. Although the heart will 
experience a degree of contractile dysfunction, the remaining blood flow can prevent the heart 
from undergoing permanent tissue damage. In contrast, during complete ischaemia, ATP levels 
will be rapidly depleted, lactate will accumulate, the heart will experience acidosis and lose 
contractile function (Armstrong, 2004). Complete ischaemia eventually results in permanent 
damage to the heart due to necrosis and myocardial infarction (Stanley et al., 1997). Besides 
flow-related ischaemia, demand-induced ischaemia also occurs, although it is less used in 
experimental studies. Demand-induced ischaemia occurs when blood flow, and therefore 
oxygen and nutrient supply, does not increase in response to increased contractility and the 
accompanying greater need for oxygen and nutrients (Stanley et al., 1997). 
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Reperfusion 
Once ischaemic tissue is reperfused, the heart reverts from anaerobic glycolysis back to 
oxidative phosphorylation to produce ATP. However, contractile function takes longer to return 
to normal upon reperfusion and this is termed myocardial stunning (Stanley et al., 1997). 
Although ischaemia without reperfusion will inevitably result in cell death, reperfusion of the 
ischaemic area has also been found to cause major tissue damage and has been termed IRI 
(Welbourn et al., 1991). Complications that arise due to IRI include arrhythmias, microvascular 
damage, myocardial stunning and cell death (Dhalla et al., 2000). Cell death is achieved 
through activation of apoptosis, necrosis or autophagy and multiple death-inducing stimuli, such 
as ROS production, Ca2+-overload and the activation of proteases can contribute to the 
activation of these death pathways (Eltzschig and Eckle, 2011; Hotchkiss et al., 2009). 
However, Ca2+-overload and oxidative stress have been found to be the biggest contributors to 
IRI (Dhalla et al., 2000). 
During ischaemia, the heart becomes acidotic due to the accumulation of H+. The excess 
intracellular H+ is exchanged for Na+ through the cardiac Na+/H+ exchanger (NHE1) during 
reperfusion, which in turn is exchanged for Ca2+ through the Na+/Ca2+ exchanger (NCX), 
resulting in Ca2+-overload during reperfusion (Stanley et al., 1997). Increased Ca2+ plays a 
crucial role in the initiation of necrosis and is associated with reduced recovery of mechanical 
functioning of the heart during reperfusion (Tani, 1990). 
Kinases that have been shown to be activated upon reperfusion include PKB/Akt, ERK and JNK 
(Mizukami and Yoshida, 1997; Mockridge et al., 2000; 1997; Omura et al., 1999; Yin et al., 
1997). PKB/Akt was shown to be activated via the PI3K pathway, and 4E-BP1, which leads to 
protein synthesis, was found to be phosphorylated downstream of PKB/Akt, but not GSK-3α 
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(Mockridge et al., 2000). Reactive oxygen and nitrogen species have been implicated in the 
mechanism of protein kinase activation (Armstrong, 2004; Mockridge et al., 2000). 
During reperfusion, excess ROS and reactive nitrogen species are produced. It was found that 
the use of antioxidants was able to protect the heart against the contractile dysfunction that is 
usually seen in IRI, suggesting that oxidative stress significantly contributes to the development 
of IRI (Dhalla et al., 1999; Temsah et al., 1999). 
Myocardial infarction 
Myocardial infarction is a pathological state arising from prolonged ischaemia. It is considered to 
be a dynamic process ischaemic injuries undergo a shift from being reversible to irreversible. As 
necrosis of the myocardium is only detectible hours after the insult, IRI-stimulated cell death is 
not immediate. The irreversibly injured myocardium eventually dies and is replaced by fibrous 
scar tissue, giving rise to the myocardial infarction (Jennings et al., 1995). 
Infarcts are classified according to location and the size of the damaged area (Alpert et al., 
2000). They can also be further defined as acute, healing or healed. Acute myocardial 
infarctions contain polymorphonuclear leucocytes, while healing myocardial infarctions contain 
fibroblasts and mononuclear cells. When no infiltration by other cells are seen and scar tissue is 
present, the myocardial infarction is defined as healed. A myocardial infarction takes at least 
five to six weeks from onset to being classified as healed (Thygesen et al., 2007). Myocardial 
infarction is a major cause of death and disability on a global scale. 
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2.4 Ataxia-telangiectasia mutated 
With the high incidences of obesity, insulin resistance, T2DM and CVD currently being 
experienced globally, and the role they play in morbidity and mortality rates, researchers are 
constantly striving to better understand the mechanisms and aetiologies behind these 
conditions. In 1970 it was noted that ataxia-telangiectasia (A-T) patients were inclined to 
develop diabetes, but it was not until more recently that the mechanisms in which ATM protein 
signalling contributes to defective insulin signalling and glucose homeostasis, started to be 
elucidated (Schalch et al., 1970). Although some studies have shed light on a cardiovascular 
role for ATM, relatively little is still known about this topic. 
2.4.1 Background on the ATM protein kinase 
Gene and protein characteristics 
The ATM protein is encoded by a single gene of the same name, which is located on 
chromosome 11q22-23 and encodes a 12 kilobase mRNA transcript (Savitsky et al., 1995). The 
human ATM protein sequence is 3 056 amino acids in length and has a molecular mass of 350 
kDa. The protein belongs to the phosphatidylinositol 3-kinase-related kinase (PIKK) superfamily 
and regions of interest in the protein include a telomere-length maintenance and DNA damage 
repair (TAN) domain, a catalytic domain (PIKKc_ATM), a FAT domain and a FATC domain as 
well as an ATP binding site, a catalytic loop and an activation loop (NCBI, accession number 
AAB65827; Savitsky et al., 1995). 
Tissues in which ATM expression has been identified include the brain, lungs, kidneys, spleen, 
pancreas, liver, small intestine, colon, placenta, ovary, testis, thymus, leukocytes, skeletal 
muscle and the heart. ATM has been shown to be localized in the cytoplasm, mitochondria and 
the nucleus (Zakikhani et al., 2012). In proliferating cells, ATM is predominantly found in the 
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nucleus and following mitosis, ATM is found in the cytoplasm (Gorr et al., 2012). It has been 
suggested that DNA-PK is involved in the regulation of ATM expression and activation as ATM 
levels decrease in response to decreased DNA-PK levels (Peng et al., 2005). Activated ATM 
phosphorylates substrates on serine or threonine residues that are followed by a glutamine 
residue (S/TQ motif) (Kim et al., 1999). 
Ataxia-telangiectasia 
Mutations in the ATM gene result in a lack of functional ATM protein and leads to A-T, which is 
a debilitating, autosomal recessive disease (Su and Swift, 2000). A-T is a rare disease, affecting 
approximately 1 in 40 000 to 1 in 200 000 people globally, while 2.8% of people are estimated to 
be A-T carriers (Rasio et al., 1995; Swift et al., 1986). Although affected individuals appear 
healthy at birth, symptoms appear early on in life. Ataxia becomes evident when the affected 
child begins to walk and continues to progress, typically leaving the child wheelchair-bound by 
the age of 10 or 11. Other symptoms typically associated with A-T are cerebellar 
neurodegeneration, oculocutaneous telangiectasia, immunodeficiency, an increased risk of 
cancer development, premature ageing and radiosensitivity (Bakkenist and Kastan, 2003; Su 
and Swift, 2000; Yang et al., 2011). Additionally, A-T patients also experience growth 
retardation, insulin resistance and glucose intolerance (Yang et al., 2011). One study found that 
up to 17% of people affected by A-T develop T2DM (Morio et al., 2009). Although carriers are 
spared these signs and symptoms, it appears as if their life-expectancies are shortened by an 
average of approximately four years due to the development of cancer and an average of 11 
years due to the development of ischaemic heart disease compared to ATM wild-type 
individuals (Su and Swift, 2000; Swift and Chase, 1983). There is currently no cure for A-T. 
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Activation of ATM 
When present in dimers or higher-order multimers, ATM is inactive as the kinase domains are 
blocked while in a complex. In response to a number of different stressors, the ATM dimer or 
multimer complexes will dissociate, leading to the activation of ATM and the phosphorylation of 
specific substrates by the activated ATM (Guo et al., 2010). Two different mechanisms in which 
ATM is activated have been elucidated. The first is in response to double-stranded DNA breaks, 
when ATM is activated via interaction with the MRE11-RAD50-NBS1 (MRN) complex (Uziel et 
al., 2003). The inactive ATM multimers dissociate into active monomers when the serine 1981 
residue in each ATM is autophosphorylated by the kinase domain of a neighbouring ATM 
molecule in the complex (Bakkenist and Kastan, 2003). Autophosphorylation of ATM has been 
described as a key event in the activation of ATM (Koslov et al., 2003). In vitro studies revealed 
that ATP is able to increase the kinase activity of ATM up to 10-fold and that the activation is 
dependent on the presence of Mn2+. The PI3K inhibitor, wortmannin, was shown to inhibit the 
ATP-dependent activation of ATM (Kozlov et al., 2003). Phosphorylation at serine 1981 is 
generally regarded as a sign of activated ATM, however, some studies have reported ATM 
kinase activity in the absence of serine 1981 phosphorylation (Guo et al., 2010; Pellegrini et al., 
2006). 
Exposure to oxidative stress, and the subsequent oxidation of ATM, is the second known 
mechanism by which ATM can be activated. Intermolecular disulfide bonds are formed at, 
amongst others, cysteine 2991, causing conformational changes in oxidized ATM. The 
formation of disulfide bonds result in ATM becoming activated while still in covalently bound 
dimers and is essential for the activation of ATM in response to oxidative stress (Guo et al., 
2010). Other known activators of ATM include hypoxia and insulin, although their mechanisms 
are unknown. 
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Two phosphatases, namely Wip1 and protein phosphatase 2A (PP2A) have been shown to 
regulate ATM phosphorylation. In unstressed cells, PP2A prevents ATM from being 
phosphorylated by associating with ATM via its scaffolding and catalytic subunits (Goodarzi et 
al., 2004). Wip1, on the other hand, dephosphorylates ATM once the initial stressor is no longer 
present (Sheeram et al., 2006). 
2.4.2 The many functions of ATM 
A large proteomic study published in 2007 has identified over 490 proteins to be substrates of 
ATM (Matsuoka et al., 2007). According to the Signaling Pathway Integrated Knowledge Engine 
(SPIKE), ATM participates in up to 953 regulations and 21 interactions with substrates (Arnon et 
al., 2011; Elkon et al., 2008) (Figure 2.5). Activated ATM is thus able to regulate a variety of 
substrates that form part of a number of signalling pathways, making ATM kinase one of the 
master controllers of signalling networks. 
 
Figure 2.5: ATM regulates and associates with a large number of substrates that form part of a number of 
signalling networks (ATM Signaling Network (spike00006) image obtained from SPIKE). 
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The nuclear role of ATM 
The most well-known and extensively studied function of ATM is in the nucleus where it plays a 
significant role in the response to double strand DNA breaks (DSB), termed the DNA damage 
response (DDR). The MRN complex acts as a sensor of DSB, which subsequently activates 
ATM, as previously described. Nuclear ATM then phosphorylates downstream substrates, 
including p53, Chk2, BRCA1 and H2AX that are involved in processes such as cell-cycle arrest, 
DNA repair or apoptosis in order to maintain genome stability (Banin et al., 1998; Burma et al., 
2001; Cortez et al., 1999; Matsuoka et al., 1998). 
DNA damage can also affect cytoplasmic ATM. DNA damaging agents, such as topotecan, 
have been shown to phosphorylate and activate cytoplasmic ATM. The activated ATM directly 
phosphorylates cytoplasmic PTEN on serine 113, causing it to translocate to the nucleus and 
initiate autophagy via the p-JUN-SESN2-AMPK pathway (Chen et al., 2015). Although PTEN is 
a known inhibitor of PKB/Akt, it was found that ATM-dependent phosphorylation of PTEN had 
no effect on the PKB/Akt pathway (Chen et al., 2015). 
It has become apparent that defective DDR signalling alone could not be responsible for the 
wide range of signs and symptoms observed in A-T patients and roles for ATM outside of the 
nucleus, involving cellular homeostasis and metabolism, have now been described (Ditch and 
Paull, 2012). A prominent effect that is believed to contribute to most of the signs and symptoms 
seen in individuals affected by A-T is the critical role of ATM in maintaining redox homeostasis 
(Ambrose and Gatti, 2013; Semlitsch et al., 2011). 
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ATM and oxidative stress 
Although the source of the stress has not been properly characterized, cells derived from A-T 
patients or animal models that lack ATM have been found to be under constant oxidative stress 
(Ousset et al., 2010; Watters, 2003). Additionally, Reichenbach et al. (1999) determined the 
antioxidant capacity of A-T patients, and found that their plasma had a lower antioxidant 
capacity than that of healthy age-matched control individuals. Mitochondria are the primary site 
for the production of intracellular ROS (Ott et al., 2007), and ATM has been found to localize to 
mitochondria and to contribute to mitochondrial functioning (Ambrose et al., 2007; Valentin-
Vega et al., 2012). In the absence of ATM, thymocytes have been shown to contain 
mitochondria that are swollen, have a disorganized structure, have decreased activity of 
complex I of the electron transport chain and have changes in their membrane potentials. 
Defective mitophagy of the damaged mitochondria was also observed (Valentin-Vega et al., 
2012). Additionally, Zakikhani et al. (2012) suggests that ATM could be involved in the 
functioning of mitochondrial complex II as this complex was found to be dysfunctional in the 
presence of the ATM inhibitor, KU-55933. The dysfunction of complex II caused decreased 
oxidative phosphorylation and the accumulation of succinate due to reduced conversion of 
succinate to fumarate which resulted in inhibition of the Krebs cycle (Zakikhani et al., 2012). It 
has thus been suggested that the mitochondrial dysfunction observed in A-T cells contributes to 
the increased amount of oxidative stress observed in these cells (Figure 2.6) (Ambrose et al., 
2007; Valentin-Vega et al., 2012). Excessively high levels of ROS have been shown to damage 
proteins and lipids, to induce oxidation of mitochondrial and nuclear DNA and to contribute to 
single and double-strand breaks in the DNA (Ambrose and Gatti, 2013). The importance of 
mitochondria in oxidative phosphorylation and the production of ATP, and the high ATP demand 
of cardiomyocytes, renders cardiomyocytes particularly susceptible to mitochondrial 
dysfunction. Mitochondrial dysfunction in cardiomyocytes cause reduced energy production and 
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contractility as well as changes in electrical properties and cell death (Rosenberg, 2004). 
Healthy mitochondria are, therefore, crucial for cardiovascular health and it appears as if ATM 
plays a role in normal functioning of mitochondria. 
One of the ways in which ATM contributes to the anti-oxidant response is by altering glucose 
metabolism in favour of the pentose phosphate pathway (PPP) as opposed to glycolysis in the 
presence of oxidative stress (Figure 2.7) (Krüger and Ralser, 2011). While both glycolysis and 
the PPP metabolize glucose, glycolysis produces ATP and leads to the use of oxygen in 
oxidative phosphorylation while the PPP does not produce ATP or require oxygen (Jalloh et al., 
2015). The PPP consists of an oxidative phase and a non-oxidative phase, the former of which 
is the main source of NADPH production. NADPH is a reducing agent and a cofactor important 
for anti-oxidants such as glutathione reductase and cytochrome p450 reductase. Glucose-6-
phosphate dehydrogenase is the rate limiting enzyme of the PPP. ATM has been shown to 
phosphorylate Hsp27 which increases the affinity of Hsp27 for glucose-6-phosphate 
dehydrogenase and in doing so, enhances the rate of the PPP and amount of NADPH produced 
(Consentino et al., 2011; Krüger and Ralser, 2011). The anti-oxidative effects originating from 
the activation of the PPP was shown to increase the viability and proliferation of cardiac 
progenitor cells in diabetic hearts (Katare et al., 2013). In human diabetic hearts that are failing, 
cardiomyocytes, endothelial cells and fibroblasts are progressively killed by apoptosis and 
necrosis due to oxidative stress (Frustaci et al., 2000). Pharmaceutical activation of ATM, and 
consequently the PPP, could be clinically significant in the cardiovascular system due to 
possible anti-oxidant effects. 
The structure and function of the diabetic heart is partly regulated by AMPK as it increases 
autophagy in damaged cells. It also contributes to the regulation of both cardiac lipid and 
glucose metabolism (Gray and Kim, 2011; Xie et al., 2011). Improved cardiac metabolism and 
function have also been reported in mice with T2DM when mTOR has been inhibited, possibly 
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due to the resultant reduction in oxidative stress (Das et al., 2013). The induction of oxidative 
stress in cells with the use of H2O2, over a period of 60 minutes, activated ATM and 
consequently caused it to activate AMPK. This was achieved by directly phosphorylating AMPK 
at threonine 172 as well as by phosphorylating and activating the tumour suppressor, LKB1, a 
known activator of AMPK (Alexander et al., 2010; Shackelford and Shaw, 2009). Activated 
AMPK inhibited mTORC1 via phosphorylation of TSC2 at threonine 1271 and serine 1387 
(Alexander et al., 2010). When mTORC1 is inhibited, decreased protein synthesis and 
increased autophagy are achieved in response to oxidative stress (Figure 2.7). Hypoxic 
conditions have also been shown to induce ATM-dependent inhibition of mTORC1. Although the 
mechanism is still unclear, hypoxic stress is able to activate ATM, causing it to phosphorylate 
and activate HIF-1α. This leads to the transcription of REDD1 (REgulated in Development and 
DNA damage responses) which inhibits the association between 14-3-3 and TCS2, causing 
TSC2 to inhibit mTORC1 (Figure 2.7) (Cam et al., 2010; DeYoung et al., 2008). 
The biosynthesis of both subunits of the HIF-1 transcription factor was shown to be increased 
as a result of the elevated ROS levels in three different ATM-/- cell models (Ousset et al., 2010). 
The higher HIF-1 levels lead to the overexpression of both GLUT1 and VEGF, which initiates an 
anti-oxidant response. It is also possible that the overexpression of these two proteins 
contributes to the development of insulin resistance and abnormal vascularisation, which are 
two of the clinical manifestations of A-T. The ubiquitously expressed glucose transporter, 
GLUT1, is responsible for basal uptake of dehydroascorbic acid (DHA) and glucose, therefore, 
overexpression of GLUT1 will lead to the increased uptake of these substances (Ousset et al., 
2010). Once converted into ascorbic acid, DHA becomes a ROS scavenger and thus has a 
beneficial anti-oxidant effect (Arrigoni and Tullio, 2002). Overexpression of GLUT1, on the other 
hand, has been shown to be detrimental as it could lead to the development of insulin 
resistance in skeletal muscle of mice and potentially plays a role in the development of the 
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insulin resistant phenotype that is present in A-T patients (Buse et al., 1996). Another symptom 
of A-T, namely telangiectasia, could be caused by the HIF-1-induced overexpression of VEGF, 
as VEGF is a crucial factor in angiogenesis (Hoeben et al., 2004). Although it still needs to be 
confirmed, it has been suggested that increased angiogenesis could contribute to plaque 
instability and the development of atherosclerotic plaques (Khurana et al., 2005). An 
angiogenesis-independent effect of VEGF in ischaemic conditions is to increase the expression 
of myoglobin, an iron- and oxygen-binding protein that is present in both cardiac and skeletal 
muscle (van Weel et al., 2004). In addition to maintaining oxygen supply through the release of 
stored oxygen during periods of high oxygen demand, such as ischaemia and strenuous 
exercise, myoglobin has also been shown to act as a NO and ROS scavenger in cardiac and 
skeletal muscle (Figure 2.6) (Ordway and Garry, 2004). 
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Figure 2.6: A number of metabolic and cardiovascular effects have been observed in the ATM-deficient 
state. Mitochondrial dysfunction, which contributes to elevated ROS levels, has been observed in ATM 
deficient cells. Elevated ROS associated with ATM-deficiency lead to increased biosynthesis of HIF-1, 
which results in an antioxidant response and maintained oxygen supply, but also insulin resistance and 
vascular dysfunction due to overexpression of GLUT1 and VEGF. ATM deficient mice have been found to 
have increased JNK levels, which lead to the serine phosphorylation of IRS-1 and ultimately contributes 
to the development of insulin resistance. Increased JNK levels could also contribute to increased 
atherosclerosis through increased AP-1 activity and LPL expression. Other pathophysiological 
consequences of ATM-deficiency are metabolic disturbances consistent with the metabolic syndrome, 
such as dyslipidaemia (elevated cholesterol, triglycerides and LDL proteins) and hypertension. 
Furthermore, the disruption of ATM-dependent phosphorylation of p53 has been shown to result in 
increased insulin resistance and atherosclerosis. Finally, ATM-deficient animals have been shown to 
have increased cardiac fibrosis and hypertrophy and β-adrenergic receptor stimulation has been 
associated with increased cardiomyocyte apoptosis due to decreased PKB/Akt activity in these animals. 
(Image from Espach et al., 2015). 
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Figure 2.7: ATM has been shown to be activated by oxidative stress, hypoxia and insulin. In response to 
oxidative stress, ATM increases the rate of the pentose phosphate pathway in order to attain an 
antioxidant effect and achieves increased autophagy and decreased protein synthesis through activation 
of the AMPK-mTORC1 pathway. Increased autophagy and decreased protein synthesis are also 
achieved via HIF-1α phosphorylation in response to hypoxia. By regulating an as yet unidentified 
phosphatase (possibly PP2A), ATM increases the phosphorylation of PKB/Akt in response to insulin 
stimulation, leading to increased protein synthesis and glucose uptake. ATM also directly phosphorylates 
4E-BP1 in response to insulin stimulation, resulting in increased protein synthesis and it has also been 
shown that ATM mediates insulin stimulated glucose uptake by phosphorylating AS160, causing GLUT4 
externalization. (Image from Espach et al., 2015) 
ATM and insulin signalling 
Rather than having a single cause, it is thought that the disruption of a number of different ATM-
dependent mechanisms contribute to the insulin resistance seen in A-T patients (Viniegra et al., 
2005). The ATM/p53 pathway is a mechanism that leads to the development of both insulin 
resistance and atherosclerosis. The ‘guardian of the genome’ tumour suppressor, p53, has an 
ATM-specific phosphorylation site at serine 15 in humans and serine 18 in mice (Nakagawa et 
al., 1999). Mouse models in which serine 18 was mutated in p53 had increased levels of 
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inflammatory cytokines as well as reduced levels of anti-oxidants (Armata et al., 2010). Although 
no effect was observed at three months of age, the mutated mice developed insulin resistance 
and glucose intolerance by the age of six months. Consequently, it was proposed that the 
accumulation of oxidative stress and the resulting damage led to the disruption of glucose 
homeostasis (Armata et al., 2010). Pharmaceutical activation of ATM with the use of 
chloroquine in high-fat fed mice reduced the size of atherosclerotic plaques, but only in 
genetically wild-type mice and not in p53-null mice (Razani et al., 2010). This indicates that the 
presence of functional p53 is required for the beneficial effects of ATM activation. It is still not 
clear which signalling network downstream of ATM and p53 results in the protection. 
Blood glucose levels were found to increase with age in ATM-/- mice while insulin secretion 
decreased with age, potentially due to dysfunction of β-cells in the pancreas (Miles et al., 2007). 
Although the mechanism has not yet been elucidated, it has been suggested that it is more 
likely to be caused by metastatic cancer, which is a common phenomenon in aged ATM-/- mice, 
rather than a direct effect of ATM in insulin secretion (Halaby et al., 2008). However, it is 
possible that ATM plays a role in β-cell homeostasis. In response to lipid loading, the pancreas 
was found to have increased expression levels of ATM (Schneider et al., 2002). Lipids are 
important for the normal functioning of the pancreatic β-cells and for their regulation of glucose 
stimulated insulin secretion (Nolan et al., 2006). Mutation of the ATM-specific phosphorylation 
site in mice contributed to hypertrophy of pancreatic islets, further suggesting a role for ATM in 
β-cell homeostasis (Armata et al., 2010). 
The previous sections described indirect ways in which ATM participates in insulin signalling, 
but more direct effects of ATM on insulin and its major signalling pathways have also been 
observed. The kinase activity of ATM is increased up to three-fold in response to insulin (Yang 
and Kastan, 2000) and insulin-like growth factor-I (IGF-I) was also able to increase the serine 
1981 phosphorylation of ATM in mice (Ching et al., 2013a). The activation of ATM upregulates 
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the promotor activity of the IGF-I receptor, increasing the expression of IGF-I receptor in 
response to IGF-I stimulation (Peretz et al., 2001). Reinforcing the notion that ATM participates 
in IGF-I signalling, it was demonstrated that PI3K, PKB/Akt, mTORC1 and S6K phosphorylation 
was reduced following IGF-I stimulation in skeletal muscle obtained from ATM-/- mice (Ching et 
al., 2013a). Phosphorylation of IRS-1 was unaffected by ATM deficiency, suggesting that ATM 
participates in IGF-I signalling downstream of IRS-1 (Ching et al., 2013a; Halaby et al., 2008). 
The anti-apoptotic and pro-survival effect of IGF-I was diminished in ATM-deficient cells. A 
deficiency in ATM did not affect IR expression as it did IGF-I receptor expression (Viniegra et 
al., 2005). 
ATM has been shown to play a role in the activation of PKB/Akt, a central protein kinase in the 
insulin signalling network. An association is formed between the catalytic PIKKc_ATM domain of 
ATM and PKB/Akt which facilitates the phosphorylation of serine 473 in PKB/Akt in response to 
insulin stimulation (Viniegra et al., 1999). It is, however, not likely that PKB/Akt is directly 
phosphorylated at serine 473 by ATM as this is not an S/T-Q motif (Golding et al., 2009; Kim et 
al., 1999). It has thus been suggested that ATM regulates an okadaic acid-sensitive 
phosphatase, most likely PP1, PP2A or PP4-6, which then increases dephosphorylation of 
PKB/Akt (Figure 2.5) (Golding et al., 2009). Phosphorylation at serine 473 in PKB/Akt does not 
achieve full activation of PKB/Akt, but this ATM-dependent phosphorylation step is essential 
before phosphorylation at threonine 308 can take place, after which PKB/Akt is fully activated 
(Halaby et al., 2008; Viniegra et al., 2005). The involvement of ATM in activation of PKB/Akt in 
response to insulin appears to be cell-type specific as phosphorylation of PKB/Akt was ATM-
dependent in some cells, but not in others (Jeong et al., 2010). It was hypothesised by Ching 
and colleagues (2013a) that the need for ATM in activation of PKB/Akt is determined by the 
upstream stimulus, as the signal would be stronger through IR activation, but weaker through 
IGF-I receptor activation. 
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Apart from affecting the activation of PKB/Akt, ATM also participates in other aspects of insulin 
signalling that are independent of PKB/Akt. Insulin stimulated phosphorylation of AS160, which 
is a Rab GTPase-activating protein crucial for the translocation of GLUT4 to the cell membrane, 
was downregulated in L6 myotubes and soleus muscle of mice in which ATM had been inhibited 
(Jeong en al., 2010; Sano et al., 2003). This resulted in reduced uptake of glucose, while 
PKB/Akt and PKC phosphorylation remained unaffected by the inhibition of ATM (Jeong et al., 
2010). GLUT4 is found predominantly in skeletal and cardiac muscle and adipose tissue and is 
responsible for insulin-stimulated glucose uptake. GLUT1, on the other hand, is responsible for 
basal glucose uptake and is found in most tissue types (Buse et al., 1996). Both GLUT4 and 
GLUT1-mediated glucose uptake has been found to be affected by ATM. In L6 myoblasts it has 
been demonstrated that there are different mechanisms that lead to reduced glucose uptake 
when ATM is inhibited or inactivated. When L6 myoblasts were engineered to contain kinase-
dead ATM, reduced translocation of GLUT4 was observed in response to insulin stimulation 
compared to L6 myoblasts containing functional ATM (Halaby et al., 2008). When ATM was 
inhibited using KU-55933 and CP466722 in L6 myotubes, less GLUT1 transporters were 
present at the cell surface compared to in untreated cells. A 48% reduction in basal glucose 
uptake was observed as well as reduced DHA uptake in response to ATM inhibition (Andrisse et 
al., 2013). By phosphorylating serine 490 of GLUT1, ATM increases the interaction between the 
glucose transporter and the binding protein GIPC1 which results in translocation of GLUT1 to 
the cell membrane (Andrisse et al., 2013; Matsuoka et al., 2007). It seems as if there is a 
discrepancy between the results obtained by Ousset et al. (2010) and Andrisse et al. (2013). 
Ousset et al. (2010) reported that they observed ATM deficiency to upregulate GLUT1 
transcription while Andrisse et al. (2013) reported that less GLUT1 was externalised to the cell 
surface during ATM deficiency. We hypothesise that, in order to compensate for the reduced 
number of GLUT1 transporters at the cell surface, GLUT1 transcription is increased in the 
absence of ATM. Further investigation is, however, required to validate this hypothesis. 
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From the above it is clear that ATM plays a significant role in the insulin signalling network and 
the uptake of glucose. Glucose intolerance and insulin resistance contribute to the eventual 
development of T2DM, as described previously in section 2.1.4. Although it is still a 
controversial viewpoint (Birnbaum and Shaw, 2011), ATM has been proposed to be involved in 
the action of metformin, which is the drug of choice in the treatment of T2DM. A genome-wide 
association study found that the ATM gene is present at the same locus as a gene that is 
closely associated with the response to metformin treatment. The study highlights that the 
metformin-dependent activation of AMPK is not observed when ATM has been pharmaceutically 
inhibited and that the glycaemic response to metformin treatment was influenced by variations 
in the ATM gene (Zhou et al., 2011). 
ATM and protein synthesis 
It was demonstrated in 293T cells that ATM regulates protein synthesis by phosphorylating 4E-
BP1 on serine 111 in response to insulin stimulation. Phosphorylation of serine 111 was not 
dependent on rapamycin, an inhibitor of mTORC1. However, successive rapamycin-sensitive 
phosphorylation events must take place on 4E-BP1, causing it to release eukaryotic initiation 
factor 4E (eIF-4E) and the initiation of translation (Figure 2.5) (Yang and Kastan, 2000). Protein 
translation is initiated when the released eIF-4E binds to an N7-methylguanosine cap of an 
mRNA molecule. Reduced body masses were observed in ATM-/- mice compared to wild-type 
mice (Barlow et al., 1996). Additionally, cells isolated from A-T patients have a higher 
requirement for serum growth factors than cells isolated from healthy individuals (Yang and 
Kastan, 2000). This further suggests a role for ATM in protein synthesis and growth promotion. 
To our knowledge, no studies have been published on the role of ATM specifically on protein 
synthesis and growth promotion in the heart. 
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Metabolic and vascular effects of ATM 
Both insulin resistance and atherosclerosis are well known for significantly contributing to the 
development of serious cardiovascular complications. Insulin resistance is known to be caused, 
at least in part, by oxidative stress (Bloch-Damti and Bashan, 2005; Evans et al., 2005) while 
both oxidative stress and DNA damage contribute to the development of atherosclerosis. Both 
oxidative stress and DNA damage have been shown to activate ATM (Guo et al., 2010; Uziel et 
al., 2003). A number of studies have demonstrated that ATM is able to protect against 
atherosclerosis and insulin resistance. Studies have also demonstrated how a clinical picture 
similar to that seen in the metabolic syndrome emerges when the expression or activation of 
ATM is downregulated and agents that activate ATM, or that have an antioxidant effect, are able 
to improve the metabolic signs and symptoms associated with ATM-deficiency (Le Guezennec 
et al., 2012; Mercer et al., 2012; Schneider et al., 2006). 
In ATM-deficient mice, aortas, macrophages, adipose tissue, skeletal muscle and liver was 
shown to have increased activity of JNK (Schneider et al., 2006). Insulin signalling is disrupted 
when JNK phosphorylates IRS-1 at serine 307, leading to an insulin resistant state (Figure 2.6). 
In line with this, mice that were lacking JNK did not develop obesity or insulin resistance 
(Hirosumi et al., 2002). Another effect of JNK is to increase the activity of the transcription factor 
activator protein 1 (AP-1). The expression of lipoprotein lipase, which has been shown to be 
atherogenic, is increased by AP-1 (Figure 2.6) (Mead and Ramji, 2002; Schneider et al., 2006). 
Our understanding of the metabolic actions of ATM have significantly been augmented by 
studying mice that are haploinsufficient for ATM (ATM+/-/ApoE-/-) and comparing their metabolic 
characteristics with ATM wild-type mice (ATM+/+/ApoE-/-). Mice that are complete ATM 
knockdowns have a very short lifespan as they develop thymic lymphoma between the ages of 
two to four months, according to The Jackson Laboratory, which renders them difficult to use for 
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experimentation (The Jackson Laboratory mouse strain datasheet). Compared to control 
animals, the haploinsufficient mice had increased levels of cholesterol, triglycerides and LDL 
and feeding these animals a high fat diet led to a higher incidence of atherosclerotic plaque 
formation than in control animals (Mercer et al., 2010; Wu et al., 2005). ATM haploinsufficiency 
further contributed to hypertension, abnormal lipid and carbohydrate metabolism, and evidence 
of mitochondrial dysfunction and DNA damage (Figure 2.4) (Mercer et al., 2010). Treating the 
ATM+/-/ApoE-/- mice with a mitochondria-targeted anti-oxidant, namely MitoQ, for 14 weeks 
resulted in less fat to be accumulated and thus decreased weight gain, decreased 
hyperglycaemia, decreased hypercholesterolemia and decreased hypertriglyceridemia than 
what was observed in untreated ATM+/-/ApoE-/- mice (Mercer et al., 2012). The use of an anti-
oxidant was therefore able to reduce the ATM deficiency-induced metabolic effects. 
Atherosclerotic lesions were also decreased with the use of chloroquine, which has been shown 
to activate ATM, in ATM+/+/ApoE-/- mice. Other effects of ATM activation with the use of 
chloroquine as seen in other animal models of insulin resistance included a decrease in blood 
pressure, JNK activity, glucose and insulin levels (Schneider et al., 2006). 
Deletion of Wip1, which is responsible for the dephosphorylation of ATM, caused ATM to be 
hyperphosphorylated. ApoE-/-Wip1-/- mice had accelerated metabolic rates compared to control 
animals, which resulted in less atherosclerotic lesions, that were also smaller in size, and less 
fat deposition than what was observed in apoE-/-Wip1+/+ mice. An ATM-mTOR-dependent 
pathway was suggested for the mechanism in which Wip1-deficiency affected the metabolic 
rates of the mice (Le Guezennec et al., 2012). 
In addition to the metabolic basis for the development of atherosclerosis discussed in section 
2.3.2, aging is also emerging as a risk factor for the development of atherosclerosis (Minamino 
and Komuro, 2007). Cellular senescence and reduced cell proliferation, telomere dysfunction 
and shortening, increased DNA damage, growth arrest and apoptosis are all aging-related 
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characteristics that are associated with atherosclerotic plaques and are believed to contribute to 
the development of atherosclerotic plaques (reviewed in Wang and Bennett, 2012). In 
endothelial cells, it was found that oxidative stress activated not only ATM, but also downstream 
targets of ATM such as PKB/Akt, p53 and p21 (Zhan et al., 2010). Increased activation of 
PKB/Akt has been associated with increased cellular senescence in human endothelial cells via 
a p53/p21-dependent mechanism (Miyauchi et al., 2004). Furthermore, the activated ATM 
localised to DSB, initiating the DDR, which is also known to trigger cellular senescence (von 
Zglinicki et al., 2005; Zhan et al., 2010). Oxidative stress-induced activation of ATM is thus able 
to induce endothelial senescence via activation of the DDR and PKB/Akt-p53-p21 pathway, 
finally leading to atherosclerosis. 
Oxidized LDL was also shown to induce ATM phosphorylation in a time dependent manner in 
VA13 fibroblasts and endothelial cells. Additionally, oxidized LDL had a more adverse effect on 
cell viability of ATM-deficient fibroblasts (AT22 cells) than on normal fibroblasts (VA13 cells), 
indicating that ATM activation plays a protective role against the toxic effect of oxidized LDL. In 
line with this, AT22 cells were found to have a higher number of chromosomal breaks due to 
oxidized LDL treatment compared to treated VA13 cells (Semlitch et al., 2011). These results 
suggest that ATM activation is a protective mechanism against oxidized LDL and their role in 
the development of atherosclerosis. 
ATM and its cardiac implications 
People affected with A-T usually pass away in their twenties due to the severity of symptoms 
that result from ATM deficiency (Morrel et al., 1986). Although there is evidence of 
cardiovascular complications that are caused by ATM deficiency, the lifespans of A-T sufferers 
are usually too short for these signs and symptoms to fully develop and to become life 
threatening. The majority of A-T research is therefore focused on mechanisms affecting the 
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more deleterious symptoms of the disease such as cancer, ataxia, immunodeficiency and 
neurodegeneration. From the previous sections it is clear that ATM significantly contributes to 
normal metabolism and the response to oxidative stress and hypoxia. Additionally, it appears as 
if a clinical picture resembling that of the metabolic syndrome is seen when ATM protein kinase 
is dysfunctional or absent and the metabolic syndrome is very strongly associated with an 
increased risk for the development of CVD. 
Individuals with a single mutated ATM copy do not have any of the severe symptoms present in 
A-T patients, but they also do not appear to be completely unaffected. Carriers of an ATM 
mutation have been shown to die earlier than non-carriers and have a higher rate of mortality 
due to quicker development of cancer as well as ischaemic heart disease (Su and Swift, 2000). 
In animal models, it has also been observed that the same metabolic alterations present in ATM 
homozygous animals are observed in ATM heterozygous animals (Shoelzon, 2002). 
Additionally, it has been demonstrated that ATM protein kinase levels are significantly 
downregulated in animals in response to a high fat diet and that this effect was independent of 
ATM genetics (Halaby et al., 2008). This is of interest as it suggests that a larger portion of the 
population could be affected by ATM related metabolic dysfunction, and cardiovascular 
complications, as ATM deficiency can be diet-induced. 
Although lipids serve as the heart’s primary source of energy substrate, glucose comprises 10-
40% of the substrate consumption of the heart and during ischaemic conditions, glucose 
becomes the substrate of choice (Gertz et al., 1988; Opie and Lopaschuk, 2004; Taegtmeyer, 
2000). Cardiac performance, especially during myocardial ischaemia, will thus be compromised 
if glucose metabolism is dysfunctional. The established role that ATM plays in insulin signalling 
and glucose uptake, suggests that a deficiency in ATM could exacerbate cell death and cardiac 
dysfunction. Although there is, to our knowledge, no published material available regarding 
myocardial substrate metabolism during the ATM-deficient state, it appears as if the cardiac 
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effects of obesity such as hypertrophy and fibroses are also observed in the ATM-deficient state 
(Eguchi et al., 2008; Foster et al., 2011). 
It is known that ATM is expressed in the heart and that stimulation of the β-adrenergic receptors 
increases ATM expression up to 2.5 fold (Foster et al., 2011). It has been suggested that this 
effect is mediated by AP-1 due to the fact that the ATM promotor area contains a fat specific 
element that is a modified AP-1 site (Ghee et al., 1998; Gueven et al., 2003). Acute β-
adrenergic receptor stimulation is beneficial for the heart, but chronic β-adrenergic receptor 
stimulation is harmful as it can lead to cardiac remodelling and apoptosis of cardiomyocytes 
(Shizukuda et al., 1998). ATM was found to be protective against chronic β-adrenergic receptor 
stimulation-induced cardiomyocyte apoptosis and cardiac remodelling in ATM haploinsufficient 
mice. The ATM deficient mice had increased cardiac hypertrophy, fibrosis and more myocyte 
apoptosis than mice with normal ATM levels, irrespective of β-adrenergic receptor stimulation 
(Figure 2.6) (Foster et al., 2011). A role for MMPs was suggested in the development of fibrosis 
as MMP-2 expression was upregulated and decreased TIMP-2 levels were seen in ATM 
deficient hearts that were treated with isoproterenol (Foster et al., 2011; Foster et al., 2012). 
When dysregulated, the proteolytic MMPs can contribute to myocardial extracellular remodelling 
as they are responsible for the degradation of the extracellular matrix (Spinale, 2002). 
Irrespective of whether ATM is present or absent, chronic β-adrenergic receptor stimulation 
results in apoptosis of cardiomyocytes. However, the choice of signalling network that 
contributes to apoptosis is dependent on whether or not ATM is present (Foster et al., 2012). A 
mechanism involving p53 and JNK is followed in wild-type hearts, while ATM deficiency results 
in reduced PKB/Akt activity and this caused the apoptosis in hearts in which ATM was deficient 
(Figure 2.6). Following myocardial infarction, ATM has been implicated in the modulation of 
cardiac remodelling. Infarcts were larger seven days post infarction in ATM-deficient mice 
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compared to controls and the larger infarcts were associated with an increase in apoptosis as 
well as fibrosis (Foster et al., 2013). 
2.4.3 Drugs used to manipulate ATM 
Homozygous ATM deficient animal models are difficult to use in studies as they develop lethal 
lymphomas at a very young age. While some investigators opt to use heterozygous ATM 
animals, another option is to use pharmaceutical agents to manipulate ATM. Pharmaceutical 
agents also make it possible to manipulate ATM transiently or at a certain time point rather than 
having a rigid ATM-deficient state as in knockout models. Agents known to activate ATM are 
insulin, metformin and chloroquine. Wortmannin, caffeine, CP466722, KU-55933 and KU-60019 
act as ATM inhibitors. Agents relevant to the current study are discussed below. Insulin has 
been omitted here as it has been extensively discussed in the previous sections. 
Chloroquine 
Chloroquine was initially developed to be used as an antimalarial drug (Slater, 1993). In many 
areas, the Plasmodium parasites responsible for malaria have, however, become resistant to 
chloroquine treatment (Sidhu et al., 2002). Other uses for chloroquine have also emerged which 
include the treatment of rheumatic diseases and for the treatment of viral infections (Freedman 
and Steinberg, 1960; Savarino et al., 2003). Long term use of chloroquine has, however, been 
shown to have toxic effects, particularly in the eyes and heart (Fragasso et al., 2009; 
Michaelides et al., 2011). It has been shown that chloroquine is capable of increasing 
autophosphorylation of serine 1981 and in doing so, activation of ATM is increased up to 2.5-
fold (Bakkenist and Kastan, 2003; Lim et al., 2012). The chloroquine-mediated activation of 
ATM is not mediated by the induction of DNA breaks, but rather by causing changes in the 
structure of chromatin (Bakkenist and Kastan, 2003). As mentioned in section 2.5.2, 
chloroquine-mediated activation of ATM has also been shown to improve metabolic and 
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vascular complications that are caused by reduced ATM levels and that this effect is possibly 
mediated by p53 (Razani et al., 2010; Schneider et al., 2006). 
Wortmannin 
Wortmannin is described as a potent and specific inhibitor of members of the PI3K family. The 
inhibition is covalent, and thus, irreversible, and non-competitive with regards to ATP. The 
degree of PI3K inhibition was shown to be directly proportional to the time of incubation with 
wortmannin as well as the concentration of wortmannin (Powis et al., 1994). As a PI3K is one of 
the first proteins in the insulin signalling cascade, its inhibition will block almost all of the insulin-
stimulated processes such as glucose uptake, protein translation and apoptosis (Figure 2.2). 
Other members of the PI3K family that have been shown to be inhibited by wortmannin when 
used at higher concentrations include DNA-PK as well as ATM (Chan et al., 2000; Sarkaria et 
al., 1998). However, the use of wortmannin to inhibit ATM is not ideal in in vivo studies as it is 
not specific for ATM (Rainey et al., 2008). 
KU-55933 
KU-55933 is an ATP-competitive and ATM-specific inhibitor with an in vitro IC50 of 13 nM and a 
Ki of 2.2 nM (Hickson et al., 2004). At a concentration of 10 μM, KU-55933 was unable to inhibit 
any other kinases in a screen that included 60 kinases and the IC50 for ATM was found to be 
more than 100-fold lower than the IC50-values for other members of the PIKK family such as 
DNA-PK, PI3K, ATR, PI4K or mTOR (Hickson et al., 2004). ATM inhibition by KU-55933 is 
maintained for at least eight hours in tissue culture and the inhibition is reversed once KU-55933 
is removed (Hickson et al., 2004; Rainey et al., 2008). A number of different effects have been 
attributed to the use of KU-55933 to inhibit ATM. As was the case with CP466722, KU-55933 
did not inhibit the activation of PKB/Akt in response to IGF-I treatment following serum 
starvation (Rainey et al., 2008). In contrast, when used at high concentrations, KU-55933 was 
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able to inhibit PKB/Akt phosphorylation at serine 473 and threonine 308 in response to both 
insulin and IGF-I in cancer cells that had abnormal PKB/Akt activity (Li and Yang, 2010). The 
authors found a strong correlation between the degree of PKB/Akt activity and the 
antiproliferative effect of KU-55933 as a bigger effect was observed in cancer cell lines with high 
basal activity of PKB/Akt (Li and Yang, 2010). KU-55933 was not able to reduce the expression 
levels of total ATM, but inhibition of ATM activation reduced growth and had an antiproliferative 
effect in cell cultures (Zakikhani et al., 2012). Zakikhani et al. (2012) further showed that the use 
of KU-55933 resulted in a significantly reduced number of living cells, decreased respiration and 
ATP levels, increased AMPK activation, increased production of lactate and glucose 
consumption and a larger number of necrotic and apoptotic cells compared to untreated 
controls. It is interesting to note that similar effects were observed with the use of metformin. In 
MCF-7 and Hela cells, KU-55933 treatment reduced SCO2 levels, a protein required for the 
assembly of cytochrome c oxidase. However, this effect appears to be tissue specific as the 
same effect was not observed in HepG2 cells (Zakikhani et al., 2012). 
KU-60019 
KU-60019 was developed as an improvement on KU-55933 as the two substances share most 
of the structural, pharmacological and biological effects (Figure 2.8) (Golding et al., 2009). 
Although KU-60019 is also reversible (Golding et al., 2012), it is more water-soluble and more 
potent than KU-55933 as the IC50-value for ATM is almost half that of KU-55933, at 6.3 nM. 
When used at 1 μM, KU-60019 had very few to no non-specific targets when screened against 
229 other protein kinases, however, PI3K was inhibited to some degree (i.e. p110β/p85α 9%, 
p120γ 3% and p110δ/p85α 27%). 
KU-60019 was able to block ionizing radiation-induced phosphorylation of PKB/Akt and also 
reduced basal PKB/Akt phosphorylation levels in unirradiated cells by up to 70% (Golding et al., 
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2009). This suggests that the effect of KU-60019 on PKB/Akt activation levels is not dependent 
on DNA damage. Dephosphorylation of PKB/Akt at serine 473 was noted as early as five 
minutes after the drug was added. In response to the decreased phosphorylation of PKB/Akt, 
decreased phosphorylation of BAD and GSK-3β was also observed. The ATM recognition site 
(S/TQ motif) is not present in PKB/Akt, which indicates that ATM is not responsible for direct 
phosphorylation of PKB/Akt. The use of okadaic acid, which is known to inhibit phosphatases, 
blocked the KU-60019-dependent decrease in PKB/Akt phosphorylation (Garcia et al., 2002; 
Golding et al., 2009). This is indicative of ATM regulating an okadaic acid sensitive phosphatase 
which dephosphorylates PKB/Akt, however, the identity of the phosphatase is still unknown. KU-
60019 reduced basal and radiation- and insulin-induced phosphorylation of PKB/Akt. Golding et 
al. (2012) were able to observe reduced phosphorylation of p53 at its ATM-specific 
phosphorylation site at a KU-60019 dose as low as 10 nM in serum-free conditions. In light of 
this, they propose that KU-60019 is more effective in serum-free conditions as their results 
suggested that the bioavailability of KU-60019 is reduced by serum. 
 
Figure 2.8: The chemical structures of three ATM inhibitors. A. 2-morpholin-4-yl-6-thianthren-1-yl-pyran-
4-one (KU-55933; Hickson et al., 2004) C. 2-((2R, 6S)-2, 6-Dimethyl-morpholin-4-yl)-N-[5-(6-morholin-4-
yl-4-oxo-4H-pyran-2-yl)-9H-thioxanthen-2-yl]-acetamide (KU-60019; Golding et al., 2009). 
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Chapter 3: Materials and Methods 
In order to investigate the role of ATM in the myocardial pathology associated with insulin 
resistance, we firstly needed to induce insulin resistance in an animal model. We made use of 
special diets to induce insulin resistance in a rat model and used different perfusion techniques 
and Western blotting to determine the effects of ATM on cardiac function and various 
intracellular signalling networks. 
3.1 Animal Models 
This study was approved by the Research Ethics Committee: Animal Care and Use (Protocol 
number SU-ACUM12-00040) and complied with the accepted standards for the use of animals 
in research as stipulated in the South African National Standards 10386: 2008. 
Age and weight matched adult male Wistar rats were used in all animal experiments, unless 
otherwise stated. All animals had free access to food and water and were housed at the Central 
Research Facility of Stellenbosch University in a temperature controlled (± 23°C) room with a 
12-hour light/dark cycle. Once the rats reached a weight of 190±10 g, they were randomly 
allocated to control or diet groups. We made use of two different diets. For the first, termed the 
diet induced obesity (DIO) diet, the rats received standard rat chow supplemented with sugar 
and condensed milk to increase the carbohydrate content. For the second diet, termed HCD, 
rats received a standard rat chow diet supplemented with Holsum cooking fat (Malaysian palm 
oil) in addition to sugar and condensed milk. This diet has an increased carbohydrate and fat 
content. The protein, fat and carbohydrate compositions of the different diets are indicated in 
Table 3.1. The rats received these diets for a period of 16 weeks after which further experiments 
were performed. A total of 380 animals were used in this study: 157 age-matched controls, 159 
HCD rats, 12 DIO rats and 52 young control rats.  
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Table 3.1: Macronutrient compositions of the two different diets used compared to a control rat chow diet. 
Diet 
Energy 
(kJ/100 g) 
Total fat 
(g/100 g) 
Protein 
(%) 
Carbohydrate 
(%) 
Control 
1272 4.8 17.1          34.6 
DIO 
1173 4.6 9.4         45.8 
HCD 
1354 11.5 8.3         42.0 
 
3.1.1 The effect of the diets on basal ATM expression levels in the heart 
Following the 16 week diet feeding period, three rats from each diet group were anaesthetized 
by means of an intra-peritoneal administration of 160 mg/kg sodium pentobarbitone (Eutha-
naze, Bayer). Once the rats showed no pedal reflex in response to a foot pinch, their hearts 
were excised, the atria were swiftly removed and the ventricles immediately freeze-clamped 
using tongs pre-cooled in liquid nitrogen. In order to determine if the DIO and/or the HCD 
reduced basal ATM expression and reduced activation in the hearts, total ATM expression as 
well as phospho-ATM levels were determined using Western blotting. Total and phospho-
PKB/Akt levels were also determined. By cutting and stripping a single membrane, ATM (350 
kDa) and PKB/Akt (60 kDa), as well as the phospho-antibodies were assessed on the same 
membrane. The membrane was stained using Ponceau stain (0.1% (w/v) Ponceau S and 5% 
(v/v) glacial acetic acid; Sigma-Aldrich) and protein loading was normalised using the Ponceau 
stain against total proteins in each lane using the ImageLab software 5.0 (Bio-Rad). Please 
refer to section 3.4 (page 68) for a detailed description of the Western blotting protocol used. 
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3.1.2 Collection of biometric and metabolic data 
Body mass, blood glucose levels and visceral fat mass 
Biometric data was collected from 12 rats per diet group. Prior to being sacrificed, unfasted 
anaesthetised rats were weighed to determine their total body mass and blood glucose levels 
were determined via a tail prick using a GlucoPlusTM glucometer and disposable test strips 
(Cipla Dibcare (pty) ltd.). Once the heart was excised, the visceral fat, including the 
retroperitoneal, perirenal and epididymal fat pads, were removed and weighed. Based on the 
results obtained, the HCD animals were selected and only the HCD animals and age-matched 
control animals were used for further experimentations. 
Oral glucose tolerance test 
A subset of rats (n=15 per group) was subjected to an oral glucose tolerance test (OGTT). After 
being food-fasted overnight (± 16 hours), the rats were weighed and basal fasting blood glucose 
levels were determined using a tail prick and a handheld GlucoPlusTM glucometer. The rats 
were then anaesthetized with a low dose of sodium pentobarbitone (50 mg/kg; Eutha-naze, 
Bayer). Carotid blood was collected from anaesthetized rats in yellow BD Vacutainer® tubes 
containing gel and clot activator for serum separation. The blood was allowed to clot on ice for 
approximately 30 minutes, after which the blood was centrifuged at 3 000 rpm for 10 minutes at 
4°C. The serum was removed, aliquoted in Eppendorf tubes and stored at -80°C until needed 
for the insulin assay. 
Following blood collection, the animals were gavaged with a 50% sucrose solution at a 
concentration of 1 g/kg body mass. Blood glucose levels were measured at regular intervals (3, 
5, 10, 15, 20, 25, 30, 45, 60, 90 and 120 minutes). The animals that were subjected to the 
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OGTT were allowed to recover for at least two weeks before they were used for Langendorff 
balloon model perfusion experiments. 
Insulin assay 
In order to quantify the insulin present in the serum samples (n=6), a Rat/Mouse Insulin 
enzyme-linked immunosorbent assay (ELISA) kit (EMD Millipore Corporation) was used 
according to the manufacturer’s instructions. This is a non-radioactive quantification kit which is 
based on sandwich ELISA. Control and HCD serum samples were analysed in duplicate. An 
online ELISA analysis tool (http://www.elisaanalysis.com/) was used to calculate the insulin 
concentrations in serum samples against a dose-response reference curve of rat insulin 
standards. The homeostasis model assessment (HOMA) was used to calculate insulin 
resistance (HOMA-IR) as described by Matthews et al. (1985). Although originally developed for 
use in human subjects, the use of HOMA-IR was recently validated against the classical insulin 
tolerance test in Wistar rats (Antunes et al., 2016; Cacho et al., 2008). HOMA-IR is calculated 
as the product of fasting glucose (mmol/L) and fasting insulin (μU/mL) concentrations divided by 
22.5. 
3.2 Drug dosage experiments 
Before any further experimentation, dose-response studies had to be conducted to determine 
the correct dosage of substances, including insulin, chloroquine diphosphate salt (further 
referred to as chloroquine) and KU-60019 to elicit the desired responses (i.e. Insulin – stimulate 
glucose uptake; chloroquine – stimulate glucose uptake and ATM activation; KU-60019 – inhibit 
glucose uptake and ATM activation). A total of 52 untreated, young male Wistar rats of 
approximately 200 – 300 g body mass were used for the dose-response studies. The rats were 
anaesthetized and the hearts removed as described in section 3.1.1. 
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3.2.1 Glucose uptake studies 
Isolation of adult ventricular cardiomyocytes 
Ventricular cardiomyocytes were isolated from untreated young male Wistar rats, weighing 
approximately 200 – 300 g according to the protocol described by Huisamen et al. (2001). 
Unheparinised rats were anaesthetized with an intra-peritoneal administration of approximately 
160 mg/kg sodium pentobarbitone (Eutha-naze, Bayer), and once no pedal reflex in response to 
a foot pinch was detected, the hearts were rapidly removed and arrested in ice-cold KHB (pH 
7.4; 119 mM NaCl, 24.9 mM NaHCO3, 4.7 mM KCl, 1.2 mM KH2PO4, 0.6 mM MgSO4·7H2O, 
0.59 mM Na2SO4, 1.25 mM CaCl2·12H2O and 10 mM glucose; Merck Pty. Ltd.). 
The hearts were mounted via the aorta onto the aortic cannula of a Langendorff perfusion 
system. Throughout the perfusion, the buffers were maintained at 37°C and continuously 
gassed with 100% oxygen. Hearts were perfused with solution A, which is a calcium-free 
HEPES buffer (6 mM KCl, 1 mM Na2HPO4, 0.2 mM NaH2PO4, 1.4 mM MgSO4, 128 mM NaCl, 
10 mM HEPES, 5.5 mM D-glucose and 2 mM pyruvate; pH 7.4; Sigma-Aldrich) for five minutes 
to flush out remaining blood. Connective tissue was then digested by perfusion in a re-
circulating manner with solution B (solution A plus 0.7% fatty acid free bovine serum albumin 
(BSA; Roche) fraction V, 1.07 mg/mL type 2 collagenase (Worthington Biomedical Corporation) 
and 17.6 mM 2, 3 butanedione monoxime (Sigma-Aldrich)). At 15 and 20 minutes, CaCl2 was 
added to solution B, resulting in final concentrations of 0.1 mM and 0.2 mM respectively. After 
35-40 minutes of digestion, or once the effluent was streaming, the hearts were removed from 
the perfusion system, the atria and connective tissue removed, and the ventricles carefully 
shredded with tweezers before being incubated in a flat-bottomed flask containing solution C 
(1:1 dilution of solution A and solution B plus 0.5% fatty acid free BSA fraction V, 0.5 % BSA 
and 0.2 mM CaCl2) in a 37°C water bath with gentle agitation. After 15 minutes, the CaCl2 
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concentration was gradually increased over five one-minute intervals to concentrations of 0.4 
mM, 0.6 mM, 0.8 mM, 1 mM and finally 1.25 mM respectively. 
The isolated ventricular cardiomyocytes were filtered through a 200 μm2 nylon mesh and gently 
centrifuged at 100 rpm for three minutes at room temperature (± 23°C). The supernatant was 
aspirated, the pellet re-suspended in solution D (solution A plus 1.25 mM CaCl2 and 2% fatty 
acid free BSA fraction V) and allowed to settle into a loose pellet for five to eight minutes. 
Following this time, the supernatant, containing dead cells, was carefully aspirated and the 
loose pellet containing live cells re-suspended in fresh solution D in a flat-bottomed flask. The 
cells were allowed to recover from the isolation process by being incubated at room temperature 
(± 23°C) under 100% oxygen for one hour with gentle agitation. Following the recovery process, 
a loose pellet was once again allowed to form, the supernatant aspirated and the remaining 
living cells washed three times in solution E (6 mM KCl, 1 mM Na2HPO4, 0.2 mM NaH2PO4, 1.4 
mM MgSO4, 128 mM NaCl, 10 mM HEPES, 1.25 mM CaCl2 and 2% fatty acid free BSA fraction 
V). The cells were gently centrifuged at 100 rpm for three minutes at room temperature (± 23°C) 
between washes and finally re-suspended in solution E before being used in the 2-deoxy-D-
[3H]glucose (2-DG) uptake assays. 
2-Deoxy-D-[3H] glucose uptake assay 
The ventricular cardiomyocytes were treated with different concentrations of insulin (1/10/100 
nM), chloroquine (10/50/100 μM) or KU-60019 (1.5/3/6 μM) and subjected to glucose uptake 
experiments immediately following isolation. The solution E/cardiomyocyte cell suspension, 
containing approximately 0.5 mg protein, was added to flat-bottomed tubes along with solution E 
to reach a final volume of 750 μL. Tubes were prepared to have a negative control set (which 
only contained solution E, cardiomyocytes and 2-DG), a phloretin-only set and three different 
drug concentrations. Each of these sets was prepared in duplicate. The GLUT inhibitor, 
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phloretin (Sigma-Aldrich), was added to the phloretin-only samples at a final concentration of 
400 μM in order to determine the basal or GLUT-independent glucose uptake.  
The samples were oxygenated and subjected to different protocols, depending on the drug 
used. Figure 3.1 depicts the treatment protocols followed for insulin, chloroquine (Sigma-
Aldrich) and KU-60019 (Selleckchem.com). The samples were incubated in a shaking water 
bath, set to 37°C, for the entire assay. At the start of the assay, the samples were equilibrated in 
the water bath for five minutes followed by the addition of the drugs as indicated in Figure 3.1. 
After the samples were treated with the different drugs, radio-labelled 2-DG (1.5 μCi/mL; Perkin 
Elmer, Boston, USA), at a final concentration of 1.8 μM, was added to initiate glucose uptake. 
Glucose uptake continued for 30 minutes until the reaction was stopped by the addition of 400 
μM phloretin to all tubes except the phloretin only set (which received phloretin at the start of the 
assay). The samples were centrifuged at 14 500 rpm for 90 seconds to collect the pellets, the 
supernatant was discarded, and the pellets were washed twice with solution A. Finally, the 
pellets were completely dissolved in 500 μL of 1 N NaOH for approximately 30 minutes in a 
60°C water bath. After the pellet was completely dissolved, distilled H2O was added to bring the 
NaOH concentration to 0.5 N. An aliquot of these samples was then quantified using scintillation 
counting and the protein concentration in each sample was determined using the Lowry method 
(Lowry et al., 1951). 
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Figure 3.1: Protocols used for the glucose uptake assay in response to different concentrations of A) 
insulin (n=6) B) Chloroquine (n=3) and C) KU-60019 (n=4). 2-DG 2-deoxy-D-[3H]glucose 
Lowry protein determination 
The Lowry method (Lowry et al., 1951) was used to determine the protein concentrations in 
each of the samples. Fifty μL of sample was used in the assay as well as 50 μL of three BSA 
protein standards with known protein concentrations (namely 0.161 mg/mL, 0.322 mg/mL and 
0.644 mg/mL). Each of the samples and standards were assayed in triplicate and a blank 
containing 0.5 N NaOH and no protein was also included in the assay. Starting with the blank, 
followed by the protein standards and samples, 1 mL of freshly prepared reaction buffer (1.96% 
Na2CO3, 0.01% CuSO4·5H2O and 0.02% Na-K-Tartrate) was added to each tube in 10 second 
intervals. After each addition of reaction buffer, the tubes were rapidly vortexed. The reaction 
was allowed to proceed for a total duration of 10 minutes after which 100 μL of folin ciocalteu’s 
phenol reagent, diluted 1:2 with distilled H2O, was added to each tube, again in 10 second time 
intervals and vortexing after each addition. The reaction was incubated at room temperature (± 
23°C) for 30 minutes to allow for colour development and the optical density was measured at 
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750 nm. The known concentrations of the BSA standards were used to prepare a standard 
curve from which the unknown protein concentrations of the samples were determined. 
Quantification of glucose uptake 
Approximately 3 μL scintillation fluid and 100 μL of sample dissolved in 0.5 N NaOH was added 
to each scintillation vial (this was done in duplicate for each sample). A vial containing only 
scintillation fluid and another containing scintillation fluid and 25 μL of 1.5 μCi/mL 2-DG was 
also prepared as blank and total counts respectively. All vials were left in the dark at room 
temperature (± 23°C) overnight (± 16 hours) to stabilize before being counted in an LS 6500 
multi-purpose scintillation counter (Beckman) to determine the disintegrations per minute. 
Uptake of 2-DG was calculated as pmol 2-DG/mg protein/30 minutes. 
3.2.2 Propidium iodide assays to determine cell viability 
Propidium iodide (PI; BioLegend) staining was used to assess cell viability following treatment of 
isolated cardiomyocytes with KU-60019 (n=2 per group) or chloroquine (n=2 per group). The 
membranes of viable cells are impermeable to PI, which is a nucleic acid intercalating agent. 
Once PI is bound to the DNA of compromised cells, the resultant increased fluorescence can be 
detected using flow cytometry. 
Cardiomyocytes were prepared as explained in section 3.4.1. For the assay, cell aliquots 
suspended in 500 μL HEPES buffer (6 mM KCl, 1 mM Na2HPO4, 0.2 mM NaH2PO4, 1.4 mM 
MgSO4, 128 mM NaCl, 10 mM HEPES) were stabilized for five minutes in a shaking water bath 
at 37°C. The cells were then treated with 0.03% DMSO (vehicle control) and 3 μM KU-60019 for 
the KU study or with 10, 50 and 100 μM chloroquine for the chloroquine study for 45 minutes. 
Duplicate samples were prepared for each condition. The samples were centrifuged to collect 
the pellets, the cells were re-suspended in fresh HEPES buffer and 5 μM PI was added to each 
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sample. The samples were incubated in the dark at room temperature (± 23°C) for 15 minutes 
to allow for the uptake of PI by compromised cells before fluorescence was measured using 
flow channel two of a Becton Dickinson FACSCalibur (BD Biosciences). Twenty thousand 
events were acquired per condition. 
3.2.3 Langendorff perfusions 
Langendorff perfusions were conducted in order to observe the effect of increasing 
concentrations of KU-60019 and chloroquine on the hearts. The balloon model was used to 
assess cardiac function during the chloroquine perfusions. Cardiac function was not assessed 
during KU-60019 perfusions as these perfusions were performed in the Langendorff mode on a 
working heart perfusion rig and functional assessments were thus not possible. Hearts were 
stabilised for 30 minutes after which they were treated with increasing chloroquine or KU-60019 
concentrations. KU-60019 treatment was followed by insulin stimulation to determine which KU-
60019 concentrations were able to inhibit the effect of insulin stimulation. The protocols used for 
perfusions are depicted in Figure 3.2. Seven hearts were perfused in each group for the 
chloroquine study, while only two hearts were perfused in each group for the KU study due to 
time constraints and a limited number of rats being available. Please refer to section 3.3 (page 
64) for a detailed description of the Langendorff perfusion technique. Following the perfusion 
protocols, the hearts were freeze-clamped and stored at -80°C until they were used in Western 
blot analysis to determine the effect of the drugs used on total ATM expression and ATM 
phosphorylation. Please refer to section 3.4 (page 68) for a detailed description of the Western 
blot technique. 
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Figure 3.2: Protocols followed for Langendorff dosage perfusions. A) KU-60019 (n=2 per group) B) 
Chloroquine (n=7 per group except 50 μM Chloroquine n=4). 
3.3 Langendorff perfusions  
The hearts were cannulated via the aorta and perfused retrogradely with KHB gassed with 95% 
O2 and 5% CO2 and with a constant hydrostatic pressure of 100 cm H2O. The perfusion buffer 
was warmed by circulating water heated by a water bath through the double-walled glassware in 
order to maintain the myocardial temperature at approximately 36.5 – 37°C. The temperature of 
the heart was continuously monitored with the use of a temperature probe inserted into the 
coronary sinus. 
3.3.1 The balloon model 
The balloon model allows for pressure data collection during drug administration in the 
Langendorff mode. The balloon model was thus utilised as we were interested in determining 
the effect of pharmacological agents on the heart as they were administered. Furthermore, 
Langendorff perfused hearts were subjected to global ischaemia as the balloon model enabled 
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the determination of time to onset of contracture and peak developed pressure during global 
ischaemia. A syringe inflatable balloon constructed from plastic clingwrap was inserted via the 
pulmonary vein, through the left atrium and into the left ventricle (Figure 3.3). The balloon was 
inflated with water to achieve a diastolic blood pressure (DP) of approximately 10 mm Hg. The 
balloon is connected to a pressure transducer which enabled the measurement of myocardial 
function. Heart rate, as beats per minute (BPM), SP and DP were measured and the Gentronics 
chart recorder v1.00 software calculated the left ventricular developed pressure (LVDevP: DP 
subtracted from the SP) and the rate pressure product (RPP; LVDevP multiplied with BPM). 
Additional measurements collected at regular intervals during experiments included myocardial 
temperature and CF. 
 
Figure 3.3: Illustration of the inflatable balloon inserted into the left ventricle of a cannulated heart. 
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3.3.2 Perfusion protocol 
Hearts were stabilised for 20 minutes before treatment commenced. The hearts were treated 
with DMSO (0.033%, vehicle control) insulin (1 U/L), wortmannin (100 nM), insulin and 
wortmannin combination, KU-60019 (3 μM) and an insulin and KU-60019 combination. The 
wortmannin concentration was previously optimised and used in our laboratory (Huisamen et 
al., 2008). Five hearts were perfused per treatment group (The HCD Insulin group, 10 minutes 
reperfusion had n=4). All treatments were administered in a recirculating manner. For the 
untreated control group, KHB was recirculated for the duration of the treatment period. 
Following the 20 minute treatment period, hearts were subjected to 20 minutes of global 
ischaemia by stopping all perfusion to the hearts, which prevented delivery of substrates and 
oxygen. The time to onset of contracture and peak developed pressure during global ischaemia 
was noted. Hearts were reperfused for either five or ten minutes, after which they were freeze-
clamped and stored at -80°C for Western blot analysis. Only the hearts that were reperfused for 
10 minutes were used for Western blot analysis as previous work in our laboratory has shown 
that this is the best time to determine differences in protein expression and activation. The 
hearts reperfused for five minutes remain in storage for future Western blot analysis. Figure 3.4 
(page 67) is a schematic representation of the protocol followed for the Langendorff perfusions 
using the balloon model. Due to an unavoidable delay in the commencement of perfusion 
studies, animals used for the 10 minute reperfusion group were on the diet longer 
(approximately 25 weeks). Cardiac function was, however, comparable in animals that were on 
the diet for 16 and 25 weeks so the data was pooled. 
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Figure 3.4: Schematic representation of the protocol followed for Langendorff perfusions using the 
balloon model and the treatment groups used for global ischaemia studies. Hearts were either freeze-
clamped following five or ten minutes of reperfusion. (n=5 per group) Ins: insulin, KHB: Krebs-Henseleit 
buffer, KU: KU-60019, Wm: wortmannin. 
3.3.3 Basal effect of ATM manipulation on signalling networks 
In order to determine the effect of ATM manipulation on signalling networks in the absence of 
IRI, additional Langendorff perfusion experiments were conducted. In these experiments, hearts 
were stabilised for 20 minutes, after which they were treated with insulin (1 U/L), KU-60019 (3 
μM) and an insulin and KU-60019 combination over 20 minutes. Three hearts were perfused per 
treatment group. The hearts were then freeze-clamped and Western blot analysis conducted to 
determine the expression and activation levels of proteins indicated in Table 3.2. The perfusion 
protocol used is indicated in Figure 3.5 and the Western blot technique used is described in 
section 3.4. 
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Figure 3.5: Schematic representation of the protocol followed for Langendorff perfusions using the 
balloon model and the treatment groups used to determine the basal effect of ATM manipulation. (n=3 per 
group) Ins: insulin, KHB: Krebs-Henseleit buffer, KU: KU-60019. 
3.4 Western blotting 
3.4.1 Preparing lysates from freeze-clamped heart tissue 
All steps for lysate preparation took place on ice. Approximately 0.1 g of freeze-clamped heart 
tissue was pulverised and homogenised in 700 μL lysis buffer in order to extract protein from the 
tissue. The lysis buffer consisted of the following components: 20 mM Tris-HCl (pH 7.5), 1 mM 
EGTA, 1 mM EDTA, 150 mM NaCl, 1 mM β-glycerophospate, 2.5 mM tetra sodium 
pyrophosphate, 10 mM sodium orthovanadate, 1% Triton X-100, 10 μg / mL leupeptin, 10 μg / 
mL aprotinin and 50 μg / mL PMSF. The heart tissue was pulverised for two cycles of four 
seconds each at 20 000 rpm using a Heidolph SilentCrusher-M homogeniser. The lysates were 
allowed to stand on ice for 15 to 30 minutes after which they were centrifuged at 15 000 rpm for 
20 minutes at 4°C to remove the cell debris. The protein-containing supernatant was collected 
and total protein concentrations were determined using the Bradford method (Bradford, 1976). 
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3.4.2 Bradford protein determination 
The Bradford protein determination method (Bradford, 1976) was used to determine the protein 
concentrations in the prepared lysates. The lysates were diluted 1:9 with distilled water and 5 μL 
of the diluted lysates was assayed. A standard curve, using known protein concentrations of 
BSA was also prepared. A volume of 900 μL of Bradford solution (120 μM coomassie brilliant 
blue G-250, 4.75% (v/v) ethanol, 8.5% (v/v) phosphoric acid) that has been filtered twice, was 
added to each sample. The samples were incubated for 15 minutes on the bench to allow for 
colour development, after which the absorbance was read at 595 nm using a Spectronic® 20 
GenesysTM spectrophotometer. Each lysate and protein standard was assayed in duplicate and 
the standard curve was used to determine the protein concentration in each lysate.  
Based on the determined protein concentrations, the lysates were diluted with lysis buffer so 
that the final lysates each contained 50 μg of protein per 15 μL. A 3X Laemmli sample buffer 
(2.5 M glycerol, 0.189 M Tris-HCl (pH 6.8), 10.1% SDS, 1.275 mM bromophenol blue, 15% β-
mercaptoethanol) was added to each lysate in a 1:2 ratio. The final lysates were incubated in 
boiling water (100°C) for five minutes in order to denature proteins and stored at -80°C. 
3.4.3 SDS-Polyacrylamide gel electrophoresis protein separation and transfer 
Before being loaded in SDS-polyacrylamide gels to separate the proteins in terms of size, the 
lysates were once again incubated in boiling water (100°C) for five minutes to denature proteins. 
Lysates used to probe for GLUT4 were never incubated in boiling water as hydrophobic 
membrane proteins such as GLUT4 form aggregates at high temperatures, prohibiting them 
from entering the gel. Equal amounts of protein (50 ng) were loaded and separated using SDS-
polyacrylamide gels. TGX Stain-FreeTM FastCastTM Acrylamide Kits (10% and 12%) (BioRad) 
and 4-15% Mini-PROTEAN® TGX Stain-FreeTM Precast Gels (Bio-Rad) were used to separate 
the proteins. Protein markers used were the PageRulerTm Prestained Protein Ladder (Thermo 
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Scientific) and HiMarkTM Pre-stained Protein Standard (Novex by Life Technologies). The 
running buffer contained the following: 25 mM Tris, 192 mM glycine and 0.1% (w/v) SDS. The 
gels were electrophoresed at 200 mA and 200 V for an hour (gradient gels: 1h30) using the Mini 
Trans-Blot® Cell system from Bio-Rad, after which the gels were Stain-Free activated for one 
minute and imaged using the ChemiDoc MP system and ImageLab software 5.0 (Bio-Rad). 
After separation and gel activation, proteins were transferred to polyvinylidene fluoride 
membranes (Immobilon®-P, Millipore) at 200 mA and 200 V for one hour (gradient gels: 1h30). 
The transfer buffer contained 25 mM Tris, 192 mM glycine and 20% (v/v) methanol (transfer 
buffer for gradient gels contained only 10% (v/v) methanol). After the transfer was completed, 
the membranes were imaged using the ChemiDoc MP system and ImageLab software 5.0 (Bio-
Rad) in order to do whole lane protein normalisation to correct for any unequal loading. 
3.4.4 Membrane blocking, antibody incubation and immunodetection 
Non-specific binding sites were blocked for one to two hours using 5% (w/v) fat-free milk made 
up in Tris-buffered saline-Tween-20 (TBST) buffer (20 mM Tris-HCl (pH 7.6), 137 mM NaCl, 
0.1% Tween-20). Membranes were then washed thoroughly with TBST for three cycles of 10 
minutes on a shaker and incubated overnight (± 16 hours) under constant agitation with primary 
antibodies at 4°C. Primary antibodies used are indicated in Table 3.2. All primary antibodies 
were acquired from Cell Signaling Technology and all primary antibodies used, except GLUT4, 
were raised in rabbit. GLUT4 was raised in mice. The following day the membranes were 
washed to remove any unbound primary antibody using TBST (three cycles of 10 minutes on a 
shaker) and incubated with the appropriate horseradish peroxidise-conjugated secondary 
antibody (either Anti-rabbit or Anti-mouse IgG HRP-linked antibody, Cell Signaling Technology) 
at room temperature (± 23°C) for one hour. Unbound secondary antibody was washed away 
using TBST (three cycles of 10 minutes). 
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In order to visualise the proteins of interest, a chemiluminescent detection system was 
employed. The membranes were incubated in ClarityTM Western ECL Blotting Substrate (Bio-
Rad) for five minutes after which the membranes were exposed using the “Chemi” or “Chemi 
High Sensitivity” settings as needed of the ChemiDoc MP system (Bio-Rad). Antibodies that 
required exposure times longer than 15 minutes due to low sensitivity were exposed on 
autoradiography film in the dark room. 
Membranes were always probed with total protein antibodies first, then stripped and probed with 
the phospho-protein antibodies. The stripping protocol was as follows: Two cycles of five 
minutes each in distilled water, seven minutes in 0.2 M NaOH, and two cycles of five minutes 
each in distilled water. All steps took place at room temperature (± 23°C) and with gentle 
agitation on a shaker. 
3.4.5 Western blot data analysis 
The ImageLab Software (version 5.0) was used to quantify and analyse the bands of interest. 
Signal intensities of the relevant protein bands (detected using chemiluminescence) as well as 
total protein stain-free fluorescence was determined using the “Lane and Bands” function of the 
ImageLab software. In order to correct for any unequal loading and/or transferring, the blots 
were normalised against total protein in lanes using the “Normalization” function of the software 
(Gürtler et al., 2013). The “Normalization” function determines the total protein present in each 
lane (as opposed to a single house keeping protein) and calculates a normalization factor based 
on the total protein present in each lane relative to the first lane. A lane with less protein 
loaded/transferred will have a higher normalization factor and a lane with more protein 
loaded/transferred will have a lower normalization factor. Unequal loading/transferring is 
corrected by multiplying the chemiluminescence signal intensities by the normalization factor for 
each lane. 
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Table 3.2: Specifications for antibodies used in Western blot analysis. 
Protein of 
interest 
Phosphorylation 
site 
Molecular 
weight 
Gel used 
Primary AB 
dilution 
Secondary AB 
dilution 
T+P ACC Ser79 280 kDa 4-15% 1:1000 in TBST 1:4000 in TBST 
T+P AMPK Thr172 62 kDa 4-15% 1:1000 in TBST 
1:4000 in 
TBST/2.5% milk 
T AS160  160 kDa 10% 1:1000 in TBST 1:4000 in TBST 
P AS160 Thr642 160 kDa 10% 1:1000 in TBST 
1:4000 in 
TBST/2.5% milk 
T+P ATM Ser1981 350 kDa 4-15% 
1:667 in 
SignalBoost* 
1:2500 in 
SignalBoost* 
T GLUT4 N/A 45 kDa 12% 
1:1000 in 
SignalBoost* 
1:4000 in 
TBST/2.5% milk 
T+P GSK-3β Ser9 46 kDa 12% 1:1000 in TBST 1:4000 in TBST 
T+P IRS-1 Ser307 180 kDa 10% 
1:1000 in 
SignalBoost* 
1:4000 in 
SignalBoost* 
T+P JNK Thr183/Tyr185 47 kDa 10% 1:1000 in TBST 1:4000 in TBST 
T+P mTOR Ser2448 289 kDa 4-15% 1:1000 in TBST 1:4000 in TBST 
T PI3K  85 kDa 4-15% 1:1000 in TBST 1:4000 in TBST 
P PI3K Tyr458 85 kDa 4-15% 1:1000 in TBST 
1:4000 in 
TBST/2.5% milk 
T+P 
PKB/Akt 
Ser473 60 kDa 12% 1:1000 in TBST 1:4000 in TBST 
T+P PTEN Ser380/Thr382/383 54 kDa 10% 1:1000 in TBST 1:4000 in TBST 
* SignalBoost
TM
 Immunoreaction Enhancer Kit (Calbiochem
®
) 
T Total; P Phospho- 
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3.5 Ex vivo working heart perfusions 
3.5.1 Perfusion protocol 
Excised hearts were arrested in ice-cold KHB (~4°C) and subsequently mounted on a Morgan 
working heart perfusion system as quickly as possible by cannulation of both the aorta and 
pulmonary veins. Immediately, once securely cannulated, the hearts were retrogradely perfused 
with filtered KHB, continuously gassed with 95% O2 and 5% CO2 and warmed to maintain 
physiological temperatures. The Langendorff perfusion occurred at a constant hydrostatic 
pressure of 100 cm H2O and the buffer was not circulated. This initial Langendorff perfusion 
step of 15 minutes was used to wash remaining blood from the heart and to stabilise the heart. 
Myocardial temperature, as measured by a temperature probe inserted into the coronary sinus, 
was continually monitored and maintained at 36.5–37°C. Coronary flow was measured regularly 
during all phases of the experiment. 
The perfusion mode was switched to the working heart mode in which the perfusate enters the 
left atrium via the cannulated pulmonary veins. The beating heart then ejects the perfusate from 
the left ventricle through the aorta, working with a preload of 15 cm H2O and against an 
afterload of 100 cm H2O. During the working heart mode, the myocardial mechanical function 
prior to ischaemia was determined by measuring aortic output (AO), heart rate, SP and DP and 
by calculating total work performed by the heart. A pressure transducer, connected to the aortic 
line, was used to determine the pressure measurements. Aortic output was measured manually 
by measuring the amount of fluid ejected by the aorta over a minute time period. 
In order to treat the hearts with different drugs and drug combinations, the perfusion mode was 
switched back to the Langendorff mode. In addition to an untreated control group, the hearts 
were treated with insulin (1 U/L), wortmannin (100 nM), insulin plus wortmannin combination, 
Stellenbosch University  https://scholar.sun.ac.za
74 
 
KU-60019 (3 μM) and an insulin plus KU-60019 combination. DMSO was used to dissolve the 
KU-60019. In order to compensate for any effect of the vehicle, an equal concentration of 
DMSO (0.033%) was added to each of the other treatment groups at the same time point when 
KU-60019 was added. All the drugs were administered in a re-circulating manner. Figure 3.6 
depicts the protocols used for working heart perfusions. Hearts from animals on the control diet 
and the HCD were perfused and six to eight hearts were perfused per treatment group. 
Immediately following the treatment period, the left anterior descending coronary artery was 
temporarily ligated using a silk suture (Ethicon®) to induce regional ischaemia. Care was given 
to consistently ligate the same area in all hearts. Myocardial temperature was closely monitored 
and maintained at 36.5°C during the ischaemic period by submerging the heart in warmed KHB. 
Regional ischaemia lasted for 35 minutes, after which the suture was released and the heart 
was reperfused in the Langendorff mode for 10 minutes. 
In order to determine the degree of recovery in myocardial mechanical function following 
ischaemia, the hearts were again switched to the working heart perfusion mode for 20 minutes. 
Mechanical function parameters were noted (AO, BPM, SP, DP and total work). Another 30 
minutes of reperfusion in the Langendorff mode was performed after which the hearts were 
stained for infarct determination. 
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Figure 3.6: Schematic representation of the protocol followed for the working heart perfusions and 
treatment groups used. (n=6-8 per group) Ins: insulin, KU: KU-60019, L: Langendorff perfusion mode, W: 
Working heart perfusion mode, Wm: wortmannin 
3.5.2 Staining of the heart and infarct determination 
Following a total reperfusion time of 60 minutes, the left anterior descending coronary artery 
was once again ligated and the heart was stained with 0.2% Evans blue (Sigma-Aldrich) dye via 
the aorta. This was done to determine the viable area that was not affected by ischaemia as the 
dye only stains the viable tissue. The hearts were then frozen at -20°C before the IFS was 
determined. 
Visualisation of the area at risk (AAR) and IFS was achieved by triphenyl tetrazolium chloride 
(TTC) staining. The frozen hearts were evenly sliced into approximately 2 mm thick disks from 
the ligation point to the apex of the heart using a scalpel. The heart disks were incubated at 
room temperature (± 23°C) in TTC staining solution (20 mM NaH2PO42H2O, 80 mM Na2HPO4 
and 29.9 mM TTC; pH 7.4) for 30 minutes. During this incubation time, metabolically active 
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tissue (AAR) is stained red due to the reduction of TTC, while necrotic tissue (IFS) remains 
white/pale due to TTC remaining unreduced (Figure 3.7). 
In order to enhance the colour development and terminate the staining reaction, the heart slices 
were fixed in 10% formaldehyde. The total surface area of the viable tissue, AAR and IFS was 
then quantified for each heart using UTHSCSA ImageTool for Windows v3.00 (developed by 
The University of Texas Health Science Center in San Antonio). 
 
Figure 3.7: Example of a heart stained using Evans blue dye and triphenyl tetrazolium chloride staining. 
The blue area is stained with Evans blue and was not affected by occlusion of the left anterior descending 
coronary artery. This is the viable tissue. The red and white areas were subjected to regional ischaemia. 
The red-stained tissue is viable as the triphenyl tetrazolium chloride has been metabolized while the white 
tissue is necrotic. 
3.5.3 Ex vivo working heart perfusions with reduced insulin concentration 
In order to investigate the effect of a reduced insulin concentration, hearts from both control and 
HCD animals were treated with 0.3 U/L insulin and a combination of 3 μM KU-60019 and 0.3 
U/L insulin (n=3 per group). The perfusion protocol was as described in Figure 3.6 and the 
endpoint was IFS determination as described in section 3.5.2. 
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3.6 Aortic ring studies 
3.6.1 Isolation and mounting of the aortic rings 
Thoracic aortas were isolated from the same animals used for the working heart perfusion 
experiments, however, only age-matched control animals were used due to time constraints. 
Immediately once the hearts were removed, the trachea and oesophagus were also removed in 
order to expose the aorta. The portion of the aorta ranging from the aortic arch to just above the 
diaphragm (thoracic portion of the aorta) was excised and placed in ice-cold KHB in order to 
maintain the integrity of the tissue. The aorta section was cleaned of perivascular fat and 
connective tissue and cut into rings of three to four millimetres in length. One of these aorta 
rings was mounted between two stainless-steel hooks of an organ bath (AD Instruments). The 
organ bath contained KHB, continuously gassed with 95% oxygen and 5% carbon dioxide and 
warmed to 37°C. One of the stainless-steel hooks was connected to a 0 – 25 g force transducer 
(TRI202PAD, Panlab) via a silk suture in order to allow measurement of the contraction and 
relaxation of the aortic ring. LabChart7 software (Dunedin) was used to record and analyse the 
aortic ring tension data. 
3.6.2 Isometric tension protocol 
A previously described isometric tension protocol was modified to study the effect of KU-60019 
on vasodilation of aortic rings (Privett et al., 2004). Mounted aortic rings were stabilised at a 
basal isometric tension of 1.5 g for 30 minutes. During the stabilisation period, the KHB was 
replaced with fresh, pre-warmed KHB every 10 minutes. Following stabilisation, an initial 
contraction-relaxation cycle was carried out to assess the viability of the aortas before actual 
experimentation began. 
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For the viability assessment, phenylephrine (PE; 100 nM) was added to stimulate contraction of 
the smooth muscle. Once contraction reached a plateau, relaxation was induced with the 
addition of acetylcholine (ACh; 10 μM). Phenylephrine is an α1-adrenergic receptor agonist and 
causes blood vessels to constrict by selectively binding to alpha1 receptors on the smooth 
muscle. Acetylcholine causes smooth muscle to relax by activating endothelial NOS, which in 
turn produces NO. Aortic rings were deemed viable if they had a minimum relaxation of 70% of 
the maximum PE-induced contraction. Only rings that displayed more than 70% relaxation were 
included in the study. Following the viability assessment, the viable aortic rings were once again 
stabilised at 1.5 g tension for 30 minutes. During this time, the organ bath was rinsed by 
replacing the buffer with fresh, pre-warmed KHB three times, at regular intervals. 
A second round of contraction was induced in the rings through the cumulative addition of PE, 
reaching final PE concentrations of 100 nM, 300 nM, 500 nM, 800 nM and 1 μM. Subsequent 
PE additions were not dependent on time, but rather when the maximum contraction was 
achieved by the previous PE concentration. When maximum contraction of the final 
concentration (1 μM) was achieved, relaxation of the aortic rings was induced using cumulative 
concentrations of ACh (positive control; 30 nM, 100 nM, 300 nM, 1 μM and 10 μM), DMSO 
(vehicle control; 0.011%, 0.022%, 0.034%, 0.045% and 0.056%) and KU-60019 (1 μM, 2 μM, 3 
μM, 4 μM and 5 μM). In order to determine if observed ACh- and KU-60019-induced relaxation 
was dependent on endothelial NOS activation and NO release, aortic rings were also pre-
treated with L-NAME (100 μM) for 30 minutes prior to PE-induced contraction. Because L-
NAME is a NOS inhibitor, it blocks the vasodilatory effects of drugs that act by activating NOS, 
such as ACh. The relaxation-inducing capacity of each of the treatment groups was calculated 
as percentage relaxation from the maximum contraction caused by PE. Each group had an n-
value of five to seven biological replicates. Figure 3.7 illustrates the protocol followed for the 
isometric tension experiments and the treatment groups used. 
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Figure 3.7: Schematic representation of the protocol followed for isometric tension studies on 
aortic rings and the treatment groups used to achieve relaxation. (n=5-7 per group) ACh: 
acetylcholine, KHB: Krebs-Henseleit buffer, PE: phenylephrine. 
3.7 Critical Appraisal 
We made use of animals of the same sex, age and genetic background. This restriction reduces 
variability and thus reduces the need for very large sample sizes. As previously mentioned, 
animals were randomly allocated to the different diet groups. This was staggered in order to 
ensure that all animals were on the diet for the same amount of time at the time of 
experimentation (i.e. 10 age-matched control and 10 HCD animals were put on the diet each 
week so that only 20 animals were ready for perfusion each week). Individuals caring for the 
animals did not know which perfusion groups the animals would be allocated to which reduced 
the risk of performance bias. Selection bias during perfusion was avoided by randomly 
allocating animals to treatment groups each day. Perfusions were not conducted systematically 
where each treatment group was completed before the next was started. Thus, hearts that 
make up a group were isolated from animals that were put on the diet in different weeks and 
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they were perfused at different times of day in order to avoid confounding effects. Although the 
approach to assessing endpoints was objective and the same across treatment groups, there 
was a risk for detection bias as perfusions were not blinded. Infarct size determination, which 
could be more subjective, was however blinded. For Langendorff balloon model perfusions, 
hearts that were still fibrillating when measurements were taken during reperfusion were 
excluded. Hearts with basal AO values lower than 20 were excluded. For infarcts, hearts were 
excluded if the percentage viable area was not between 40-60%. 
3.8 Statistical analysis 
GraphPad Prism 5 software was used to perform statistical analysis. Results are displayed as 
mean ± standard error of the mean (SEM), unless otherwise stated. When comparing two 
groups, an unpaired Student’s t-test was utilised. When comparing more than two groups, a 
one- or two-way analysis of variance (ANOVA) with a Bonferroni post-hoc test was utilised, 
where appropriate. Differences with a p-value of smaller than 0.05 was considered significant. 
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Chapter 4: Results 
4.1 Identification of the diet to be used 
4.1.1 Determination of ATM expression levels 
Halaby et al. (2008) have shown that rats fed a high fat diet had reduced ATM expression levels 
in their skeletal muscle compared to chow-fed rats. In order to determine whether either the DIO 
or the HCD was able to reduce ATM expression, the Western blotting technique was used to 
determine basal ATM expression and activation in the hearts of animals on the diets compared 
to chow-fed control animals. Because of its central role in the insulin signalling network, 
PKB/Akt expression and activation was also determined in the two diets and compared to the 
hearts of age-matched control animals. 
The HCD, but not the DIO diet was found to significantly decrease basal cardiac ATM 
expression after 16 weeks compared to the chow-fed control animals (Control 1.00 ± 0.06; HCD 
0.33 ± 0.11; p < 0.05) (Figure 4.1 B). Although ATM activation was not affected by either diet, 
the P/T ATM ratio was significantly increased by the HCD compared to the control diet (Control 
1.00 ± 0.07; HCD 3.38 ± 1.02; p < 0.01) (Figures 4.1 C and D). Similarly, the HCD diet 
significantly decreased total PKB/Akt expression (Control 1.00 ± 0.09; HCD 0.70 ± 0.01; p < 
0.05), while PKB/Akt phosphorylation (Ser473) was unaltered compared to the control diet 
(Figures 4.1 E and F). This also resulted in an increased P/T PKB/Akt ratio (Control 1.00 ± 0.01; 
HCD 1.29 ± 0.08; p < 0.05) (Figure 4.1 G). 
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Figure 4.1: The effect of 16 week diet (DIO and HCD) compared to control diet on basal total and p-ATM 
and PKB/Akt levels in rat hearts. A) Western blot chemiluminescent results of ATM, p-ATM, PKB/Akt and 
p-PKB/Akt and Ponceau S staining of the membrane against which the chemiluminescent results were 
normalised. All antibodies were probed on the same membrane. B) Bar graph depicting analysed results 
for total ATM. C) Bar graph depicting analysed results for p-ATM (Ser1981). D) Bar graph depicting 
phospho to total ratio of ATM. E) Bar graph depicting analysed results for total PKB/Akt. F) Bar graph 
depicting analysed results for p-PKB/Akt (Ser473). G) Bar graph depicting phospho to total ratio of 
PKB/Akt. Results are indicated relative to the control diet. * p < 0.05 ** p < 0.005 (n=3 per group).  
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4.1.2 Biometric data 
After the 16-week diet feeding program, biometric data including body mass, visceral fat mass 
and non-fasting glucose levels were measured in DIO, HCD and age-matched control animals 
in order to determine the ability of the diets to induce obesity and glucose intolerance. The 
results are summarised in Table 4.1. The DIO diet increased the visceral fat mass by 81.7% 
compared to the control diet (Control 16.88 ± 1.33 g; DIO 30.74 ± 2.68 g; p < 0.0001). Body 
mass and non-fasting glucose levels were, however, unaffected by the DIO diet compared to 
the control diet. In contrast, the HCD significantly increased the body mass by 15.1% (Control 
444.4 ± 11.4 g; HCD 511.5 ± 15.19 g; p < 0.05), the visceral fat mass by 131.4% (Control 16.88 
± 1.33 g; HCD 39.13 ± 2.36 g; p < 0.0001) and the non-fasting glucose levels by 11.6% 
compared to the control diet (Control 6.9 ± 0.15 mmol/L; HCD 7.7 ± 0.28 mmol/L; p < 0.05). 
Taken together, these results suggest that the HCD model has a more pronounced effect on the 
measured parameters and is thus more successful in inducing obesity and hyperglycemia in the 
animals compared to the DIO model. We therefore conducted the rest of the experiments using 
only the HCD model. 
Table 4.1: Body mass, visceral fat mass and non-fasting glucose levels of the DIO and HCD animals 
compared to age-matched control animals following a 16-week diet feeding program. (n=12 per group) 
Parameters Control DIO HCD 
Body mass 444.4 ± 11.4 g 496.4 ± 19.3 g 511.5 ± 15.2 g (*) 
Visceral fat mass 16.9 ± 1.3 g 30.7 ± 2.7 g (***) 39.1 ± 2.4 g (***) 
Non-fasting glucose levels 6.9 ± 0.1 mmol/L 7.0 ± 0.2 mmol/L 7.7 ± 0.3 mmol/L (*) 
* p < 0.05; ** p < 0.005; *** p < 0.0001 
  
Stellenbosch University  https://scholar.sun.ac.za
84 
 
4.1.3 Further characterisation of the high caloric diet 
In order to further determine whether the HCD is able to induce insulin resistance and glucose 
intolerance in the animals, fasting glucose levels and insulin levels were determined, the 
HOMA-IR index was calculated and an OGTT was performed. The HCD animals had 
significantly increased fasting glucose levels (Control 4.6 ± 0.1 mmol/L; HCD 5.8 ± 0.2 mmol/L; 
p < 0.0001) as well as significantly higher insulin levels (Control 0.15 ± 0.004 ng/mL; HCD 0.18 
± 0.009 ng/ml; p < 0.05) compared to control animals. Furthermore, the HOMA-IR index was 
also significantly higher in the HCD animals compared to the control animals (Control 0.95 ± 
0.10; HCD 1.35 ± 0.14; p < 0.05) (Table 4.2). 
Results from the OGTT indicated that animals that received the HCD had consistently increased 
glucose levels compared to animals that were on the control diet (Figure 4.2 A) Additionally, the 
area under the curve was also significantly bigger for the HCD group compared to the control 
group (Control 652.9 ± 24.3; HCD 747.9 ± 33.2; p < 0.05) (Figure 4.2 B). Taken together, these 
results indicate that the HCD induced hyperglycemia, hyperinsulinemia and insulin resistance in 
the animals and is thus a sufficient model to be used in the study. 
Table 4.2: Characteristics of animals fed the HCD compared to the control diet. 
Parameter Control HCD 
Fasting glucose levels (n=15)+ 4.6 ± 0.1 mmol/L 5.8 ± 0.2 mmol/L (***) 
Insulin levels (n=6) + 0.15 ± 0.004 ng/mL 0.18 ± 0.009 ng/ml (*) 
HOMA-IR (n=6) + 0.95 ± 0.10 1.35 ± 0.14 (*) 
* p<0.05; *** p<0.0001 
+ 
n-values are per group 
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Figure 4.2: Results of the oral glucose tolerance test in the HCD group compared to the control group. A) 
Glucose concentrations over time (n=12-15 per time point). B) Total area under the curves in the control 
and HCD animals (n=15 per group). * p<0.05; ** p<0.005; *** p<0.0001 
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4.2 Drug dosage experiments 
4.2.1 Insulin 
Glucose uptake 
Glucose uptake experiments were done in isolated ventricular cardiomyocytes from control 
animals using insulin concentrations of 1 nM, 10 nM and 100 nM. Glucose uptake was 
significantly increased in response to 100 nM insulin compared to the untreated control 
(Untreated 1.0; 100 nM Ins 2.8 ± 0.5; p < 0.01) (Figure 4.3). This indicates that 100 nM insulin is 
sufficient to significantly stimulate glucose uptake in cardiomyocytes. 
 
Figure 4.3: Bar graph depicting the glucose uptake, relative to the untreated group, by cardiomyocytes 
after stimulation with increasing insulin concentrations (1 nM, 10 nM and 100 nM). ** p<0.01; (n=6 per 
group). 
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4.2.2 Chloroquine 
In order to determine whether chloroquine is a viable drug to use to activate cardiac ATM, a 
number of drug dose-response studies were conducted, including glucose uptake, cell viability 
assay, Langendorff perfusions to assess cardiac function and Western blot analysis.  
Glucose uptake 
Firstly, glucose uptake was measured in response to increasing chloroquine concentrations in 
isolated cardiomyocytes. None of the chloroquine concentrations used, including 10 μM, 50 μM 
and 100 μM, significantly changed glucose uptake levels compared to untreated levels (Figure 
4.4). 
 
Figure 4.4: Bar graph depicting the glucose uptake, relative to the untreated group, by cardiomyocytes 
after stimulation with increasing concentrations of chloroquine (10 μM, 50 μM and 100 μM) Chl 
Chloroquine; Ins Insulin (n=3 per group). 
  
Stellenbosch University  https://scholar.sun.ac.za
88 
 
Cell viability 
We then performed a PI assay to determine if chloroquine treatment leads to necrosis of 
isolated cardiomyocytes. Analysed chloroquine concentrations included 10 μM, 50 μM and 100 
μM. Compared to the untreated group, significantly more necrosis was measured in cells treated 
with 10 μM (115.4 ± 0.97%; p < 0.005) and 50 μM (108.1 ± 0.22%; p < 0.05) chloroquine (Figure 
4.5). This indicates that chloroquine has a cardiotoxic effect. 
 
Figure 4.5: Bar graphs showing the percentage change in propidium iodide uptake from untreated cells 
by isolated cardiomyocytes treated with increasing concentrations of chloroquine. * p < 0.05; ** p < 0.005 
Chl Chloroquine (n=2 per group). 
Langendorff perfusion and Western blotting 
Lastly, Langendorff perfusion experiments were conducted, after which the hearts were freeze-
clamped for total and phospho-ATM determination using Western blot analysis. The RPP was 
significantly reduced after 10 minutes of treatment with each of the chloroquine concentrations 
used compared to untreated controls (Figure 4.6 A). The decrease in RPP was caused by both 
a decrease in LVDevP and in heart rate, as is shown in Figures 4.6 B and C respectively. Fifty 
percent of hearts treated with 50 μM chloroquine ceased to function within the first five minutes 
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after being perfused with chloroquine. For this reason, we omitted the highest chloroquine 
concentration, namely 100 μM, from the perfusion experiments. 
None of the chloroquine concentrations used had a significant effect on the total or 
phosphorylation (Ser1981) levels of ATM and the P/T ATM ratio was also unaffected (Figure 
4.7). 
 
Figure 4.6: Bar graphs showing cardiac function following treatment of Langendorff perfused hearts with 
0 μM (untreated), 10 μM, 30 μM and 50 μM chloroquine. A) Rate pressure product (mm Hg beats/minute). 
B) Left ventricular developed pressure (mm Hg). C) Heart rate (Beats per minute). * p < 0.05; ** p < 
0.005; *** p < 0.0001 Chl Chloroquine (n=7 per group except 50 μM Chloroquine n=4).  
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Figure 4.7: The effect of perfusion with increasing chloroquine concentrations on ATM expression and 
activation. A) Western blot chemiluminescent results of ATM, phospho ATM and stain-free total protein. 
B) Bar graph depicting analysed results for total ATM. C) Bar graph depicting analysed results for 
phospho-ATM (Ser 1981). D) Bar graph depicting phospho to total ratio of ATM. Chl Chloroquine (n=3 per 
group). 
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4.2.3 KU-60019 
Glucose uptake 
We measured glucose uptake by cardiomyocytes following treatment with insulin alone, or 
insulin in combination with increasing concentrations of KU-60019 in order to identify the best 
dosage of KU-60019. Although glucose uptake appeared to decrease slightly with increasing 
concentrations of KU-60019, the change in glucose uptake was not significant (Figure 4.8). 
 
Figure 4.8: Bar graph depicting the glucose uptake, relative to the untreated group, by cardiomyocytes 
after stimulation with a combination of 100 nM insulin and increasing concentrations of KU-60019 (1.5 
μM, 3 μM and 6 μM). Ins Insulin; KU KU-60019. (n=4 per group). 
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Western blotting 
Hearts isolated from young control rats were perfused with insulin and increasing concentrations 
of KU-60019. Following perfusion, the hearts were freeze-clamped and subjected to Western 
blotting using total ATM and phospho-ATM antibodies. A significantly lower P/T ATM ratio was 
observed in hearts perfused with 3 μM KU-60019 in combination with insulin compared to both 
untreated hearts (Untreated 0.97 ± 0.06; 3 μM 0.67 ± 0.01; p < 0.05) and hearts treated with 
insulin alone (Ins 1.17 ± 0.09; 3 μM 0.67 ± 0.01; p < 0.05) (Figure 4.9). A KU-60019 dosage of 3 
μM was thus able to decrease ATM phosphorylation to lower levels than what is seen in 
untreated hearts. 
In order to confirm this, age-matched control rats were perfused with 3 μM KU-60019 for 20 
minutes and freeze-clamped. Western blots probing for total and phospho-ATM were performed 
on the freeze-clamped heart tissue. Treatment with 3 μM KU-60019 had no effect on total ATM 
levels compared to the untreated group (Figure 4.10 A). Treatment with 3 μM KU-60019 
significantly reduced phosphorylation of ATM (Ser1981) compared to the untreated group 
(Untreated 1.09 ± 0.09; 3 μM KU 0.61 ± 0.10; p < 0.01) (Figure 4.10 B). A KU-60019 
concentration of 3 μM was thus selected to be used in the study. 
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Figure 4.9: The effect of perfusion with increasing KU-60019 concentrations on ATM expression and 
activation. A) Western blot chemiluminescent results of ATM, phospho-ATM and Ponceau total protein 
stain. B) Bar graph depicting analysed results for total ATM. C) Bar graph depicting analysed results for 
phospho-ATM (Ser 1981). D) Bar graph depicting phospho to total ratio of ATM. Ins insulin; KU KU-60019 
* p < 0.05 (n=2). 
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Figure 4.10: Total and phospho-ATM levels in hearts of age-matched control rats that were perfused with 
3 μM KU-60019. A) Total ATM. B) Phospho-ATM. ** P < 0.01 KU KU-60019 (n=5 per group). 
Cell viability 
A PI assay was performed to assess whether 3 μM of KU-60019 or the DMSO vehicle increased 
necrosis of isolated cardiomyocytes. Cell viability was unaffected by both the DMSO vehicle and 
the 3 μM KU-60019 (Figure 4.11). 
 
Figure 4.11: Bar graphs showing the percentage change in propidium iodide uptake from untreated cells 
by isolated cardiomyocytes treated with 3 μM KU-60019 prepared in DMSO or treated with the DMSO 
alone as vehicle control. (n=2 per group). 
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4.3 Langendorff perfusions (Balloon model) and global ischaemia 
Hearts isolated from control and HCD fed animals were subjected to Langendorff perfusion 
using the balloon model. These hearts were treated with insulin (1 U/L), wortmannin (100 nM) 
and KU-60019 (3 μM) after which they underwent 20 minutes of global ischaemia and five or 10 
minutes of reperfusion. An inflatable balloon, attached to a pressure transducer, was inserted 
into the left ventricle to measure cardiac function. 
4.3.1 The effect of the vehicle control 
We firstly assessed whether the vehicle control, namely DMSO, affected cardiac function. 
Perfusion with 0.033% DMSO, which is the final concentration of the vehicle used to dissolve 
KU-60019, had no effect on the LVDevP or RPP. There were no significant changes following 
the treatment period (before IRI) or in the percentage recovery following IRI (Figure 4.12). 
Additionally, the HCD also had no basal effect on cardiac function when compared to the control 
group. 
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Figure 4.12: Comparison of cardiac function in untreated and DMSO-treated (vehicle control) hearts. A) 
Left ventricular developed pressure (mm Hg) before IRI. B) Percentage recovery in left ventricular 
developed pressure following IRI. C) Rate pressure product (mm Hg beats/minute) before IRI. D) 
Percentage recovery in rate pressure product following IRI. (n=5 per group). 
4.3.2 The effect of insulin, wortmannin and KU-60019 on cardiac function of Langendorff 
perfused control and HCD hearts 
The Langendorff perfusion technique was used to perfuse hearts from animals that have been 
on the HCD for 16 and 25 weeks and their age-matched controls. The length of time on the diet 
caused no significant differences in cardiac function (data not shown) so the data was pooled 
together for further analysis. 
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LVDevP 
The treatment groups had no effect on LVDevP prior to ischaemia in either the control or HCD 
hearts. At both five and 10 minutes reperfusion, the LVDevP was significantly lower compared 
to before ischaemia. Global ischaemia therefore significantly reduced LVDevP. After five 
minutes of reperfusion, both wortmannin and KU-60019 treated hearts had significantly higher 
LVDevP compared to untreated hearts. This effect was observed in control hearts and in HCD 
hearts, but it was no longer seen at 10 minutes reperfusion. Co-treatment with KU-60019 and 
insulin resulted in significantly higher LVDevP compared to treatment with insulin alone. This 
was seen at five and 10 minutes reperfusion in both the control and HCD hearts. Higher 
LVDevP was also seen in both control and HCD hearts co-treated with wortmannin and insulin 
compared to treatment with insulin alone. This effect was only observed at 10 minutes and not 
at five minutes reperfusion. In control and HCD hearts, insulin treatment prior to ischaemia 
caused significantly reduced LVDevP at 10 minutes reperfusion compared to untreated hearts. 
HCD insulin treated hearts had significantly higher LVDevP at 10 minutes reperfusion compared 
to control hearts treated with insulin. Results for LVDeVP are summarised in Table 4.3. 
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Table 4.3: Left ventricular developed pressure (mm Hg) before and after ischaemia/reperfusion injury in 
treated control and HCD hearts. Data expressed as mean with standard error of the mean. 
  Before 
Ischaemia 
(n=9-10) 
5 min 
Reperfusion 
(n=8-10) 
10 min 
Reperfusion 
(n=4-5) 
Control 
Untreated 103.0 ± 6.9 23.5 ± 5.3 (c) 50.0 ± 10.1 (b) 
Insulin 99.9 ± 3.5 24.0 ± 2.2 (c) 17.8 ± 2.5 (c)(*) 
Wortmannin 89.8 ± 3.5 50.9 ± 6.6 (c)(**) 35.2 ± 3.3 (c) 
Wortmannin + Insulin 105.0 ± 4.0 ($) 20.9 ± 4.8 (c)($$) 34.0 ± 5.8 (c)(#) 
KU-60019 101.5 ± 4.0 71.1 ± 10.0 (b)(***) 66.0 ± 5.9 (c) 
KU-60019 + Insulin 109.6 ± 4.8 55.1 ± 6.2 (c)(###) 63.0 ± 17.1 (b)(#) 
HCD 
Untreated 98.4 ± 4.3 27.4 ± 4.6 (c) 49.5 ± 1.9 (c) 
Insulin 104.3 ± 4.2 25.8 ± 4.4 (c) 30.8 ± 5.1 (c)(*)(+) 
Wortmannin 102.0 ± 7.1 51.7 ± 10.4 (c)(*) 56.2 ± 9.7 (b) 
Wortmannin + Insulin 100.0 ± 5.6 28.1 ± 7.3 (c) 50.3 ± 6.2 (c)(#) 
KU-60019 95.9 ± 4.1 64.0 ± 16.5 (a)(*) 49.3 ± 4.3 (c) 
KU-60019 + Insulin 107.7 ± 5.9 65.4 ± 9.2 (b)(##) 59.5 ± 9.3 (c)(#) 
a p < 0.05; b p < 0.005; c p < 0.0001; Compared to Before Ischaemia 
$ p < 0.05; $$ p < 0.005; Compared to Wortmannin 
* p < 0.05; ** p < 0.005; *** p < 0.001; Compared to Untreated 
# p < 0.05; ## p < 0.005 ### p < 0.0005; Compared to Insulin 
+ p < 0.05; Compared to Control 
RPP 
As with LVDevP, none of the treatment groups had a significant effect on RPP before the 
ischaemic period and all groups had decreased RPP values following both five and 10 minutes 
reperfusion. At five minutes reperfusion, control hearts that had been treated with wortmannin 
and KU-60019 had significantly higher RPP values than untreated control hearts. At 10 minutes 
reperfusion, only KU-60019 treated hearts had increased RPP values compared to untreated 
control hearts. Neither wortmannin nor KU-60019 treatment had an effect on RPP values in 
HCD hearts. Treatment with KU-60019 plus insulin resulted in significantly higher RPP values at 
both five and 10 minutes reperfusion compared to insulin only treated hearts. This effect 
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observed in both the control and HCD hearts. KU-60019 treatment caused significantly lower 
RPP values in HCD hearts compared to control hearts. Results for RPP values are summarised 
in Table 4.4. 
Table 4.4: Rate pressure product (mm Hg beats/minute) before and after ischaemia/reperfusion injury in 
treated control and HCD hearts. Data expressed as mean with standard error of the mean. 
  Before 
Ischaemia 
(n=9-10) 
5 min Reperfusion 
(n=5-9) 
10 min Reperfusion 
(n=4-5) 
Control 
Untreated 29120 ± 1454 4478 ± 696 (c) 5858 ± 2127 (c) 
Insulin 27650 ± 1943 6322 ± 829 (c) 4115 ± 694 (c) 
Wortmannin 27000 ± 2061 8978 ± 1388 (c)(*) 8104 ± 2251 (c) 
Wortmannin + Insulin 30290 ± 1776 5540 ± 1549 (c) 6506 ± 991 (c) 
KU-60019 28180 ± 1304 13000 ± 1488 (c)(***) 14800 ± 2166 (c)(*) 
KU-60019 + Insulin 31180 ± 1370 10270 ± 1499 (c)(#) 16190 ± 4535 (c)(#) 
HCD 
Untreated 28870 ± 1642 7032 ± 1366 (c) 8853 ± 2309 (c) 
Insulin 30650 ± 1934 5472 ± 1225 (c) 6655 ± 816 (c) 
Wortmannin 27300 ± 2444 8022 ± 1946 (c) 11030 ± 2052 (c) 
Wortmannin + Insulin 29790 ± 1757 9972 ± 1548 (c)(#) 8806 ± 2013 (c) 
KU-60019 29400 ± 1123 9870 ± 1393 (c) 7220 ± 928 (c)(+) 
KU-60019 + Insulin 31540 ± 1320 11100 ± 1736 (c)(#) 17650 ± 1574 (c)(##) 
c p < 0.0001; Compared to Before Ischaemia 
* p < 0.05; *** p < 0.0001; Compared to untreated 
# p < 0.05; ## p < 0.005; Compared to insulin 
+ p < 0.05; Compared to Control 
Heart Rate 
None of the treatment groups had a significant effect on heart rate before ischaemia in either 
control or HCD hearts. At 10 minutes reperfusion, HCD hearts treated with KU-60019 prior to 
ischaemia had significantly lower heart rates than control hearts treated with KU-60019 prior to 
ischaemia. Decreased heart rates were observed in both control and HCD hearts at five and 10 
minutes reperfusion compared to before ischaemia in all treatment groups. However, at 10 
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minutes reperfusion, hearts that were treated with insulin alone prior to ischaemia no longer had 
decreased heart rates compared to prior to the ischaemic period. Additionally, HCD hearts that 
were treated with wortmannin had unaltered heart rates at five and 10 minutes reperfusion. A 
two-way ANOVA was performed to further investigate the effect of insulin on heart rate as 
insulin appeared to increase heart rate during reperfusion. Insulin treatment prior to global 
ischaemia resulted in significantly increased heart rates at both five and 10 minutes reperfusion 
compared to untreated hearts (Figure 4.13). Heart rate data is summarised in Table 4.5. 
Table 4.5: Heart rate (beats/minute) before and after ischaemia/reperfusion injury in treated control and 
HCD hearts. Data expressed as mean with standard error of the mean. 
  Before 
Ischaemia 
(n=9-10) 
5 min 
Reperfusion 
(n=4-10) 
10 min 
Reperfusion 
(n=3-5) 
Control 
Untreated 288 ± 16 182 ± 18 (c) 164 ± 16 (c) 
Insulin 273 ± 15 217 ± 19 (a) 234 ± 24 
Wortmannin 309 ± 18 183 ± 24 (c) 221 ± 40 (a) 
Wortmannin + Insulin 288 ± 13 171 ± 29 (c) 202 ± 24 (b) 
KU-60019 280 ± 15 179 ± 19 (c) 220 ± 17 (a) 
KU-60019 + Insulin 286 ± 8 173 ± 17 (c) 253 ± 8 (a) 
HCD 
Untreated 292 ± 18 187 ± 18 (c) 196 ± 29 (a) 
Insulin 312 ± 20 210 ± 29 (b) 263 ± 38 
Wortmannin 277 ± 20 212 ± 29 210 ± 43 
Wortmannin + Insulin 299 ± 14 208 ± 28 (b) 169 ± 15 (c) 
KU-60019 309 ± 10 145 ± 13 (c) 146 ± 7 (c)(+) 
KU-60019 + Insulin 298 ± 14 160 ± 15 (c) 231 ± 35 (a) 
a p < 0.05; b p < 0.005; c p < 0.0001; Compared to Before Ischaemia 
+ p < 0.05; Compared to Control 
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Figure 4.13: The effect of insulin treatment prior to global ischaemia on heart rate during reperfusion. A) 
Two-way ANOVA to illustrate the effect of insulin treatment on heart rate (beats/minute) at five minutes 
reperfusion (n=6-9). B) Two-way ANOVA to illustrate the effect of insulin treatment on heart rate 
(beats/minute) at 10 minutes reperfusion (n=4-5).  
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Coronary Flow 
Treatment with KU-60019 significantly increased CF in both control and HCD hearts 
immediately once the KU-60019 was administered. This effect of KU-60019 was still observed 
at five minutes reperfusion. At 10 minutes reperfusion, the effect of KU-60019 on the increase of 
CF disappeared. Ischaemia had no effect on CF as CF remained unchanged in all other 
treatment groups. Coronary flow results are summarised in Table 4.6. 
Table 4.6: Coronary flow (mL/min) before and after ischaemia/reperfusion injury in treated control and 
HCD hearts. Data expressed as mean with standard error of the mean. 
  Before 
Ischaemia 
(n=9-10) 
5 min 
Reperfusion 
(n=8-10) 
10 min 
Reperfusion 
(n=3-5) 
Control 
Untreated 15.05 ± 0.89 13.75 ± 0.62 12.80 ± 1.11 
Insulin 14.20 ± 1.23 14.25 ± 0.59 14.30 ± 2.06 
Wortmannin 12.90 ± 1.24 15.10 ± 0.60 11.90 ± 0.99 
Wortmannin + Insulin 14.25 ± 1.14 14.22 ± 0.69 13.10 ± 0.29 
KU-60019 20.55 ± 0.95 (***) 18.20 ± 1.09 (**) 16.13 ± 1.28 (a) 
KU-60019 + Insulin 20.35 ± 0.92 (###) 17.00 ± 0.77 (a)(#) 13.50 ± 1.06 (b) 
HCD 
Untreated 15.40 ± 0.94 14.67 ± 1.18 13.50 ± 1.50 
Insulin 14.22 ± 1.19 14.56 ± 0.80 16.00 ± 1.16 
Wortmannin 14.35 ± 1.22 14.83 ± 1.04 13.80 ± 0.56 
Wortmannin + Insulin 14.80 ± 1.04 15.45 ± 0.82 12.88 ± 0.72 
KU-60019 21.75 ± 0.78 (***) 18.50 ± 0.80 (b)(*) 20.50 ± 5.77 
KU-60019 + Insulin 20.80 ± 0.94 (###) 17.39 ± 1.02 (a)(#) 14.30 ± 1.11 (b) 
a p < 0.05; b p < 0.005; Compared to Before Ischaemia 
* p < 0.05; ** p < 0.005; *** p < 0.0001; Compared to untreated 
# p < 0.05; ### p < 0.0001; Compared to insulin  
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Time to contracture and peak developed pressure during global ischaemia 
Control and HCD hearts that were treated with insulin alone had a significantly longer time to 
onset of contracture during global ischaemia compared to untreated hearts (Table 4.7). Insulin 
treatment had no effect on the peak developed pressure in either the control or HCD hearts. 
Wortmannin treatment had no effect on the time to contracture in control hearts. Interestingly, 
the peak developed pressure was significantly lower in wortmannin treated control hearts 
compared to untreated control hearts. Co-treatment with insulin and wortmannin resulted in 
increased developed pressure compared to treatment with wortmannin alone. In HCD hearts, 
treatment with wortmannin significantly reduced the time to onset of contracture and co-
treatment with insulin was not able to inhibit this effect of wortmannin. Wortmannin did not have 
an effect on the peak developed pressure in HCD hearts when compared to untreated HCD 
hearts. 
Treatment with KU-60019 resulted in a longer time to onset of contracture in control hearts 
compared to untreated control hearts. This was accompanied with a significantly lower peak 
developed pressure in control hearts treated with KU-60019 compared to untreated control 
hearts. In HCD hearts, KU-60019 treatment had no effect on time to onset of contracture when 
compared to untreated hearts, however, a significantly lower peak developed pressure was 
observed in KU-60019 treated HCD hearts compared to untreated HCD hearts. Control and 
HCD hearts that were co-treated with KU-60019 and insulin took significantly longer to reach 
contracture than hearts treated with insulin alone. Co-treatment also resulted in significantly 
reduced peak developed pressures compared to hearts treated with insulin alone or KU-60019 
alone. This was seen in both the control and HCD hearts (Table 4.7). 
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Table 4.7: Time to contracture (min) and peak developed pressure (mmHg) achieved during ischaemia in 
treated control and HCD hearts. Data expressed as mean with standard error of the mean (n=7-10). 
 Time To Contracture Peak Developed Pressure 
 Control HCD Control HCD 
Untreated 13 ± 0.5 14 ± 0.7 48.2 ± 5.0 42.8 ± 2.2 
Insulin 16 ± 0.5 (***) 16 ± 0.6 (*) 41.0 ± 3.9 41.7 ± 3.6 
Wortmannin 15 ± 0.8 11 ± 1.2 (+)(*) 34.3 ± 3.4 (*) 42.5 ± 3.0 
Wortmannin + Insulin 14 ± 1.0 12 ± 1.2 (#) 46.7 ± 1.9 ($$) 35.0 ± 2.2 (+++) 
KU-60019 16 ± 0.9 (*) 14 ± 0.9 32.57 ± 3.9 (*) 32.2 ± 3.6 (*) 
KU-60019 + Insulin 18 ± 0.6 (#) 19 ± 0.6 (#)(¤¤¤) 16.9 ± 3.0 (###)(¤¤) 17.8 ± 4.4 (###)(¤) 
* p < 0.05; *** p < 0.0005; Compared to untreated 
+ p < 0.05; +++ p < 0.001; Compared to Control 
# p < 0.05; ### p < 0.0005; Compared to insulin 
$$ p < 0.007; Compared to wortmannin 
¤ p < 0.05; ¤¤ p < 0.007; ¤¤¤ p < 0.0001; Compared to KU-60019 
4.4 Western blotting 
Hearts from age-matched control and HCD animals were perfused using the Langendorff 
balloon model. ATM signalling was manipulated using insulin (1 U/L), wortmannin (100 nM) 
and/or KU-60019 (3 μM), and the hearts were freeze-clamped before and after IRI in order to 
determine the effect of ATM manipulation on signalling networks through Western blot analysis. 
Proteins of interest included JNK, IRS-1, PI3K, PTEN, PKB/Akt, mTOR, GSK-3β, AS160, 
GLUT4, AMPK, acetyl-CoA carboxylase (ACC) and ATM. Untreated control hearts were loaded 
on all HCD gels and the HCD data was normalized to the untreated controls. This was done to 
enable comparisons between the control data and HCD data. The control data was also 
normalised to untreated controls. 
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4.4.1 Signalling before IRI 
Western blot analysis of hearts that were freeze-clamped directly following the treatment period, 
prior to IRI, was performed by Ms A. Seboko, an Honours(MedSci) student that was under Ms. 
Y. Espach’s supervision. The age-matched control and HCD hearts were treated with insulin 
(activator), KU-60019 (ATM specific inhibitor) and a combination of KU-60019 and insulin. 
JNK 
In control hearts, ATM inhibition using KU-60019 significantly reduced JNK expression 
(Untreated 1; KU 0.72 ± 0.02; p < 0.005). Co-treatment with both KU-60019 and insulin restored 
total JNK to untreated levels. None of the treatment groups had an effect on JNK 
phosphorylation in control hearts. The results of JNK Western blot analysis in control hearts are 
indicated in Figure 4.14. 
There was no significant difference in total or phospho JNK levels between control and HCD 
hearts. Compared to untreated HCD hearts, treatment with insulin significantly increased total 
JNK expression (Untreated 0.92 ± 0.02; Ins 1.14 ± 0.04; p < 0.005) and decreased JNK 
phosphorylation (Untreated 1.01 ± 0.01; Ins 0.81 ± 0.01; p < 0.0001) in HCD hearts. This 
translated into a significantly reduced P/T ratio when treating with insulin compared to untreated 
hearts (Untreated 1.1 ± 0.01; Ins 0.71 ± 0.02; p < 0.0001). When HCD hearts were co-treated 
with KU-60019 and insulin, insulin was still able to significantly reduce JNK phosphorylation 
compared to treatment with KU-60019 alone (KU 0.99 ± 0.01; KU + Ins 0.87 ± 0.001; p < 0.005). 
Consequently, the P/T JNK ratio was significantly lower in the co-treated group compared to the 
KU-60019 group (KU 0.97 ± 0.01; KU + Ins 0.74 ± 0.04; p < 0.0001). Although KU-60019 
treatment had no significant effect on total or phospho JNK levels, it did cause the P/T ratio to 
be significantly lower compared to untreated hearts (Untreated 1.1 ± 0.01; KU 0.97 ± 0.01; p < 
0.005). The results of JNK Western blot analysis in HCD hearts are indicated in Figure 4.15. 
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Figure 4.14: JNK expression and phosphorylation levels in control hearts following treatment with insulin, 
KU-60019 and a combination of insulin and KU-60019. A) Western blot chemiluminescent results of JNK 
and p-JNK and stain-free total protein stain of the membrane. B) Bar graph depicting analysed results for 
total JNK. C) Bar graph depicting analysed results for p-JNK (Thr 183/ Tyr 185). D) Bar graph depicting 
phospho to total ratio of JNK. ** p < 0.005 (n=2-3 per group). 
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Figure 4.15: JNK expression and phosphorylation levels in HCD hearts normalised to untreated control 
hearts, following treatment with insulin, KU-60019 and a combination of insulin and KU-60019. A) 
Western blot chemiluminescent results of JNK and p-JNK and stain-free total protein stain of the 
membrane. B) Bar graph depicting analysed results for total JNK. C) Bar graph depicting analysed results 
for p-JNK (Thr 183/ Tyr 185). D) Bar graph depicting phospho to total ratio of JNK. ** p < 0.005; *** p < 
0.0001 (n=2-3 per group).  
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IRS-1 
Insulin treatment significantly increased both the expression (Untreated 1.00 ± 0.16; Ins 2.16 ± 
0.08; p < 0.0001) and phosphorylation of IRS-1 (serine 307) (Untreated 1.00 ± 0.11; Ins 14.52 ± 
0.75; p < 0.0001) compared to the untreated group in control hearts. The P/T ratio was also 
significantly higher in insulin treated hearts compared to untreated control hearts (Untreated 
1.01 ± 0.04; Ins 6.48 ± 0.19; p < 0.005). Co-treatment with KU-60019 significantly decreased the 
effect of insulin on total (Ins 2.16 ± 0.08; KU + Ins 1.08 ± 0.04; p < 0.0001) and phospho-IRS-1 
(Ins 14.52 ± 0.75; KU + Ins 0.07 ± 0.01; p < 0.0001) levels and it also resulted in a decreased 
P/T ratio compared to the group treated with insulin only (Ins 6.48 ± 0.19 ± 0.07 ± 0.02; p < 
0.0001). Compared to the untreated group, KU-60019 treatment decreased total IRS-1 levels in 
control hearts (Untreated 1.00 ± 0.16; KU 0.43 ± 0.04; p < 0.05), however the p-IRS-1 and P/T 
IRS-1 ratio remained unchanged by KU-60019 treatment in control hearts. Co-treatment with 
insulin and KU-60019 resulted in significantly higher total IRS-1 levels compared to the KU-
60019 only group (KU 0.43 ± 0.04; KU + Ins 1.08 ± 0.04; p < 0.005), which translated into a 
significantly smaller P/T IRS-1 ratio in the co-treatment group compared to the KU-60019 only 
group (KU 2.58 ± 0.52; KU + Ins 0.07 ± 0.02; p < 0.05). The results of IRS-1 Western blot 
analysis in control hearts are indicated in Figure 4.16. 
Hearts from animals that were on the HCD had significantly higher IRS-1 expression levels 
compared to hearts from animals on the control diet (Control untreated 1; HCD untreated 4.96 ± 
0.08; p < 0.05) HCD hearts that were co-treated with KU-60019 and insulin had significantly less 
total IRS-1 expression compared to hearts that were treated only with insulin (Ins 6.60 ± 1.26; 
KU + Ins 0.31 ± 0.06; p < 0.005). The results of IRS-1 Western blot analysis in HCD hearts are 
indicated in Figure 4.17. 
 
Stellenbosch University  https://scholar.sun.ac.za
109 
 
 
Figure 4.16: IRS-1 expression and phosphorylation levels in control hearts following treatment with 
insulin, KU-60019 and a combination of insulin and KU-60019. A) Western blot chemiluminescent results 
of IRS-1 and p-IRS-1 and stain-free total protein stain of the membrane. B) Bar graph depicting analysed 
results for total IRS-1. C) Bar graph depicting analysed results for p-IRS-1 (Ser307). D) Bar graph 
depicting phospho to total ratio of IRS-1. * p < 0.05; ** p < 0.005; *** p < 0.0001 (n=3 per group). 
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Figure 4.17: IRS-1 expression levels in HCD hearts following treatment with insulin, KU-60019 and a 
combination of insulin and KU-60019. A) Western blot chemiluminescent results of IRS-1 and stain-free 
total protein stain of the membrane. B) Bar graph depicting analysed results for total IRS-1 * p < 0.05; ** p 
< 0.005 (n=3 per group). 
P85 subunit of PI3K 
In control hearts, insulin treatment resulted in decreased total PI3K expression levels compared 
to the untreated group (Untreated 1.00 ± 0.01; Ins 0.81 ± 0.003; p < 0.0001). Surprisingly, the 
insulin group also had a significantly lower P/T PI3K ratio compared to the untreated control 
group (Untreated 1.00 ± 0.03; Ins 0.75 ± 0.02; p < 0.05). When KU-60019 was administered in 
combination with insulin, total PI3K levels were significantly reduced compared to the insulin 
only group (Ins 0.81 ± 0.003; KU + Ins 0.62 ± 0.003; p < 0.0001). The same effect was seen on 
the phosphorylation levels of PI3K (Ins 0.83 ± 0.005; KU + Ins 0.37 ± 0.05; p < 0.005). However, 
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the P/T PI3K ratio was unchanged in the KU-60019 + insulin group compared to the insulin only 
group. Compared to the untreated group, KU-60019 treatment reduced both the total PI3K 
(Untreated 1.00 ± 0.01; KU 0.75 ± 0.002; p < 0.0001) and the phosphorylation of PI3K 
(Untreated 1.00 ± 0.04; KU 0.69 ± 0.01; p < 0.005). The P/T PI3K ratio, however, remained 
unchanged in the KU-60019 group compared to the untreated group. Compared to the KU-
60019 only group, the KU-60019 + insulin group had significantly lower total PI3K (KU 0.75 ± 
0.002; KU + Ins 0.62 ± 0.003; p < 0.005), lower phosphorylated PI3K (KU 0.69 ± 0.01; KU + Ins 
0.37 ± 0.05; p < 0.005) and a lower P/T PI3K ratio (KU 0.93 ± 0.01; KU + Ins 0.60 ± 0.08; p < 
0.05). The results of PI3K Western blot analysis in control hearts are indicated in Figure 4.18. 
In HCD hearts, none of the treatment groups had a significant effect on the PI3K total 
expression levels or on the phosphorylation levels of PI3K. There were, however, significant 
effects on the P/T PI3K ratio. Insulin treatment significantly reduced the P/T PI3K ratio 
compared to the untreated group (Untreated 1.72 ± 0.08; Ins 1.05 ± 0.04; p < 0.0001). 
Treatment with KU-60019 also reduced the P/T PI3K ratio compared to the untreated group 
(Untreated 1.72 ± 0.08; KU 1.22 ± 0.07; p < 0.005). Co-treatment with both KU-60019 and 
insulin resulted in a significantly higher P/T PI3K ratio than when treated with insulin alone (Ins 
1.05 ± 0.04; KU + Ins 1.77 ± 0.02; p < 0.0001) or with KU-60019 alone (KU 1.22 ± 0.07; KU + 
Ins 1.77 ± 0.02; p < 0.0001). The results of PI3K Western blot analysis in HCD hearts are 
indicated in Figure 4.19. 
The HCD hearts had a significantly higher P/T PI3K ratio compared to the control hearts 
(Untreated control 1.00 ± 0.03; Untreated HCD 1.72 ± 0.08; p < 0.0001) despite the total PI3K 
and phospho-PI3K levels being unchanged between the two groups (Figure 4.19 D). 
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Figure 4.18: PI3K p85 expression and phosphorylation levels in control hearts following treatment with 
insulin, KU-60019 and a combination of insulin and KU-60019. A) Western blot chemiluminescent results 
of PI3K and p-PI3K and stain-free total protein stain of the membrane. B) Bar graph depicting analysed 
results for total PI3K. C) Bar graph depicting analysed results for p-PI3K (Tyr458). D) Bar graph depicting 
phospho to total ratio of PI3K. * p < 0.05; ** p < 0.005; *** p < 0.0001 (n=2-3 per group). 
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Figure 4.19: PI3K p85 expression and phosphorylation levels in control hearts following treatment with 
insulin, KU-60019 and a combination of insulin and KU-60019. A) Western blot chemiluminescent results 
of PI3K and p-PI3K and stain-free total protein stain of the membrane. B) Bar graph depicting analysed 
results for total PI3K. C) Bar graph depicting analysed results for p-PI3K (Tyr458). D) Bar graph depicting 
phospho to total ratio of PI3K. ** p < 0.005; *** p < 0.0001 (n=2-3 per group). 
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PTEN 
The phosphatase PTEN acts as a negative regulator of insulin signalling by dephosphorylating 
PIP3. Total PTEN levels were significantly lower in control hearts treated with KU-60019 
compared to the untreated control group (Untreated 1.00 ± 0.06; KU 0.55 ± 0.04; p < 0.05). 
When co-treated with insulin and KU-60019, insulin was able to abolish the effect of KU-60019 
and restore total PTEN levels to untreated levels (KU 0.55 ± 0.04; KU + Ins 1.03 ± 0.14; p < 
0.05). Treatment with KU-60019 also caused PTEN phosphorylation (Ser380/Thr382/Thr383) to 
decrease significantly compared to the untreated group (Untreated 1.00 ± 0.04; KU 0.38 ± 0.04; 
p < 0.0001) and this resulted in the P/T PTEN ratio to be lower in the KU-60019 group 
compared to the untreated group (Untreated 1.01 ± 0.09; KU 0.69 ± 0.06; p < 0.05). Insulin was 
unable to block the effect of KU-60019 on PTEN phosphorylation as the KU-60019 and insulin 
group had significantly lower phospho-PTEN levels compared to the insulin only group (Ins 0.87 
± 0.003; KU + Ins 0.51 ± 0.01; p < 0.0001). The results of PTEN Western blot analysis in control 
hearts are indicated in Figure 4.20. 
Compared to the untreated control hearts, untreated HCD hearts had significantly lower total 
PTEN expression levels (Untreated control 1.00; Untreated HCD 0.49 ± 0.005; p < 0.0001) as 
well as lower PTEN phosphorylation levels (Untreated control 1.00; Untreated HCD 0.50 ± 0.09; 
p < 0.005). Total PTEN levels were unaffected by the treatment groups in HCD hearts. Insulin 
treatment caused PTEN phosphorylation (Ser380/Thr382/Thr383) to be significantly lower than 
the untreated group (Untreated 0.50 ± 0.09; Ins 0.04 ± 0.02; p < 0.005) and this translated into a 
significantly lower P/T PTEN ratio in the insulin treated HCD group (Untreated 1.20 ± 0.07; Ins 
0.06 ± 0.03; p < 0.001). KU-60019 treatment had no effect on the total PTEN or the PTEN 
phosphorylation levels, but the P/T PTEN ratio was significantly lower in the KU-60019 group 
compared to the untreated group (Untreated 1.20 ± 0.07; KU 0.49 ± 0.06; p < 0.0001). The 
results of PTEN Western blot analysis in HCD hearts are indicated in Figure 4.21.  
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Figure 4.20: PTEN expression and phosphorylation levels in control hearts following treatment with 
insulin, KU-60019 and a combination of insulin and KU-60019. A) Western blot chemiluminescent results 
of PTEN and p-PTEN and stain-free total protein stain of the membrane. B) Bar graph depicting analysed 
results for total PTEN. C) Bar graph depicting analysed results for p-PTEN (Ser380/Thr382/Thr383). D) 
Bar graph depicting phospho to total ratio of PTEN. * p < 0.05; *** p < 0.0001 (n=3 per group). 
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Figure 4.21: PTEN expression and phosphorylation levels in HCD hearts following treatment with insulin, 
KU-60019 and a combination of insulin and KU-60019. A) Western blot chemiluminescent results of 
PTEN and p-PTEN and stain-free total protein stain of the membrane. B) Bar graph depicting analysed 
results for total PTEN. C) Bar graph depicting analysed results for p-PTEN (Ser380/Thr382/Thr383). D) 
Bar graph depicting phospho to total ratio of PTEN. ** p < 0.005; *** p < 0.0001 (n=3 per group). 
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PKB/Akt 
PKB/Akt plays a central role in the insulin signalling network. As expected, insulin stimulation 
resulted in a significant increase in total PKB/Akt expression (Untreated 1.00 ± 0.001; Ins 1.36 ± 
0.04; p < 0.005), PKB/Akt phosphorylation of Ser473 (Untreated 1.00 ± 0.21; Ins 2.85 ± 0.39; p 
< 0.005) and a significantly higher P/T ratio (Untreated 0.79 ± 0.004; Ins 2.10 ± 0.25; p < 0.005) 
compared to the untreated group in hearts from animals that were on the control diet. Treatment 
with KU-60019 resulted in an increase in total PKB/Akt compared to the untreated group 
(Untreated 1.00 ± 0.001; KU 1.34 ± 0.05; p < 0.05), but PKB/Akt phosphorylation and the P/T 
ratio remained unchanged in response to KU-60019. Treatment with a combination of KU-60019 
and insulin resulted in a decrease in PKB/Akt expression compared to treatment with only 
insulin (Ins 1.36 ± 0.04; KU + Ins 0.92 ± 0.05; p < 0.005) or with only KU-60019 (KU 1.34 ± 0.05; 
KU + Ins 0.92 ± 0.05; p < 0.005). It also caused increased phosphorylation of PKB/Akt 
compared to treatment with only KU-60019 (KU 1.38 ± 0.01; KU + Ins 2.77 ± 0.03; p < 0.05), 
resulting in an increased P/T ratio in the KU-60019 + insulin group compared to the KU-60019 
only group (KU 1.18 ± 0.12; KU + Ins 3.02 ± 0.12; p < 0.0001). The results of PKB/Akt Western 
blot analysis in control hearts are indicated in Figure 4.22. 
As in the control hearts, insulin treatment caused an increase in total PKB/Akt (Untreated HCD 
1.15 ± 0.04; Ins 1.57 ± 0.03; p < 0.005) in the HCD hearts. Interestingly, KU-60019 treatment 
also increased PKB/Akt expression (Untreated 1.15 ± 0.04; KU 1.64 ± 0.02; p < 0.005) 
compared to untreated HCD hearts. No differences were observed in PKB/Akt phosphorylation 
levels or in the P/T PKB/Akt ratio. The results of PKB/Akt Western blot analysis in HCD hearts 
are indicated in Figure 4.23. 
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Figure 4.22: PKB/Akt expression and phosphorylation levels in control hearts following treatment with 
insulin, KU-60019 and a combination of insulin and KU-60019. A) Western blot chemiluminescent results 
of PKB/Akt and p-PKB/Akt and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total PKB/Akt. C) Bar graph depicting analysed results for p-PKB/Akt (Ser473). D) 
Bar graph depicting phospho to total ratio of PKB/Akt. * p < 0.05; ** p < 0.005; *** p < 0.0001 (n=2-3 per 
group). 
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Figure 4.23: PKB/Akt expression and phosphorylation levels in HCD hearts following treatment with 
insulin, KU-60019 and a combination of insulin and KU-60019. A) Western blot chemiluminescent results 
of PKB/Akt and p-PKB/Akt and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total PKB/Akt. C) Bar graph depicting analysed results for p-PKB/Akt (Ser473). D) 
Bar graph depicting phospho to total ratio of PKB/Akt. * p < 0.05; ** p < 0.005; *** p < 0.0001 (n=2-3 per 
group). 
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mTOR 
None of the treatment groups affected total mTOR levels in control hearts. Co-treatment with 
KU-60019 and insulin resulted in increased phosphorylation of mTOR (Ser2448) compared to 
treatment with insulin alone (Ins 1.00 ± 0.004; KU + Ins 1.42 ± 0.01; p < 0.0001) or compared to 
treatment with KU-60019 alone (KU 1.10 ± 0.004; KU + Ins 1.42 ± 0.01; p < 0.0001). There 
were no differences in P/T mTOR ratios between the groups. The results of mTOR Western blot 
analysis in control hearts are indicated in Figure 4.24. 
The HCD hearts had significantly more basal total mTOR (Untreated control 1.00 ± 0.01; 
Untreated HCD 1.80 ± 0.08; p < 0.0001) and phosphorylated mTOR (Untreated control 1.00 ± 
0.009; Untreated HCD 1.66 ± 0.004; p < 0.05) compared to the untreated control hearts. There 
was, however, no difference in the P/T ratio between the untreated control and HCD groups. 
Insulin treatment had no effect on total mTOR levels in HCD hearts, but mTOR phosphorylation 
was significantly higher in insulin treated hearts compared to untreated hearts (Untreated 1.66 ± 
0.004; Ins 2.62 ± 0.20; p < 0.0001). This resulted in an increased P/T ratio in insulin treated 
HCD hearts (Untreated 0.93 ± 0.04; Ins 1.29 ± 0.09; p < 0.005). Compared to treatment with 
insulin only, treatment with a combination of insulin and KU-60019 caused an increase in total 
mTOR (Ins 2.03 ± 0.07; KU + Ins 2.31 ± 0.04; p < 0.05), a decrease in mTOR phosphorylation 
(Ins 2.62 ± 0.20; KU + Ins 2.02 ± 0.02; p < 0.05) and a resultant decrease in P/T ratio (Ins 1.29 
± 0.09; KU + Ins 0.88 ± 0.02; p < 0.005). Co-treatment with KU-60019 and insulin also 
significantly increased total mTOR levels compared to treatment with only KU-60019 (KU 1.94 ± 
0.008; KU + Ins 2.31 ± 0.04; p < 0.005). There was no difference in mTOR phosphorylation or 
the P/T ratio between the co-treatment and KU-60019 only groups. The results of mTOR 
Western blot analysis in HCD hearts are indicated in Figure 4.25. 
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Figure 4.24: mTOR expression and phosphorylation levels in control hearts following treatment with 
insulin, KU-60019 and a combination of insulin and KU-60019. A) Western blot chemiluminescent results 
of mTOR and p-mTOR and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total mTOR. C) Bar graph depicting analysed results for p-mTOR (Ser2448). D) Bar 
graph depicting phospho to total ratio of mTOR. *** p < 0.0001 (n=3 per group). 
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Figure 4.25: mTOR expression and phosphorylation levels in HCD hearts following treatment with insulin, 
KU-60019 and a combination of insulin and KU-60019. A) Western blot chemiluminescent results of 
mTOR and p-mTOR and stain-free total protein stain of the membrane. B) Bar graph depicting analysed 
results for total mTOR. C) Bar graph depicting analysed results for p-mTOR (Ser2448). D) Bar graph 
depicting phospho to total ratio of mTOR. * p < 0.05; ** p < 0.005; *** p < 0.0001 (n=2-3 per group). 
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GSK-3β 
In response to insulin treatment, total GSK-3β expression levels were decreased compared to 
the untreated group in control hearts (Untreated 1.00 ± 0.01; Ins 0.66 ± 0.04; p < 0.0001). 
Insulin treatment also decreased GSK-3β phosphorylation (Ser9) compared to the untreated 
group (Untreated 1.00 ± 0.03; Ins 0.70 ± 0.04; p < 0.005), but the P/T ratio remained unchanged 
by insulin treatment. Treatment with KU-60019 significantly decreased both GSK-3β expression 
(Untreated 1.00 ± 0.01; KU 0.81 ± 0.01; p < 0.05) and phosphorylation (Untreated 1.00 ± 0.03; 
KU 0.67 ± 0.03; p < 0.005), leading to a decreased P/T ratio compared to the untreated group 
(Untreated 1.00 ± 0.02; KU 0.77 ± 0.06; p < 0.05). The results of GSK-3β Western blot analysis 
in control hearts are indicated in Figure 4.26. 
There was no difference in total GSK-3β, GSK-3β phosphorylation or the P/T ratio of GSK-3β 
between untreated control hearts and untreated HCD hearts. As was seen in control hearts, 
treatment with KU-60019 significantly decreased total GSK-3β levels (Untreated 0.90 ± 0.07; KU 
0.60 ± 0.03; p < 0.05) as well as GSK-3β phosphorylation levels (Untreated 1.07 ± 0.08; KU 
0.53 ± 0.01; p < 0.05) in HCD hearts. The P/T ratio, however, remained unchanged by KU-
60019 treatment when compared to the untreated group. The results of GSK-3β Western blot 
analysis in HCD hearts are indicated in Figure 4.27.  
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Figure 4.26: GSK-3β expression and phosphorylation levels in control hearts following treatment with 
insulin, KU-60019 and a combination of insulin and KU-60019. A) Western blot chemiluminescent results 
of GSK-3β and p-GSK-3β and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total GSK-3β. C) Bar graph depicting analysed results for p-GSK-3β (Ser9). D) Bar 
graph depicting phospho to total ratio of GSK-3β. * p < 0.05; ** p < 0.005; *** p < 0.0001 (n=3 per group). 
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Figure 4.27: GSK-3β expression and phosphorylation levels in HCD hearts following treatment with 
insulin, KU-60019 and a combination of insulin and KU-60019. A) Western blot chemiluminescent results 
of GSK-3β and p-GSK-3β and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total GSK-3β. C) Bar graph depicting analysed results for p-GSK-3β (Ser9). D) Bar 
graph depicting phospho to total ratio of GSK-3β. * p < 0.05 (n=2-3 per group). 
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AS160 
Insulin treatment caused an increase in total AS160 in control hearts compared to untreated 
control hearts (Untreated 1.00 ± 0.13; Ins 1.62 ± 0.03; p < 0.005). An increase in AS160 
phosphorylation was also seen in response to insulin (Untreated 1.00 ± 0.18; Ins 3.07 ± 0.32; p 
< 0.05). There was no difference in P/T ratio between the untreated and insulin groups. Insulin 
also caused an increase in total AS160 when co-treated with KU-60019 (KU 1.17 ± 0.08; KU + 
Ins 1.93 ± 0.08; p < 0.005). Co-treatment with KU-60019 and insulin caused greater 
phosphorylation of AS160 than what was observed in samples treated with only insulin (Ins 3.07 
± 0.32; KU + Ins 6.73 ± 0.46; p < 0.005) or with KU-60019 treatment alone (KU 3.00 ± 0.20; KU 
+ Ins 6.73 ± 0.46; p < 0.005). An increased P/T ratio was observed in samples treated with KU-
60019 compared to untreated samples (Untreated 0.99 ± 0.05; KU 2.43 ± 0.37; p < 0.05). Co-
treatment with KU-60019 and insulin also resulted in a significantly bigger P/T AS160 ratio 
compared to treatment with insulin alone (Ins 1.90 ± 0.21; KU + Ins 3.48 ± 0.11; p < 0.005). The 
results of AS160 Western blot analysis in control hearts are indicated in Figure 4.28. 
Total and phospho-AS160 levels were unaffected by the HCD compared to the control diet. 
None of the treatment groups had a significant effect on total AS160 levels. Treatment with KU-
60019 resulted in a significant decrease in AS160 phosphorylation compared to the untreated 
group (Untreated 1.03 ± 0.17; KU 0.47 ± 0.01; p < 0.05), however, the P/T ratio did not differ 
between the untreated and KU-60019 treated groups. The results of AS160 Western blot 
analysis in HCD hearts are indicated in Figure 4.29. 
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Figure 4.28: AS160 expression and phosphorylation levels in control hearts following treatment with 
insulin, KU-60019 and a combination of insulin and KU-60019. A) Western blot chemiluminescent results 
of AS160 and p-AS160 and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total AS160. C) Bar graph depicting analysed results for p-AS160 (Thr642). D) Bar 
graph depicting phospho to total ratio of AS160. * p < 0.05; ** p < 0.005 (n=2-3 per group). 
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Figure 4.29: AS160 expression and phosphorylation levels in HCD hearts following treatment with 
insulin, KU-60019 and a combination of insulin and KU-60019. A) Western blot chemiluminescent results 
of AS160 and p-AS160 and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total AS160. C) Bar graph depicting analysed results for p-AS160 (Thr642). D) Bar 
graph depicting phospho to total ratio of AS160. * p < 0.05 (n=2-3 per group). 
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GLUT4 
None of the treatment groups had a significant effect on total GLUT4 levels in either the control 
or HCD hearts. The untreated HCD hearts did have significantly less total GLUT4 compared to 
the untreated control hearts. GLUT4 Western blot results are indicated in Figure 4.30. 
 
Figure 4.30: GLUT4 expression levels in control diet and HCD hearts following treatment with insulin, 
KU-60019 and a combination of insulin and KU-60019. A) Western blot chemiluminescent results of 
GLUT4 and stain-free total protein stain of the membrane of the control diet samples. B) Western blot 
chemiluminescent results of GLUT4 and stain-free total protein stain of the membrane of the HCD 
samples. C) Bar graph depicting analysed results for total GLUT4 in control samples. D) Bar graph 
depicting analysed results for total GLUT4 in HCD samples. *** p < 0.0001 (n=3 per group). 
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AMPK 
Treatment with insulin caused a significant increase in total AMPK in control hearts compared to 
untreated control hearts (Untreated 1.00 ± 0.003; Ins 1.46 ± 0.05; p < 0.0001). Insulin had no 
effect on AMPK phosphorylation, but because of the increased total AMPK, insulin treated 
hearts had a significantly lower P/T AMPK ratio compare to the untreated group (Untreated 1.00 
± 0.03; Ins 0.72 ± 0.20; p < 0.05). KU-60019 had no effect on total AMPK compared to the 
untreated group, but co-treatment with KU-60019 and insulin resulted in total AMPK levels that 
were significantly lower than what was seen in the insulin group (Ins 1.46 ± 0.05; KU + Ins 1.16 
± 0.05; p < 0.05). This resulted in a higher P/T AMPK ratio in the control KU-60019 + insulin 
group compared to the insulin only group (Ins 0.72 ± 0.20; KU + Ins 1.05 ± 0.08; p < 0.05). 
Compared to treatment with KU-60019 alone, co-treatment with KU-60019 and insulin resulted 
in increased total AMPK (KU 0.90 ± 0.01; KU + Ins 1.16 ± 0.05; p < 0.05) and increased 
phosphorylation of AMPK (KU 0.82 ± 0.11; KU + Ins 1.21 ± 0.04; p < 0.05). The P/T ratio 
remained similar between the two groups. The results of AMPK Western blot analysis in control 
hearts are indicated in Figure 4.31. 
Total AMPK levels were similar between the control and HCD groups, but the HCD had 
significantly less phosphorylation of AMPK compared to the control group (Untreated control 
1.00 ± 0.02; Untreated HCD 0.56 ± 0.04; p < 0.05). Although there were no changes in total 
AMPK or AMPK phosphorylation between the two groups, the insulin treated group had a 
significantly lower P/T ratio than the untreated group (Untreated 0.71 ± 0.09; Ins 0.22 ± 0.10; p < 
0.05). ATM inhibition through treatment with KU-60019 resulted in reduced total AMPK levels 
(Untreated 0.91 ± 0.002; KU 0.66 ± 0.03; p < 0.005), reduced AMPK phosphorylation levels 
(Untreated 0.56 ± 0.04; KU 0.12 ± 0.03; p < 0.05) and a reduced P/T ratio (Untreated 0.71 ± 
0.09; KU 0.18 ± 0.04; p < 0.005) compared to the untreated group. The results of AMPK 
Western blot analysis in HCD hearts are indicated in Figure 4.32. 
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Figure 4.31: AMPK expression and phosphorylation levels in control hearts following treatment with 
insulin, KU-60019 and a combination of insulin and KU-60019. A) Western blot chemiluminescent results 
of AMPK and p-AMPK and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total AMPK. C) Bar graph depicting analysed results for p-AMPK (Thr172). D) Bar 
graph depicting phospho to total ratio of AMPK. * p < 0.05; *** p < 0.0001 (n=2-3 per group). 
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Figure 4.32: AMPK expression and phosphorylation levels in HCD hearts following treatment with insulin, 
KU-60019 and a combination of insulin and KU-60019. A) Western blot chemiluminescent results of 
AMPK and p-AMPK and stain-free total protein stain of the membrane. B) Bar graph depicting analysed 
results for total AMPK. C) Bar graph depicting analysed results for p-AMPK (Thr172). D) Bar graph 
depicting phospho to total ratio of AMPK. * p < 0.05; ** p < 0.005 (n=2-3 per group). 
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ACC 
In hearts from animals that were on the control diet, insulin treatment significantly decreased 
total ACC (Untreated 1.00 ± 0.02; Ins 0.20 ± 0.003; p < 0.0001) and decreased phosphorylation 
of ACC (Untreated 1.00 ± 0.03; Ins 0.38 ± 0.04; p < 0.0001) compared to the untreated group. 
The overall effect was a significantly higher P/T ACC ratio in the insulin treated group compared 
to the untreated group (Untreated 1.00 ± 0.01; Ins 1.90 ± 0.23; p < 0.005). Treatment with KU-
60019 resulted in increased ACC levels compared to the untreated group (Untreated 1.00 ± 
0.02; KU 1.54 ± 0.06; p < 0.0001), however, ACC phosphorylation and the P/T ratio remained 
similar between the untreated and KU-60019 groups. KU-60019, co-treated with insulin, caused 
increased total ACC levels compared to the insulin only group (Ins 0.20 ± 0.003; KU + Ins 1.46 ± 
0.006; p < 0.0001). The KU-60019 plus insulin group also had increased ACC phosphorylation 
compared to the insulin group (Ins 0.38 ± 0.04; KU + Ins 1.05 ± 0.005; p < 0.0001), but the 
overall effect on the P/T ratio was a decrease in the KU-60019 + insulin group compared to the 
insulin only group (Ins 1.90 ± 0.23; KU + Ins 0.77 ± 0.05; p < 0.0001). The results of ACC 
Western blot analysis in control hearts are indicated in Figure 4.33. 
HCD hearts had significantly higher total ACC compared to control diet hearts (Untreated 
control 1.00 ± 0.01; Untreated HCD 4.36 ± 0.79; p < 0.005). Although he ACC phosphorylation 
was also higher in the HCD hearts (Untreated control 1.00 ± 0.02; Untreated HCD 1.60 ± 0.16; p 
< 0.005), the P/T ratio was significantly lower in the HCD hearts compared to the control diet 
hearts (Untreated control 1.00 ± 0.006; Untreated HCD 0.33 ± 0.03; p < 0.0001). Compared to 
untreated HCD hearts, insulin treatment resulted in increased total ACC levels (Untreated HCD 
1.60 ± 0.16; Ins 7.74 ± 0.09; p < 0.005). Opposite to what was observed in the control hearts, 
KU-60019 and insulin co-treatment caused a decrease in total ACC levels compared to the 
insulin treated group (Ins 7.74 ± 0.09; KU + Ins 4.08 ± 0.39; p < 0.005) an a decrease in ACC 
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phosphorylation compared to the insulin only group (Ins 1.81 ± 0.02; KU + Ins 1.11 ± 0.05; p < 
0.005). The results of ACC Western blot analysis in HCD hearts are indicated in Figure 4.34. 
 
Figure 4.33: ACC expression and phosphorylation levels in control hearts following treatment with insulin, 
KU-60019 and a combination of insulin and KU-60019. A) Western blot chemiluminescent results of ACC 
and p-ACC and stain-free total protein stain of the membrane. B) Bar graph depicting analysed results for 
total ACC. C) Bar graph depicting analysed results for p-ACC (Ser79). D) Bar graph depicting phospho to 
total ratio of ACC. ** p < 0.005; *** p < 0.0001 (n=3 per group). 
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Figure 4.34: ACC expression and phosphorylation levels in HCD hearts following treatment with insulin, 
KU-60019 and a combination of insulin and KU-60019. A) Western blot chemiluminescent results of ACC 
and p-ACC and stain-free total protein stain of the membrane. B) Bar graph depicting analysed results for 
total ACC. C) Bar graph depicting analysed results for p-ACC (Ser79). D) Bar graph depicting phospho to 
total ratio of ACC. ** p < 0.005; *** p < 0.0001 (n=2-3 per group). 
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ATM 
In response to insulin treatment, there was a significant increase in total ATM (Untreated 1.00 ± 
0.06; Ins 1.57 ± 0.005; p < 0.0001) as well as ATM phosphorylation (Untreated 1.00 ± 0.01; Ins 
1.20 ± 0.02; p < 0.0001) compared to untreated control hearts. The P/T ratio was however 
significantly lower in the insulin treated group than the untreated control group (Untreated 1.06 ± 
0.05; Ins 0.76 ± 0.01; p < 0.005). Although KU-60019 treatment surprisingly led to an increase 
in total ATM levels (Untreated 1.00 ± 0.06; KU 1.22 ± 0.04; p < 0.05), phosphorylation of ATM 
was decreased by KU-60019 treatment (Untreated 1.00 ± 0.01; KU 0.86 ± 0.02; p < 0.005), 
resulting in a lower P/T ATM ratio in KU-60019 treated hearts compared to untreated hearts 
(Untreated 1.06 ± 0.05; KU 0.72 ± 0.02; p < 0.005). Co-treatment with insulin and KU-60019 
resulted in more total ATM compared to when hearts were treated with KU-60019 alone (KU 
1.22 ± 0.04; KU + Ins 1.49 ± 0.01; p < 0.05). The KU-60019 and insulin co-treatment group had 
significantly less ATM phosphorylation than either the insulin only group (Ins 1.20 ± 0.02; KU + 
Ins 0.68 ± 0.005; p < 0.0001) or the KU-60019 only group (KU 0.86 ± 0.02; KU + Ins 0.68 ± 
0.005; p < 0.005). In line with this, the KU-60019 and insulin co-treatment group had a lower P/T 
ratio than both the insulin only group (Ins 0.76 ± 0.01; KU + Ins 0.46 ± 0.0004; p < 0.005) and 
the KU-60019 only group (KU 0.72 ± 0.02; KU + Ins 0.46 ± 0.0004; p < 0.05). The results of 
ATM Western blot analysis in control hearts are indicated in Figure 4.35. 
In HCD hearts, none of the treatment groups had an effect on total ATM or ATM 
phosphorylation levels. The P/T ratios were also similar across all the groups. The results of 
ATM Western blot analysis in HCD hearts are indicated in Figure 4.36. 
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Figure 4.35: ATM expression and phosphorylation levels in control hearts following treatment with insulin, 
KU-60019 and a combination of insulin and KU-60019. A) Western blot chemiluminescent results of ATM 
and p-ATM and stain-free total protein stain of the membrane. B) Bar graph depicting analysed results for 
total ATM. C) Bar graph depicting analysed results for p-ATM (Ser1981). D) Bar graph depicting phospho 
to total ratio of ATM. * p < 0.05; ** p < 0.005; *** p < 0.0001 (n=2-3 per group). 
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Figure 4.36: ATM expression and phosphorylation levels in HCD hearts following treatment with insulin, 
KU-60019 and a combination of insulin and KU-60019. A) Western blot chemiluminescent results of ATM 
and p-ATM and stain-free total protein stain of the membrane. B) Bar graph depicting analysed results for 
total ATM. C) Bar graph depicting analysed results for p-ATM (Ser1981). D) Bar graph depicting phospho 
to total ratio of ATM. (n=2-3 per group). 
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4.4.2 Signalling after IRI 
Hearts from age-matched control and HCD animals were perfused with a Langendorff ex vivo 
perfusion protocol. The hearts were treated with insulin (activator), wortmannin (PI3K inhibitor), 
KU-60019 (ATM inhibitor) and activator-inhibitor combinations. Following the treatment period, 
the hearts were subjected to 20 minutes global ischaemia after which they were reperfused for 
10 minutes. The hearts were freeze-clamped and Western blot analysis used to determine the 
effect of the treatments on insulin signalling intermediates. 
JNK 
None of the treatments had a significant effect on total JNK, JNK phosphorylation or the P/T 
JNK ratio in control hearts (Figure 4.37). In the HCD hearts, co-treatment with KU-60019 and 
insulin resulted in significantly less total JNK compared to treatment with KU-60019 alone 
(Figure 4.38 B). None of the treatment groups had an effect on JNK phosphorylation or the P/T 
ratio in HCD hearts (Figure 4.38 C-D). When comparing only the KU-60019 treated hearts to 
untreated hearts, KU-60019 significantly reduced JNK phosphorylation in both control and HCD 
hearts (Figure 4.39 A). 
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Figure 4.37: JNK expression and phosphorylation levels following ischaemia and reperfusion in control 
hearts treated with insulin, wortmannin and KU-60019. A) Representative western blot chemiluminescent 
results of JNK and p-JNK and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total JNK. C) Bar graph depicting analysed results for p-JNK (Thr183/Tyr185). D) Bar 
graph depicting phospho to total ratio of JNK. (n=4 per group). 
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Figure 4.38: JNK expression and phosphorylation levels following ischaemia and reperfusion in HCD 
hearts treated with insulin, wortmannin and KU-60019. A) Representative western blot chemiluminescent 
results of JNK and p-JNK and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total JNK. C) Bar graph depicting analysed results for p-JNK (Thr183/Tyr185). D) Bar 
graph depicting phospho to total ratio of JNK. * p < 0.05 (n=4 per group, except Control Untreated n=2). 
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Figure 4.39: The effect of KU-60019 on JNK phosphorylation (Thr183/Tyr185). A) Two-way ANOVA to 
illustrate the effect of KU-60019 on JNK phosphorylation compared to untreated hearts in control and 
HCD hearts. B) Two-way ANOVA to illustrate the effect of KU-60019 on insulin stimulated JNK 
phosphorylation in control and HCD hearts. * p < 0.05 (n=4 per group). 
IRS-1 
The treatment groups had no effect on total IRS-1 levels or on IRS-1 (Ser307) phosphorylation 
in the control and the HCD hearts (Figures 4.40 & 4.41). In the control hearts, co-treatment with 
wortmannin and insulin resulted in a higher P/T ratio compared to treatment with insulin or 
wortmannin alone. KU-60019 also increased the P/T ratio in control hearts when compared to 
untreated control hearts (Figure 4.40 D). The P/T IRS-1 ratio was unchanged in the treatment 
groups in HCD hearts. Although no significant difference was detected between the P/T IRS-1 
ratio in untreated control and untreated HCD hearts using a one way ANOVA, an unpaired 
Student’s t-test between the two groups indicated that the HCD untreated hearts had a 
significantly higher P/T IRS-1 ratio compared to the untreated control hearts (Figure 4.41 D). 
Two-way ANOVA to determine the effect of KU-60019 on IRS-1 phosphorylation detected no 
significant effect (Figure 4.42). 
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Figure 4.40: IRS-1 expression and phosphorylation levels following ischaemia and reperfusion in control 
hearts treated with insulin, wortmannin and KU-60019. A) Representative western blot chemiluminescent 
results of IRS-1 and p-IRS-1 and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total IRS-1. C) Bar graph depicting analysed results for p-IRS1 (Ser307). D) Bar 
graph depicting phospho to total ratio of IRS1. * p < 0.05; *** p < 0.0001 (n=4 per group). 
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Figure 4.41: IRS-1 expression and phosphorylation levels following ischaemia and reperfusion in HCD 
hearts treated with insulin, wortmannin and KU-60019. A) Representative western blot chemiluminescent 
results of IRS-1 and p-IRS-1 and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total IRS-1. C) Bar graph depicting analysed results for p-IRS-1 (Ser307). D) Bar 
graph depicting phospho to total ratio of IRS-1. * p < 0.05 (Unpaired Student’s t-test) (n=4 per group, 
except Control Untreated n=2). 
Stellenbosch University  https://scholar.sun.ac.za
145 
 
 
Figure 4.42: The effect of KU-60019 on IRS-1 phosphorylation (Ser307). A) Two-way ANOVA to illustrate 
the effect of KU-60019 on IRS-1 phosphorylation compared to untreated hearts in control and HCD 
hearts. B) Two-way ANOVA to illustrate the effect of KU-60019 on insulin stimulated IRS-1 
phosphorylation in control and HCD hearts. (n=4 per group). 
P85 subunit of PI3K 
In control hearts, treatment with wortmannin resulted in significantly increased PI3K 
phosphorylation following IRI (Untreated 1.00 ± 0.01; Wm 1.72 ± 0.19; p < 0.005) (Figure 4.43 
C). None of the other groups had an effect on total PI3K, PI3K phosphorylation or P/T PI3K ratio 
in control hearts (Figure 4.43). The P/T ratio was significantly lower in untreated HCD hearts 
than in untreated control hearts after IRI (Untreated control 1.00; Untreated HCD 0.48 ± 0.01; p 
< 0.05) (Figure 4.44D). ATM inhibition with KU-60019 resulted in increased insulin stimulated 
phosphorylation of PI3K (Figure 4.45B). 
Stellenbosch University  https://scholar.sun.ac.za
146 
 
 
Figure 4.43: PI3K (p85 subunit) expression and phosphorylation levels following ischaemia and 
reperfusion in control hearts treated with insulin, wortmannin and KU-60019. A) Representative western 
blot chemiluminescent results of PI3K and p-PI3K and stain-free total protein stain of the membrane. B) 
Bar graph depicting analysed results for total PI3K. C) Bar graph depicting analysed results for p-PI3K 
(Tyr458). D) Bar graph depicting phospho to total ratio of PI3K. ** p < 0.005 (n=4 per group). 
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Figure 4.44: PI3K expression and phosphorylation levels following ischaemia and reperfusion in HCD 
hearts treated with insulin, wortmannin and KU-60019. A) Representative western blot chemiluminescent 
results of PI3K and p-PI3K and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total PI3K. C) Bar graph depicting analysed results for p-PI3K (Tyr458). D) Bar graph 
depicting phospho to total ratio of PI3K. * p < 0.05 (n=4 per group, except Control Untreated n=2). 
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Figure 4.45: The effect of KU-60019 on PI3K p85 phosphorylation (Tyr458). A) Two-way ANOVA to 
illustrate the effect of KU-60019 on PI3K phosphorylation compared to untreated hearts in control and 
HCD hearts. B) Two-way ANOVA to illustrate the effect of KU-60019 on insulin stimulated PI3K 
phosphorylation in control and HCD hearts. ** p < 0.005 (n=4 per group). 
PTEN 
Following IRI, total PTEN, PTEN phosphorylation and the P/T PTEN ratios of all groups were 
comparable in both the control (Figure 4.46) and HCD (Figure 4.47) hearts. ATM inhibition prior 
to IRI had no effect on PTEN phosphorylation after ten minutes of reperfusion (Figure 4.48). 
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Figure 4.46: PTEN expression and phosphorylation levels following ischaemia and reperfusion in control 
hearts treated with insulin, wortmannin and KU-60019. A) Representative western blot chemiluminescent 
results of PTEN and p-PTEN and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total PTEN. C) Bar graph depicting analysed results for p-PTEN 
(Ser380/Thr382/Thr383). D) Bar graph depicting phospho to total ratio of PTEN. (n=4 per group). 
 
Stellenbosch University  https://scholar.sun.ac.za
150 
 
 
Figure 4.47: PTEN expression and phosphorylation levels following ischaemia and reperfusion in HCD 
hearts treated with insulin, wortmannin and KU-60019. A) Representative western blot chemiluminescent 
results of PTEN and p-PTEN and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total PTEN. C) Bar graph depicting analysed results for p-PTEN 
(Ser380/Thr382/Thr383). D) Bar graph depicting phospho to total ratio of PTEN. (n=4 per group, except 
Control Untreated n=2). 
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Figure 4.48: The effect of KU-60019 on PTEN phosphorylation (Ser380/Thr382/Thr383). A) Two-way 
ANOVA to illustrate the effect of KU-60019 on PTEN phosphorylation compared to untreated hearts in 
control and HCD hearts. B) Two-way ANOVA to illustrate the effect of KU-60019 on insulin stimulated 
PTEN phosphorylation in control and HCD hearts. (n=4 per group). 
PKB/Akt 
The treatment groups had no effect on PKB/Akt expression or phosphorylation following IRI in 
either the control (Figure 4.49) or HCD (Figure 4.50) hearts. A two-way ANOVA revealed that 
treatment of KU-60019 significantly reduced insulin stimulated PKB/Akt (Ser473) 
phosphorylation in HCD hearts (Figure 4.51 B). 
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Figure 4.49: PKB/Akt expression and phosphorylation levels following ischaemia and reperfusion in 
control hearts treated with insulin, wortmannin and KU-60019. A) Representative western blot 
chemiluminescent results of PKB/Akt and p-PKB/Akt and stain-free total protein stain of the membrane. 
B) Bar graph depicting analysed results for total PKB/Akt. C) Bar graph depicting analysed results for p-
PKB/Akt (Ser473). D) Bar graph depicting phospho to total ratio of PKB/Akt. (n=4 per group). 
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Figure 4.50: PKB/Akt expression and phosphorylation levels following ischaemia and reperfusion in HCD 
hearts treated with insulin, wortmannin and KU-60019. A) Representative western blot chemiluminescent 
results of PKB/Akt and p-PKB/Akt and stain-free total protein stain of the membrane. B) Bar graph 
depicting analysed results for total PKB/Akt. C) Bar graph depicting analysed results for p-PKB/Akt 
(Ser473). D) Bar graph depicting phospho to total ratio of PKB/Akt. (n=4 per group, except Control 
Untreated n=2). 
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Figure 4.51: The effect of KU-60019 on PKB/Akt phosphorylation (Ser473). A) Two-way ANOVA to 
illustrate the effect of KU-60019 on PKB/Akt phosphorylation compared to untreated hearts in control and 
HCD hearts. B) Two-way ANOVA to illustrate the effect of KU-60019 on insulin stimulated PKB/Akt 
phosphorylation in control and HCD hearts. * p < 0.05 (n=4 per group). 
mTOR 
Expression and activation of mTOR was unaffected by the treatment groups in the control 
(Figure 4.52) and HCD (Figure 4.53) hearts. Treatment with KU-60019 had no effect on mTOR 
phosphorylation during reperfusion (Figure 4.54). 
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Figure 4.52: mTOR expression and phosphorylation levels following ischaemia and reperfusion in control 
hearts treated with insulin, wortmannin and KU-60019. A) Representative western blot chemiluminescent 
results of mTOR and p-mTOR and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total mTOR. C) Bar graph depicting analysed results for p-mTOR (Ser2448). D) Bar 
graph depicting phospho to total ratio of mTOR. (n=4 per group). 
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Figure 4.53: mTOR expression and phosphorylation levels following ischaemia and reperfusion in HCD 
hearts treated with insulin, wortmannin and KU-60019. A) Representative western blot chemiluminescent 
results of mTOR and p-mTOR and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total mTOR. C) Bar graph depicting analysed results for p-mTOR (Ser2448). D) Bar 
graph depicting phospho to total ratio of mTOR. (n=4 per group, except Control Untreated n=2). 
Stellenbosch University  https://scholar.sun.ac.za
157 
 
 
Figure 4.54: The effect of KU-60019 on mTOR phosphorylation (Ser2448). A) Two-way ANOVA to 
illustrate the effect of KU-60019 on mTOR phosphorylation compared to untreated hearts in control and 
HCD hearts. B) Two-way ANOVA to illustrate the effect of KU-60019 on insulin stimulated mTOR 
phosphorylation in control and HCD hearts. (n=4 per group). 
GSK-3β 
In control hearts, total GSK-3β was unaffected by the treatment groups during reperfusion. 
Treatment with wortmannin resulted in significantly reduced phosphorylation of GSK-3β 
compared to the untreated group (Untreated 1.00 ± 0.07; Wm 0.52 ± 0.11; p < 0.05). The P/T 
GSK-3β ratio was unchanged by the treatments in control hearts (Figure 4.55). The untreated 
HCD hearts had higher total GSK-3β levels compared to the untreated control hearts (Untreated 
control 1.00; Untreated HCD 1.56 ± 0.07; p < 0.05). Treatment with wortmannin significantly 
reduced total GSK-3β levels during reperfusion in HCD hearts (Untreated 1.56 ± 0.07; Wm 0.96 
± 0.15; p < 0.05). Phosphorylation of GSK-3β and the P/T ratios were unchanged by the 
treatment groups following IRI in HCD hearts (Figure 4.56). Treatment with KU-60019 had no 
effect on GSK-3β phosphorylation during reperfusion (Figure 4.57). 
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Figure 4.55: GSK-3β expression and phosphorylation levels following ischaemia and reperfusion in 
control hearts treated with insulin, wortmannin and KU-60019. A) Representative western blot 
chemiluminescent results of GSK-3β and p-GSK-3β and stain-free total protein stain of the membrane. B) 
Bar graph depicting analysed results for total GSK-3β. C) Bar graph depicting analysed results for p-GSK-
3β (Ser9). D) Bar graph depicting phospho to total ratio of GSK-3β. * p < 0.05 (n=4 per group). 
Stellenbosch University  https://scholar.sun.ac.za
159 
 
 
Figure 4.56: GSK-3β expression and phosphorylation levels following ischaemia and reperfusion in HCD 
hearts treated with insulin, wortmannin and KU-60019. A) Representative western blot chemiluminescent 
results of GSK-3β and p-GSK-3β and stain-free total protein stain of the membrane. B) Bar graph 
depicting analysed results for total GSK-3β. C) Bar graph depicting analysed results for p-GSK-3β (Ser9). 
D) Bar graph depicting phospho to total ratio of GSK-3β. * p < 0.05 (n=4 per group, except Control 
Untreated n=2). 
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Figure 4.57: The effect of KU-60019 on GSK-3β phosphorylation (Ser9). A) Two-way ANOVA to illustrate 
the effect of KU-60019 on GSK-3β phosphorylation compared to untreated hearts in control and HCD 
hearts. B) Two-way ANOVA to illustrate the effect of KU-60019 on insulin stimulated GSK-3β 
phosphorylation in control and HCD hearts. (n=4 per group). 
AS160 
There were no changes in total AS160 or phosphorylation of AS160 in control hearts during 
reperfusion. The P/T ratios were also unchanged (Figure 4.58). Untreated HCD hearts had a 
significantly lower P/T AS160 ratio compared to untreated control hearts (Untreated control 
1.00; Untreated HCD 0.30 ± 0.04; p < 0.05) (Figure 4.59 D). Total AS160 was unaffected by the 
treatment groups during reperfusion. Treatment with KU-60019 significantly increased insulin-
stimulated AS160 phosphorylation during reperfusion (Figures 4.59 C and 4.60 B). 
Stellenbosch University  https://scholar.sun.ac.za
161 
 
 
Figure 4.58: AS160 expression and phosphorylation levels following ischaemia and reperfusion in control 
hearts treated with insulin, wortmannin and KU-60019. A) Representative western blot chemiluminescent 
results of AS160 and p-AS160 and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total AS160. C) Bar graph depicting analysed results for p-AS160 (Thr642). D) Bar 
graph depicting phospho to total ratio of AS160. (n=4 per group). 
Stellenbosch University  https://scholar.sun.ac.za
162 
 
 
Figure 4.59: AS160 expression and phosphorylation levels following ischaemia and reperfusion in HCD 
hearts treated with insulin, wortmannin and KU-60019. A) Representative western blot chemiluminescent 
results of AS160 and p-AS160 and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total AS160. C) Bar graph depicting analysed results for p-AS160 (Thr642). D) Bar 
graph depicting phospho to total ratio of AS160. * p < 0.05 (n=4 per group, except Control Untreated 
n=2). 
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Figure 4.60: The effect of KU-60019 on AS160 phosphorylation (Thr642). A) Two-way ANOVA to 
illustrate the effect of KU-60019 on AS160 phosphorylation compared to untreated hearts in control and 
HCD hearts. B) Two-way ANOVA to illustrate the effect of KU-60019 on insulin stimulated AS160 
phosphorylation in control and HCD hearts. * p < 0.05 (n=4 per group). 
GLUT4 
Total GLUT4 levels were similar in all the treatment groups during reperfusion in both the age-
matched control and HCD hearts (Figure 4.61). 
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Figure 4.61: Total GLUT4 expression levels following ischaemia and reperfusion in hearts treated with 
insulin, wortmannin and KU-60019. A) Representative western blot chemiluminescent results of GLUT4 
and stain-free total protein stain of the membrane of age-matched control hearts. B) Representative 
western blot chemiluminescent results of GLUT4 and stain-free total protein stain of the membrane of 
HCD hearts C) Bar graph depicting analysed results for total GLUT4 in age-matched control hearts. (n=4 
per group). D) Bar graph depicting analysed results for total GLUT4 in HCD hearts. (n=4 per group, 
except Control Untreated n=2). 
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AMPK 
Total AMPK, AMPK phosphorylation and the P/T AMPK ratios were unchanged by the treatment 
groups in both the control (Figure 4.62) and HCD (Figure 4.63) hearts. Treatment with KU-
60019 had no effect on AMPK phosphorylation (Figure 4.64). 
 
Figure 4.62: AMPK expression and phosphorylation levels following ischaemia and reperfusion in control 
hearts treated with insulin, wortmannin and KU-60019. A) Representative western blot chemiluminescent 
results of AMPK and p-AMPK and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total AMPK. C) Bar graph depicting analysed results for p-AMPK (Thr172). D) Bar 
graph depicting phospho to total ratio of AMPK. (n=4 per group). 
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Figure 4.63: AMPK expression and phosphorylation levels following ischaemia and reperfusion in HCD 
hearts treated with insulin, wortmannin and KU-60019. A) Representative western blot chemiluminescent 
results of AMPK and p-AMPK and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total AMPK. C) Bar graph depicting analysed results for p-AMPK (Thr172). D) Bar 
graph depicting phospho to total ratio of AMPK. (n=4 per group, except Control Untreated n=2). 
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Figure 4.64: The effect of KU-60019 on AMPK phosphorylation (Thr172). A) Two-way ANOVA to 
illustrate the effect of KU-60019 on AMPK phosphorylation compared to untreated hearts in control and 
HCD hearts. B) Two-way ANOVA to illustrate the effect of KU-60019 on insulin stimulated AMPK 
phosphorylation in control and HCD hearts. (n=4 per group). 
ACC 
KU-60019 treatment increased total ACC levels in control hearts compared to the untreated 
control hearts (Untreated 1.00 ± 0.13; KU 3.31 ± 0.49; p < 0.005). None of the other treatment 
groups affected total ACC levels (Figure 4.65 B) and there were no changes in ACC 
phosphorylation during reperfusion in control hearts (Figure 4.65 C). Compared to untreated 
control hearts, the P/T ACC ratio was reduced in response to treatment with insulin (Untreated 
0.99 ± 0.04; Ins 0.40 ± 0.03; p < 0.0001), wortmannin (Untreated 0.99 ± 0.04; Wm 0.37 ± 0.03; p 
< 0.0001) and KU-60019 (Untreated 0.99 ± 0.04; KU 0.56 ± 0.07; p < 0.005). Co-treatment with 
KU-60019 and insulin resulted in a higher P/T ratio compared to treatment with insulin alone 
(Ins 0.40 ± 0.03; KU + Ins 0.88 ± 0.09; p < 0.0001) or KU-60019 alone (KU 0.56 ± 0.07; KU + 
Ins 0.88 ± 0.09; p < 0.05) (Figure 4.65 D). Total ACC, ACC phosphorylation and the P/T ACC 
ratios were unchanged during reperfusion by all the treatment groups in HCD hearts (Figure 
4.66). When a two-way ANOVA is performed, it is revealed that KU-60019 treatment 
significantly increased the phosphorylation of ACC in HCD hearts compared to untreated HCD 
hearts (Figure 4.67 A). 
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Figure 4.65: ACC expression and phosphorylation levels following ischaemia and reperfusion in control 
hearts treated with insulin, wortmannin and KU-60019. A) Representative western blot chemiluminescent 
results of ACC and p-ACC and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total ACC. C) Bar graph depicting analysed results for p-ACC (Ser79). D) Bar graph 
depicting phospho to total ratio of ACC. * p < 0.05; ** p < 0.005; *** p < 0.0001 (n=4 per group). 
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Figure 4.66: ACC expression and phosphorylation levels following ischaemia and reperfusion in HCD 
hearts treated with insulin, wortmannin and KU-60019. A) Representative western blot chemiluminescent 
results of ACC and p-ACC and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total ACC. C) Bar graph depicting analysed results for p-ACC (Ser79). D) Bar graph 
depicting phospho to total ratio of ACC. (n=4 per group, except Control Untreated n=2). 
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Figure 4.67: The effect of KU-60019 on ACC phosphorylation (Ser79). A) Two-way ANOVA to illustrate 
the effect of KU-60019 on ACC phosphorylation compared to untreated hearts in control and HCD hearts. 
B) Two-way ANOVA to illustrate the effect of KU-60019 on insulin stimulated ACC phosphorylation in 
control and HCD hearts. (n=4 per group). 
ATM 
Total ATM, ATM phosphorylation and the P/T ATM ratios were unchanged by the treatment 
groups in both the control (Figure 4.68) and HCD (Figure 4.69) hearts. Treatment with KU-
60019 had no effect on ATM phosphorylation during reperfusion (Figure 4.70). 
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Figure 4.68: ATM expression and phosphorylation levels following ischaemia and reperfusion in control 
hearts treated with insulin, wortmannin and KU-60019. A) Representative western blot chemiluminescent 
results of ATM and p-ATM and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total ATM. C) Bar graph depicting analysed results for p-ATM (Ser1981). D) Bar 
graph depicting phospho to total ratio of ATM. (n=4 per group). 
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Figure 4.69: ATM expression and phosphorylation levels following ischaemia and reperfusion in HCD 
hearts treated with insulin, wortmannin and KU-60019. A) Representative western blot chemiluminescent 
results of ATM and p-ATM and stain-free total protein stain of the membrane. B) Bar graph depicting 
analysed results for total ATM. C) Bar graph depicting analysed results for p-ATM (Ser1981). D) Bar 
graph depicting phospho to total ratio of ATM. (n=4 per group, except Control Untreated n=2). 
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Figure 4.70: The effect of KU-60019 on ATM phosphorylation (Ser1981). A) Two-way ANOVA to illustrate 
the effect of KU-60019 on ATM phosphorylation compared to untreated hearts in control and HCD hearts. 
B) Two-way ANOVA to illustrate the effect of KU-60019 on insulin stimulated ATM phosphorylation in 
control and HCD hearts. (n=4 per group). 
4.5 Ex vivo working heart perfusions 
Hearts were isolated from animals that have been on the HCD for 16 weeks as well as from 
age-matched control animals. The hearts were perfused in an ex vivo fashion and exposed to 
IRI in order to assess cardiac function before and after IRI as well as the resultant IFS. Cardiac 
function was assessed after 25 minutes of reperfusion. The hearts were also exposed to various 
pharmaceutical agents, such as insulin (1 U/L), wortmannin (100nM) and KU-60019 (3 μM), 
prior to being subjected to IRI in order to manipulate the ATM signalling and to assess the effect 
thereof on cardiac functioning and IFS. Infarct sizes are displayed as percentage of the AAR 
with AAR being 51.58 ± 0.73% and not varying between all groups. 
4.5.1 The effect of the HCD on cardiac function and infarct size following IRI 
The HCD had no effect on any of the measured parameters of cardiac function before or after 
IRI in untreated hearts compared to the control diet (Table 4.8). Ischaemia/reperfusion injury 
did, however, significantly reduce AO, heart rate, SP, DP and total work performed by both 
control and HCD hearts (Table 4.8). Out of the control hearts, 43% did not show functional 
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recovery following IRI, while 51% of the HCD hearts did not have any functional recovery 
following IRI. There was no significant difference in IFS between the two groups (Control 33.24 
± 2.6%; HCD 30.60 ± 2.7%; p=0.49) (Figure 4.71). 
Table 4.8: Cardiac function before and after ischaemia/reperfusion injury in untreated control and HCD 
hearts (n=7-8 per group). 
Parameter Diet Before IRI After IRI 
Coronary Flow 
(mL/min) 
Control 17.8 ± 1.1 16.2 ± 1.5 
HCD 16.9 ± 1.2 15.7 ± 1.1 
Aortic Output 
(mL/min) 
Control 36.8 ± 3.4 3.8 ± 2.0 (c) 
HCD 31.3 ± 1.6 4.0 ± 2.7 (c) 
Heart Rate 
(beats/minute) 
Control 289.0 ± 11.1 168.3 ± 49.9 (a) 
HCD 263.6 ± 11.1 124.8 ± 47.9 (a) 
Aortic Systolic 
Pressure (mm Hg) 
Control 88.4 ± 2.1 49.8 ± 14.6 (a) 
HCD 89.3 ± 1.1 40.9 ± 15.5 (a) 
Aortic Diastolic 
Pressure (mm Hg) 
Control 71.8 ± 1.2 38.4 ± 13.6 (a) 
HCD 72.3 ± 0.8 34.0 ± 12.9 (a) 
Total Work (mWatts) 
Control 10.3 ± 1.2 2.5 ± 0.8 (c) 
HCD 9.8 ± 0.5 2.2 ± 0.9 (c) 
a p < 0.05; c p < 0.001 Compared to Before IRI. 
 
Figure 4.71: The effect of the HCD on infarct size following 35 minutes of regional ischaemia and 60 
minutes of reperfusion (n=6 per group). 
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4.5.2 The effect of insulin, wortmannin and KU-60019 on cardiac function and infarct size 
following IRI in control and HCD fed rat hearts 
Cardiac function results 
Ischaemia-reperfusion injury had no effect on CF in either the control or HCD hearts. 
Additionally, none of the treatments had a significant effect on CF following IRI (Table 4.9). Not 
all of the hearts recovered functionally following IRI. As indicated in Table 4.10, 57% of control 
hearts had functional recovery while 49% of HCD hearts recovered functionally after IRI across 
all the groups. Hearts that failed to generate an AO were excluded from the “After IRI” data 
analyses. As anticipated, AO was significantly decreased in all groups following IRI in both the 
control and HCD hearts. The only exception was the control KU-60019 group (Table 4.10). In 
the control hearts, KU-60019 was able to block the effect of insulin and significantly reduce the 
AO back to vehicle control levels (Table 4.10). Aortic output was significantly lower in HCD 
insulin treated hearts compared to control insulin treated hearts. 
Total work was significantly decreased following IRI in both the control and HCD hearts in all the 
treatment groups. Compared to the vehicle control, insulin significantly increased the total work 
in the control hearts following IRI. This effect of insulin was blocked with the use of both 
inhibitors (wortmannin and KU-60019) in control hearts. Insulin was unable to increase total 
work performed by the HCD hearts compared to the untreated hearts and as a result, total work 
performed by the insulin-treated HCD hearts was significantly reduced compared to the total 
work performed by insulin-treated control hearts (Table 4.11). 
Aortic SP decreased significantly following IRI. Insulin treatment significantly increased aortic 
SP following IRI compared to vehicle control treated hearts and this effect of insulin was blocked 
by both wortmannin and KU-60019. Insulin was unable to increase aortic SP in HCD hearts 
(Table 4.12). Heart rate was not affected by IRI or by any of the treatments used (Table 4.13).  
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Table 4.9: Coronary flow (mL/min) before and after ischaemia/reperfusion injury in treated control and 
HCD hearts. Data expressed as mean with standard error of the mean (n=6-8). 
 Before IRI
&
 After IRI 
Control 
Vehicle Control 17.75 ± 1.07 16.20 ± 1.45 
Insulin 20.17 ± 2.01 16.42 ± 1.33 
Wortmannin 16.69 ± 1.48 15.36 ± 1.28 
Wortmannin + Insulin 20.29 ± 2.42 14.50 ± 2.07 
KU-60019 17.94 ± 1.68 16.75 ± 1.06 
KU-60019 + Insulin 18.57 ± 1.25 19.07 ± 2.90 
HCD 
Vehicle Control 16.94 ± 1.15 15.67 ± 1.11 
Insulin 18.44 ± 1.49 15.81 ± 1.63 
Wortmannin 16.5 ± 1.18 15.75 ± 3.28 
Wortmannin + Insulin 19.06 ± 1.00 17.21 ± 1.71 
KU-60019 18.63 ± 1.92 18.00 ± 2.30 
KU-60019 + Insulin 17.94 ± 1.65 15.25 ± 1.11 
&
 Basal coronary flow measurements before treatments were given. 
 
Table 4.10: Aortic output (mL/min) before and after ischaemia/reperfusion injury in treated control and 
HCD hearts. Data expressed as mean with standard error of the mean (n=6-8). 
  
Before IRI
& After IRI 
Hearts 
Recovered 
Control 
Vehicle Control 36.79 ± 3.37 10.00 ± 2.78 (b) 3/7 (42.9%)  
Insulin 40.75 ± 3.61 18.10 ± 3.05 (b) 5/6 (83.3%) 
Wortmannin 39.43 ± 3.70 11.13 ± 3.80 (c) 4/7 (57.1%) 
Wortmannin + Insulin 38.00 ± 4.32 8.00 ± 4.00 (a) 2/7 (28.6%) 
KU-60019 35.86 ± 4.36 19.50 ± 6.24 4/8 (50.0%) 
KU-60019 + Insulin 36.57 ± 3.05 10.25 ± 1.78 (c) (#) 6/7 (85.7%) 
HCD 
Vehicle Control 31.29 ± 1.55 16.00 ± 4.00 (b) 2/7 (28.6%) 
Insulin 33.75 ± 2.89 7.60 ± 1.69 (c) (+) 5/8 (62.5%) 
Wortmannin 36.40 ± 5.56 7.00 ± 4.04 (a) 3/6 (50.0%) 
Wortmannin + Insulin 39.00 ± 4.52 8.75 ± 3.25 (b) 4/7 (57.1%) 
KU-60019 35.00 ± 3.23 8.67 ± 2.67 (b) 3/7 (42.9%) 
KU-60019 + Insulin 35.33 ± 3.04 15.25 ± 8.56 (a) 4/8 (50.0%) 
&
 Basal coronary flow measurements before treatments were given. 
a p < 0.05; b p < 0.005; c p < 0.0001; Compared to Before IRI 
# p < 0.05; Compared to Insulin 
+ p < 0.05; Compared to Control 
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Table 4.11: Total work (mWatts) before and after ischaemia/reperfusion injury in treated control and HCD 
hearts. Data expressed as mean with standard error of the mean (n=6-8). 
  Before IRI
&
 After IRI 
Control 
Vehicle Control 11.20 ± 0.98 4.02 ± 0.50 (c) 
Insulin 12.61 ± 1.00 6.44 ± 0.80 (b) (*) 
Wortmannin 10.81 ± 1.38 4.33 ± 0.70 (b) 
Wortmannin + Insulin 12.14 ± 0.89 4.14 ± 1.23 (b) 
KU-60019 11.14 ± 1.39 5.63 ± 1.40 (a) 
KU-60019 + Insulin 11.46 ± 0.81 5.17 ± 0.81 (c) 
HCD 
Vehicle Control 9.77 ± 0.53 4.32 ± 0.86 (c) 
Insulin 10.19 ± 1.00 4.18 ± 0.62 (c) (+) 
Wortmannin 11.30 ± 1.59 3.85 ± 1.02 (b) 
Wortmannin + Insulin 11.77 ± 0.96 4.79 ± 0.65 (c) 
KU-60019 11.80 ± 0.96 4.02 ± 0.66 (c) 
KU-60019 + Insulin 11.22 ± 0.88 4.55 ± 1.18 (b) 
&
 Basal coronary flow measurements before treatments were given. 
a p < 0.05; b p < 0.005; c p < 0.0001; Compared to Before IRI 
* p < 0.05; Compared to Vehicle control 
+ p = 0.05; Compared to Control 
Table 4.12: Aortic systolic pressure (mmHg) before and after ischaemia/reperfusion injury in treated 
control and HCD hearts. Data expressed as mean with standard error of the mean (n=6-8). 
  Before IRI
&
 After IRI 
Control 
Vehicle Control 88.38 ± 2.08 79.60 ± 1.50 (a) 
Insulin 91.33 ± 1.05 84.20 ± 1.02 (c) (*) 
Wortmannin 91.00 ± 1.67 81.67 ± 1.12 (b) 
Wortmannin + Insulin 90.17 ± 2.27 78.00 ± 2.42 (b) 
KU-60019 90.88 ± 2.11 82.33 ± 1.96 (a) 
KU-60019 + Insulin 91.57 ± 1.86 82.14 ± 0.55 (c) 
HCD 
Vehicle Control 89.29 ± 1.09 81.75 ± 1.81 (b) 
Insulin 87.13 ± 1.58 81.50 ± 2.46 
Wortmannin 89.14 ± 2.34 82.00 ± 1.23 
Wortmannin + Insulin 89.25 ± 1.41 81.00 ± 0.41 (b) 
KU-60019 90.25 ± 1.91 80.00 ± 0.86 (c) 
KU-60019 + Insulin 89.71 ± 2.04 80.71 ± 0.92 (b) 
&
 Basal coronary flow measurements before treatments were given. 
a p < 0.05; b p < 0.005; c p < 0.0001; Compared to Before IRI 
* p < 0.05; Compared to Vehicle control 
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Table 4.13: Heart rate (beats/minute) before and after ischaemia/reperfusion injury in treated control and 
HCD hearts. Data expressed as mean with standard error of the mean (n=6-8). 
  Before IRI
&
 After IRI 
Control 
Vehicle Control 289.0 ± 11.1 269.2 ± 12.9 
Insulin 291.8 ± 16.1 281.4 ± 15.7 
Wortmannin 260.4 ± 13.4 263.2 ± 6.6 
Wortmannin + Insulin 286.8 ± 9.7 252.2 ± 22.1 
KU-60019 254.0 ± 15.3 255 ± 13.4 
KU-60019 + Insulin 287.6 ± 9.3 280.6 ± 9.2 
HCD 
Vehicle Control 263.6 ± 11.1 249.5 ± 18.1 
Insulin 276.1 ± 11.4 296.3 ± 15.9 
Wortmannin 275.6 ± 14.5 268.0 ± 20.8 
Wortmannin + Insulin 306.3 ± 10.7 308.5 ± 13.2 
KU-60019 272.9 ± 11.3 286.5 ± 9.8 
KU-60019 + Insulin 286.0 ± 14.3 302.0 ± 19.6 
& 
Basal coronary flow measurements before treatments were given. 
Infarct size results 
In HCD hearts, both insulin treatment and wortmannin treatment resulted in larger IFS 
compared to the vehicle control HCD group (HCD vehicle control 30.60 ± 2.65%; HCD Ins 46.74 
± 5.89%, p < 0.05; HCD Wm 45.98 ± 6.19%, p < 0.05). Although only borderline significant, co-
treatment with insulin and wortmannin in HCD hearts resulted in smaller IFS compared to 
treatment with insulin or wortmannin alone (HCD Wm + Ins 31.24 ± 3.00%; HCD Ins 46.74 ± 
5.89%, p = 0.056; HCD Wm 45.98 ± 6.19%, p = 0.058). Wortmannin had no effect on IFS in 
control hearts (Figure 4.72). 
Insulin treatment also resulted in larger IFS in control hearts compared to the vehicle control 
group (Control vehicle control 33.24 ± 2.61%; Control ins 53.49 ± 5.30%; p < 0.005). KU-60019 
reduced this effect of insulin in control hearts (Control ins 53.49 ± 5.30%; Control KU + Ins 
39.06 ± 4.07%; p = 0.056). In HCD hearts, KU-60019 treatment resulted in significantly reduced 
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IFS compared to the vehicle control group (HCD vehicle control 30.60 ± 2.65%; HCD KU 22.58 
± 1.75%; p < 0.05). KU-60019 treatment was however not able to reduce the insulin-stimulated 
effect on IFS (HCD KU 22.58 ± 1.75%; HCD KU + Ins 54.31 ± 3.04%; p < 0.0001). Hearts from 
HCD animals had smaller IFS compared to hearts from control animals when treated with KU-
60019 (Control KU 36.39 ± 5.14%; HCD KU 22.58 ± 1.75%; p < 0.05) while co-treatment with 
KU-60019 and insulin resulted in larger infarcts in HCD hearts compared to control hearts 
(Control KU + Ins 39.06 ± 4.07%; HCD KU + Ins 54.31 ± 3.04%; p < 0.05) (Figure 4.73). 
 
Figure 4.72: The effect of insulin (1 U/L) and wortmannin (100 nM) on infarct size following 35 minutes of 
regional ischaemia and 60 minutes of reperfusion * P < 0.05; ** p < 0.005; # p < 0.06 (n=6 per group). 
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Figure 4.73: The effect of insulin (1 U/L) and KU-60019 (3 μM) on infarct size following 35 minutes of 
regional ischaemia and 60 minutes of reperfusion * p < 0.05; ** p < 0.005; *** p < 0.0001; # p = 0.056 
(n=6 per group). 
4.5.3 The effect of reduced insulin concentration on infarct size following IRI 
Because of the unexpected finding that insulin increased IFS, perfusions were performed in 
which the hearts were treated with lower insulin concentrations (0.3 U/L vs 1 U/L). With the 
reduced insulin concentration, insulin treatment no longer resulted in increased IFS (Figure 
4.74). 
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Figure 4.74: The effect of a reduced insulin concentration (0.3 U/L) and KU-60019 (3 μM) on infarct size 
following 35 minutes of regional ischaemia and 60 minutes of reperfusion (n=3-6 per group). 
4.6 Aortic ring studies 
Aortic rings were harvested from age-matched control animals and mounted in an organ bath 
where isometric tension experiments were conducted. This was done to further investigate the 
possible vasodilatory effect of KU-60019 as KU-60019 significantly increased the CF in the 
perfusion experiments, without changing the pressure development. Figure 4.75 indicates the 
percentage relaxation of aortic rings treated with ACh, KU-60019 and DMSO. Acetylcholine was 
used as a positive control for relaxation. Pre-treatment with L-NAME abolished the vasodilatory 
effect of ACh, reducing the final relaxation from 74.7 ± 3.8% when treated with ACh alone to 6.9 
± 0.8% when pre-treated with L-NAME (p < 0.0001). Although it did not have such a 
pronounced relaxation effect as ACh, treatment with KU-60019 also resulted in vasodilation. 
The percentage relaxation when treated with KU-60019 was 44.7 ± 5.4% compared to 74.7 ± 
3.8% when treated with ACh (p < 0.0001). Pre-treatment with L-NAME was able to abolish the 
vasodilatory effect of KU-60019, resulting in a final percentage relaxation of only 8.5 ± 1.4% (p < 
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0.0001). At each concentration used, KU-60019 had a significantly greater percentage 
relaxation than DMSO, indicating that the vasodilatory effect of KU-60019 is not caused by the 
DMSO vehicle. 
 
Figure 4.75: Graph indicating percentage relaxation of aortic rings in response to cumulative 
concentrations of DMSO, KU-60019 and acetylcholine and the effect of pre-incubation with the NOS-
inhibitor, L-NAME. * p < 0.05; **, ## and ++ p < 0.005; ***, ###, &&& p < 0.0005; ****, ####, ++++ and 
&&&& p < 0.0001 (n=5-7 per group). 
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4.7 Results at a glance 
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Chapter 5: Discussion 
With an increase in urbanization, consumption of a “Western diet” and sedentary lifestyles, the 
global burden of disease is shifting more towards non-communicable diseases. According to the 
WHO, there are four main types of non-communicable diseases, including cancer, chronic 
respiratory diseases, CVD and diabetes (WHO, Noncommunicable Diseases). The latter two 
conditions are linked as diabetes is considered a major risk factor for the development of CVD. 
Effective prevention and management of these complex conditions is dependent on a clear 
understanding of the molecular mechanisms implicated in their aetiologies. 
Insulin resistance, glucose intolerance and diabetes are often listed as symptoms of A-T and 
patients with A-T have been documented to be affected by ischaemic heart disease. There is 
thus a possibility that ATM deficiency could play a role in the development of these conditions. 
However, the majority of studies that investigate ATM are focused on its role as an anti-cancer 
target and as a result, very little is known about the mechanisms in which ATM deficiency lead 
to insulin resistance, glucose intolerance, diabetes and heart disease. 
The aim of the current study was thus to investigate the potential role of ATM in the 
development of myocardial pathology associated with insulin resistance. We made use of an 
insulin resistant rat model and manipulated ATM activity using pharmaceutical agents. In the 
perfusion protocols, insulin, wortmannin and KU-60019 were administered prior to ischaemia, 
were present during ischaemia and were only washed out at the onset of reperfusion. During 
administration, all pharmaceutical agents were re-circulated. We made use of a 
supraphysiological insulin concentration. Western blot analyses to investigate insulin signalling 
networks were performed in the presence of the pharmaceutical agents prior to ischaemia as 
well as during reperfusion once the pharmaceutical agents have been washed out of the hearts. 
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5.1 Summary of key findings 
The key findings of the study are listed below: 
 The HCD resulted in decreased basal total ATM and PKB/Akt levels, increased body 
mass, visceral fat mass, non-fasting and fasting glucose levels, increased insulin levels, 
increased HOMA-IR values and increased glucose levels during an OGTT compared to 
the control diet. 
 Cardiac function and IFS following IRI were comparable in untreated hearts from animals 
on the control diet and the HCD. 
 High concentration insulin treatment increased IFS in control and HCD hearts while 
lower insulin concentration treatment had no effect on IFS. 
 Insulin treatment improved haemodynamic function in control hearts. Insulin had no 
effect on haemodynamic function in HCD hearts. 
 In control hearts, not all proteins of the insulin signalling network were responsive to 
insulin before ischaemia and the insulin signalling pathway was not activated by insulin 
during reperfusion. 
 In HCD hearts, insulin did not activate the insulin signalling pathway before ischaemia or 
during reperfusion. 
 ATM inhibition increased cardiac function during early reperfusion following global 
ischaemia in control and HCD hearts. 
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 ATM had no effect on IFS in control hearts. HCD hearts had smaller infarcts in response 
to KU-60019 treatment alone, but KU-60019 treatment was unable to reduce insulin-
stimulated IFS. 
 In control hearts, ATM was activated by insulin and inhibited by KU-60019. Neither 
insulin nor KU-60019 had an effect on ATM activity in HCD hearts. 
 In control hearts, PI3K activation was reduced while PTEN and GSK-3β was activated in 
response to KU-60019 while PKB/Akt, AMPK and ACC were unaffected. 
 Treatment with KU-60019 attenuated the insulin signalling network in HCD hearts. 
 ATM inhibition increased CF in perfused hearts and had a NO-dependent vasodilatory 
effect on isolated aorta rings. 
 Chloroquine did not activate cardiac ATM or contribute to increased glucose uptake in 
cardiomyocytes. Chloroquine treatment led to increased necrosis of cardiomyocytes and 
reduced cardiac function. 
5.2 Comparison between the diets (control, DIO and HCD) 
In order to investigate the effect of ATM in the myocardial pathology associated with insulin 
resistance, we firstly required an animal model that displayed insulin resistance. Two diets were 
assessed for their ability to induce insulin resistance and obesity in adult male Wistar rats. The 
first diet had an increased carbohydrate content (DIO) while the second had an increased 
carbohydrate and fat content (HCD) compared to the control chow diet. These diets generally 
lead to hyperphagia as the rats find them highly palatable. 
Diets were used to induce obesity and insulin resistance in the animal models, as opposed to 
genetic mutations, as it better resembles the development of obesity in humans. It also 
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eliminates the possibility of observing unwanted confounding effects of genetic alterations. 
Furthermore, the use of diets to induce obesity and insulin resistance in animals has been 
shown to be effective when studying CVD (Rosini et al., 2012). 
5.2.1 Biometric data 
Although the DIO diet caused an increase in visceral fat mass, the body mass and glucose 
levels were comparable to that of the control diet. It, therefore, did not have the desired effect 
and was not used further.  
Rats on the HCD had significantly increased body masses and visceral fat masses compared to 
rats on the control chow diet (Table 4.1). The HCD had a greater fat and carbohydrate content 
and reduced protein content compared to the control diet. The HCD also had a higher energy 
content than the control diet (Table 3.1). Although food intake was not measured during this 
study, a diet high in sugar and fat has been shown to induce hyperphagia in rats (Lucas and 
Sclafani, 1990). The increased energy content, together with the likely hyperphagia caused by 
the high sugar and fat content of the diet, resulted in rats on the HCD consuming more energy 
than they could expend, ultimately leading to weight gain. 
A high fat-high sugar diet has previously been shown to successfully induce insulin resistance in 
Sprague-Dawley rats (Motshakeri et al., 2015). Animals on the HCD had increased fasting and 
non-fasting glucose levels, together with increased serum insulin levels compared to the control 
chow-fed group. This scenario is characteristic of insulin resistance as cells are resistant to the 
effect of insulin, resulting in hyperglycaemia as glucose is not taken up into cells. The increased 
serum glucose levels in turn result in increased insulin secretion. The presence of insulin 
resistance in animals that received the HCD is also evident through the increase in the HOMA-
IR index compared to animals on the control diet. Furthermore, rats that were on the HCD had 
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consistently higher glucose levels during an OGTT than animals that were on the control diet, 
signifying glucose intolerance in the HCD. 
Since both diets (DIO and HCD) had increased carbohydrate content, in the form of condensed 
milk and sucrose, and decreased protein content compared to the control diet, it is likely the 
high fat content of the HCD that contributed to the increased obesity, insulin resistance and 
glucose intolerance observed in the HCD but not the DIO diet. 
5.2.2 Basal ATM expression and activation levels 
Western blot analysis was performed on hearts from animals on the control, DIO and HCD diets 
in order to determine the ATM and PKB/Akt expression and activation levels. The DIO diet, 
which had only increased carbohydrates, had no effect on ATM or PKB/Akt. The HCD, which 
had increased fat content as well as increased carbohydrate content, caused a significant 
decrease in basal ATM expression in cardiac tissue. Although total ATM was reduced in the 
HCD, phospho-ATM levels were equal between the diets. This is an indication that ATM 
phosphorylation is up-regulated in the HCD in order to achieve normal activation levels 
eventhough there is less total ATM available. This is indicated by the increased P/T ATM ratio in 
the HCD compared to the control diet (Figure 4.1). 
A high fat diet has been shown to cause an increase in oxidative stress and a decrease in 
antioxidant capacity in heart tissue in rats (Noeman et al., 2011). We speculate that the activity 
of ATM could be increased in the HCD in response to the oxidative stress associated with a diet 
high in fat. Oxidative stress is a known activator of ATM (Guo et al., 2010). 
A decrease in ATM expression due to high dietary fat intake is consistent with the findings in 
skeletal muscle by Halaby et al. (2008). They suggested that the decreased ATM expression 
that is associated with consumption of a high-fat diet contributes to the development of insulin 
resistance by down-regulation of PKB/Akt activity in skeletal muscle. However, in contrast to 
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Halaby et al. (2008), who found an associated decrease in PKB/Akt activation, we found no 
change in phosphorylation of PKB/Akt (Ser473) in the HCD compared to the control diet. In fact, 
due to a significant decrease in PKB/Akt expression in the HCD, hearts from HCD-fed rats had 
an increased P/T PKB/Akt ratio compared to hearts from animals on the control diet. 
5.2.3 Myocardial function in HCD fed animals 
The heart adapts to stress caused by insulin resistance and obesity by altering its structure, 
function, metabolism and efficiency. Although these changes benefit the heart in the short term, 
they may contribute to decreased contractility and cardiac dysfunction in the long term 
(Peterson, 2006). It is well documented that obesity and insulin resistance are risk factors for 
the development of CVD in humans. However, contradictory results have been obtained in 
animal models. Park et al. (2005) observed a decline in cardiac function in diet-induced insulin 
resistant mice and du Toit et al. (2008) observed increased IFS and decreased AO recovery in 
diet-induced obese rats. In contrast, Wensley et al. (2013) found that there was no difference in 
the structure and function of hearts from obese and insulin resistant rats compared to control 
hearts. Nduhirabandi (2014) also found that myocardial function was not adversely affected by a 
high caloric diet in rats. Paradixically, in our laboratory and elsewhere, there have also been 
reports of improved cardiac function in obesity. 
In the current study, even though the HCD did result in increased insulin resistance, glucose 
intolerance and obesity and reduced total ATM levels compared to the control diet, we did not 
observe any noteworthy differences in any of the measured parameters of cardiac function 
between hearts from the two diets, either before or after IRI (Table 4.8). This indicates that the 
HCD used in this study did not adversely affect cardiac function following a 16-week feeding 
period or that the effect of our HCD was not pronounced enough. It is possible that adverse 
cardiac effects in response to the HCD will only become visible after a longer feeding period. It 
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is also possible that our age-matched control animals had reduced cardiac function compared to 
young healthy animals. We did not evaluate the effect of age on cardiac function in the current 
study, however, in a parallel study van Vuuren (2015) found that cardiomyocytes isolated from 
the age-matched control animals had reduced insulin-stimulated glucose uptake compared to 
cardiomyocytes from young control animals. This indicates that, although they are more insulin 
responsive than hearts from HCD animals, hearts from age-matched control animals did display 
insulin resistance to some degree. This would minimise the effects seen when comparing the 
HCD hearts to hearts of the compromised control animals.  
Both the control and HCD hearts had AO values lower than what is considered normal in young, 
healthy control hearts. Usually hearts with AO values lower than 36 mL/min would be discarded 
in our laboratory. However, we have found that hearts from animals that are older can have 
reduced AO despite being mounted correctly. Hearts with AO values lower than 36 mL/min were 
therefore retained in the study if they were optimally mounted on the perfusion rig and were able 
to maintain the AO for the work heart perfusion time of 15 min. 
5.2.4 Infarct sizes in HCD fed animals 
Obesity and insulin resistance increase the myocardium’s susceptibility to ischaemia-
reperfusion injury (Wensley et al., 2013) and obesity is commonly accepted as a risk factor for 
myocardial infarction (Yusuf et al., 2005). Although the heart uses fatty acid oxidation as its 
main source of energy production, cardiac metabolism shifts in favour of glycolysis during 
ischaemia. The insulin resistant heart, however, has a greater dependency on fatty acid 
oxidation due to its reduced ability to utilize glucose. It is therefore expected that hearts from 
obese, insulin resistant animals will have larger IFS due to the inability of these hearts to 
produce energy through anaerobic glycolysis (Thim et al., 2006). However, IFS have varied in 
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animal studies of diabetes and obesity (Miki et al., 2013). We found IFS to be similar in hearts 
from animals on the control diet and the HCD (Figure 4.71). 
The inconsistency observed in cardiac function and IFS between different studies is possibly 
due to the use of different diet compositions, different diet feeding durations and the use of 
animals with different genetic backgrounds as well as to the inherent biological variation in the 
response of animals. 
5.3 Cardiac function following ischaemia/reperfusion injury in response to pre-treatment 
with insulin, wortmannin and KU-60019 
During ischaemia, the lack of oxygen results in cessation of oxidative phosphorylation and an 
increase in anaerobic glycolysis. This in turn causes an accumulation of lactate and protons and 
a decrease in pH. By exchanging protons for Na+, and Na+ for Ca2+, there is an eventual Ca2+ 
overload in the ischaemic cell (Hausenloy and Yellon, 2013; Kalogeris et al., 2012). Calcium 
overload plays a significant role in the cardiac dysfunction observed in response to IRI (Nayler, 
1981). 
Ischaemic contracture, when DP gradually rises during a myocardial ischaemic period, is a 
marker of ischaemic injury (Reichelt et al., 2007; Torrance et al., 2000). Contracture develops in 
response to mitochondrial injury, depletion of ATP (which is needed for the dissociation of 
actin/myosin cross-bridges) and Ca2+ overload (Torrance et al., 2000). Delayed onset of 
contracture and a reduced peak developed pressure is an indication of reduced susceptibility to 
ischaemic injury. 
Calcium overload, together with phosphate overload and the increase in ROS production during 
reperfusion, contribute to the mitochondrial inner membrane becoming permeable, a 
phenomenon known as opening of the mitochondrial permeability transition pore. This leads to a 
loss of protons and subsequently, a loss of the electrochemical proton gradient required for ATP 
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production (Honda and Ping, 2006). After ATP is depleted, the damaged mitochondria swell and 
rupture. Ruptured mitochondria can release pro-apoptotic proteins or affected cardiomyocytes 
will eventually die due to necrosis caused by ATP depletion (Baines, 2009). 
Due to the decline in ATP during ischaemia, cardiac contractility is significantly reduced. 
Contractility is further reduced as a result of proteolysis of proteins that make up the sarcomere 
and posttranslational modifications caused by ROS (Chen and Ogut, 2006). Upon reperfusion, 
restoration of myocardial contractility could be delayed as a result of myocardial stunning. In 
myocardial stunning, post-ischaemic dysfunction is completely reversible and CF is restored to 
normal rates (Bolli and Marbán, 1999). In contrast, myocardial infarction is the result of 
irreparable damage to the heart when myocardial cell death has occurred. Both necrosis and 
apoptosis contribute to cell death during IRI (Yellon and Baxter, 1999). In an attempt to protect 
the heart against IRI, pro-survival signalling pathways such as the PI3K-PKB/Akt pathway and 
the ERK1/2 signalling cascades are activated. Both of these pathways have anti-apoptotic 
effects (reviewed in Hausenloy and Yellon, 2004).  
5.3.1 Insulin 
Insulin is widely believed to protect the heart against IRI. This is achieved through metabolic 
optimization and activation of the anti-apoptotic/pro-survival PI3K-PKB/Akt pathway (Sato et al., 
2014). It has also been shown that insulin plays a protective role by reducing oxidative stress 
through increased NO production and reduced superoxide anion production (Ji et al., 2010). In 
working heart ex vivo perfusions, we found that the presence of insulin in the perfusate before 
ischaemia, increased the total work performed (Table 4.11) and increased the post-ischaemic 
aortic SP in control hearts (Table 4.12). Although not significant (potentially due to low n-
values), insulin treatment also tended to increase the AO in control hearts (Table 4.10). 
Furthermore, insulin resulted in an increased heart rate during early reperfusion (5 and 10 
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minutes) following global ischaemia (Figure 4.13) and an increase in the time to contracture in 
control hearts (Table 4.7). Together, these results indicate improved cardiac haemodynamic 
function in insulin-treated control hearts. 
In contrast, insulin treatment prior to ischaemia did not improve AO, total work or aortic SP in 
HCD hearts as it did in control hearts (Tables 4.10-a). To the contrary, total work and AO was 
significantly reduced in HCD hearts compared to control hearts in response to insulin. These 
results indicate that HCD hearts were resistant to the protective effects of insulin, consistent 
with the insulin resistant status of the animals. However, as in the control hearts, insulin 
treatment increased heart rate during early reperfusion (Figure 4.13) and increased time to 
contracture during global ischaemia (Table 4.7) in HCD hearts. This is an indication that HCD 
hearts have insulin-stimulated cardiac protection during ischaemia and early reperfusion, but 
this effect is lost later in reperfusion as was seen in the working heart data. 
Compared to vehicle control hearts, the presence of insulin in the perfusate before ischaemia 
resulted in larger infarcts in both control and HCD hearts (Figure 4.72). These results were 
unexpected as insulin is believed to be protective against IRI in control and obese hearts (du 
Toit et al., 2008; Ji et al., 2010). The timing at which insulin is administered has been proposed 
to have an effect on cardioprotection. Jonassen et al. (2001) found that insulin reduced IFS with 
45% when administered at the onset of reperfusion. Protection was, however, lost when insulin 
was only administered 15 minutes into reperfusion. They further showed that insulin pre-
treatment had no effect on IFS. This indicates that the time of insulin administration influences 
whether or not insulin will have a cardioprotective effect. Insulin administration before ischaemia 
may enhance the metabolic demand of the heart before and during ischaemia, as insulin is a 
positive inotrope. This could deplete critical metabolic supplies, such as oxygen and substrates, 
and result in larger IFS. Cardioprotection, in the form of reduced IFS, has however been 
observed in response to insulin pre-treatment. Fuglesteg et al. (2009) observed 60% smaller 
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infarcts in hearts that were pre-conditioned with insulin, in the form of three insulin treatment 
cycles of five minutes each, compared to untreated hearts. However, in pre-conditioning, the 
stimulus (insulin) is washed out of the system before the onset of the index ischaemia while 
insulin was present in our system throughout the ischaemic period and only washed out at the 
beginning of reperfusion. Furthermore, the metabolic state of the hearts influences the degree of 
protection offered by insulin as du Toit et al. (2008) observed a greater reduction in IFS in 
response to insulin in hearts from obese animals than what was seen in hearts from age-
matched control animals. Furthermore, the fed/fasted state of animals used also influences the 
response to insulin administration (Slettom et al., 2016). 
It was however demonstrated in some studies that IFS was increased in response to insulin 
treatment which is consistent with what was found in this study. Fullmer et al. (2013) found that 
the presence of insulin during pre-conditioning, when the heart is exposed to short periods of 
ischaemia before a prolonged ischaemic period, resulted in increased IFS. Insulin was present 
throughout their perfusion protocol. Increased IFS, in spite of improved cardiac function 
recovery in response to insulin pre-treatment, has previously been observed in our laboratory 
(Webster, unpublished data). Shimizu et al. (2010) also observed unfavourable cardiac 
outcomes in response to insulin. They found that excessive insulin-induced signalling resulted in 
systolic dysfunction. 
Although we used an insulin concentration previously used in our research group and shown to 
result in increased cardiac function (namely 1 U/L; Webster et al., 2014), we suspected that the 
increased IFS observed in our hearts to which insulin were administered could be due to the 
insulin concentration used being too high. We therefore performed perfusions using a reduced 
insulin concentration (0.3 U/L) and determined IFS of the hearts. With the reduced insulin 
concentration, IFS were no longer larger compared to the untreated hearts (Figure 4.74). 
However, insulin was still not able to reduce IFS to smaller than what were found in the 
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untreated group. Consistent with this, Jonassen et al. (2001) also found that pre-treatment with 
0.3 U/L insulin had no effect on IFS compared to untreated controls. In a study by du Toit et al. 
(2008), IFS were found to be significantly reduced compared to the untreated group when 
treated with 0.03 U/L insulin, while an insulin concentration of 0.05 U/L had no effect on IFS in 
control hearts. It is thus possible that our reduced insulin concentration of 0.3 U/L was still too 
high to reduce IFS. 
In light of the above, we believe that the effect of insulin varies depending on the timing of 
administration, the concentration used and the metabolic state of the hearts being treated. Due 
to different study designs used, it is not possible to directly compare the effect of insulin on IFS 
observed in different studies (Slettom et al., 2016). In the current study, in which 1 U/L insulin 
was administered, in a re-circulating manner, 10 minutes prior to ischaemia and washed out at 
the onset of reperfusion, increased IFS were observed in both control and HCD hearts 
compared to untreated control hearts. 
5.3.2 Wortmannin 
Wortmannin is a potent, non-specific inhibitor of the PI3K family, which is able to abrogate 
insulin signalling (Lam et al., 1994). As it is a member of the PI3K family, ATM has also been 
shown to be inhibited by wortmannin with an IC50 of 100 nM (Chan et al., 2000). We included 
the use of wortmannin in our study to compare the effects of this known inhibitor of insulin 
signalling with the effects of an ATM-specific inhibitor, KU-60019. We hypothesised that KU-
60019 will also have an effect on insulin signalling. 
In our study, cardiac function was enhanced by wortmannin during early reperfusion in control 
hearts as increased LVDevP and RPP was seen at five minutes reperfusion in Langendorff 
perfusions. Although RPP remained unaltered in HCD hearts, LVDevP was also increased in 
early reperfusion in HCD hearts in response to wortmannin treatment (Tables 4.3 and 4.4). 
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Improved LVDevP following IRI in response to wortmannin treatment has been seen before as 
wortmannin inhibited the production of superoxide in perfused rat hearts (Young et al., 2000). 
Young et al. (2000) further showed that wortmannin did not affect cardiac function in the 
absence of ischaemia and reperfusion, indicating that its effect was dependent on IRI. 
Wortmannin had no effect on cardiac function later in reperfusion as none of the myocardial 
mechanical function parameters that were tested in working heart perfusions (namely CO, AO, 
heart rate, pressure development and total work performed) were altered by wortmannin 
administration in either the control or HCD hearts (Tables 4.9-4.13). This is an interesting 
observation as wortmannin is an irreversible inhibitor of PI3K and the effect is thus not expected 
to be lifted during reperfusion after washout of wortmannin. 
Infarct size was not altered by wortmannin treatment, either alone or in conjunction with insulin, 
in control hearts. In HCD hearts, IFS was larger in wortmannin treated hearts than in untreated 
hearts. Co-treatment with insulin abolished this effect of wortmannin (Figure 4.72). In line with 
our findings, Tsang et al. (2004) and Ravingerova et al. (2009) also found that wortmannin did 
not increase IFS in control rat hearts and Jonassen et al. (2001) did not see a change in IFS in 
response to wortmannin and insulin co-treatment either. It is possible that wortmannin increased 
IFS in HCD hearts due to further inhibition of the already compromised insulin signalling network 
in these hearts. This is however not supported by our Western blot data as none of the proteins 
that participate in insulin signalling that were analysed, were affected by wortmannin treatment 
in HCD hearts. 
The Western blot analyses were performed following 20 minutes of global ischaemia and 10 
minutes of reperfusion. In control hearts, wortmannin treatment did not have the expected effect 
on insulin signalling intermediates. In the presence of insulin, wortmannin increased serine 
phosphorylation with consequent inhibition of IRS-1, which is upstream of PI3K, as seen in the 
P/T IRS-1 ratio (Figure 4.40). However, the p85 subunit of PI3K was phosphorylated following 
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wortmannin treatment (Figure 4.43). In line with activation of the insulin signalling pathway, the 
P/T ratio of ACC was reduced with wortmannin treatment, signifying ACC activation and an 
increase in fatty acid synthesis and reduced oxidation of fatty acids. None of the other proteins 
downstream of PI3K, namely PKB/Akt, mTOR and AS160, were activated by wortmannin 
treatment following activation of PI3K. The activity of GSK-3β was increased in control hearts 
that had been treated with wortmannin (Figure 4.55). This is consistent with inhibition of insulin 
signalling. The PI3K-PKB/Akt-pathway is activated during reperfusion (Matsui et al., 2001). The 
activation of PI3K in the presence of wortmannin, a known PI3K inhibitor, indicates that 
wortmannin was not successful in inhibition of PI3K under the circumstances used in this study, 
namely in reperfusion following ischaemia. 
5.3.3 KU-60019 
We made use of a small molecule inhibitor, namely KU-60019, which is specific for ATM 
inhibition (Golding et al., 2009). No macroscopic or histopathological alterations were observed 
in rat hearts following administration of 10 mM KU-60019 via an osmotic pump (Vecchio et al., 
2014). The metabolic effect of KU-60019 or its predecessor (KU-55933) has never been 
investigated in the cardiac context and not much is known about the cardiac effect of ATM 
deficiency or inhibition. 
It has been shown that ATM participates in the insulin signalling network in other tissues and 
that ATM-deficient animal models display insulin resistance similar to that seen in the metabolic 
syndrome. In skeletal muscle, ATM is involved in the activation of PKB/Akt in response to 
insulin. ATM also contributes to insulin-stimulated glucose uptake in skeletal muscle by possibly 
being involved with GLUT4 translocation to the cell surface (Halaby et al., 2008). A role for ATM 
in adipocyte functioning has been revealed as ATM-/- cells had reduced C/EBPα and PPARγ 
levels, transcription factors that are crucial for adipocyte differentiation (Takagi et al., 2015). It 
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was further showed that ATM deficient mice also had reduced adiponectin and leptin levels, 
reduced subcutaneous fat and increased visceral fat tissue. Interestingly, when adipose 
functioning was restored, glucose tolerance was improved, suggesting that defective functioning 
of adipose tissue contributes to the insulin resistance observed in A-T (Takagi et al., 2015). 
ATM also participates in IGF-1 mediated signalling in skeletal muscle, possibly downstream of 
IRS-1 (Ching et al., 2013a). ATM inhibition with the use of KU-60019 has been demonstrated to 
interfere with pro-survival signalling through reduced PKB/Akt phosphorylation in glioma cells 
(Golding et al., 2009). However, ATM does not participate in insulin-stimulated activation of 
PKB/Akt in all tissue types as has been shown in skeletal muscle (Ching et al., 2013a). 
We were interested to see whether or not ATM is involved in the cardiac pathology associated 
with IRI and how ATM could be involved in insulin mediated signalling in the heart. During 
ischaemia, cardiac metabolism shifts from fatty acid oxidation to glucose oxidation. The insulin 
signalling network is therefore important during ischaemia. Improved cardiac function is seen 
when glucose oxidation is increased during ischaemia (Traegtmeyer et al., 1997) and it is 
therefore expected that ATM deficiency would result in decreased cardiac functioning following 
an ischaemic period due to the associated insulin resistance and glucose intolerance. 
Schiekofer et al. (2014) indicated that a single nucleotide polymorphism located near the ATM 
gene is associated with coronary artery disease in men and they suggested that ATM could thus 
be associated with CVD. The authors did not elucidate a mechanism in which ATM activity 
could contribute to cardiovascular health. Another polymorphism, located in the ATM promotor 
region, was associated with ATM expression, the degree of coronary stenosis and the 
prevalence of diabetes mellitus in a Chinese cohort (Li et al., 2011). A role for ATM in cardiac 
structure and function has been suggested. ATM deficiency caused increased basal cardiac 
fibrosis and apoptosis and this was exacerbated in response to β-adrenergic receptor 
stimulation and following myocardial infarction (Foster et al., 2011; Foster et al., 2012; Daniel et 
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al., 2014). Interestingly, ATM deficiency delayed the inflammatory response following 
myocardial infarction, attenuated left ventricular dysfunction and resulted in decreased mortality 
early following myocardial infarction (Foster et al., 2013). However, decreased activation of 
PKB/Akt (pro-survival) and increased activation of GSK-3β (pro-apoptotic) was observed in ATM 
deficient hearts one day following myocardial infarction (Daniel et al., 2014). Although ATM 
deficiency appeared to be beneficial early post-IRI (1-7 days), ATM deficient animals had a 
decreased survival rate, increased cardiac dysfunction and remodelling associated with 
apoptosis, fibrosis and hypertrophy late post-IRI (28 days) (Daniel et al., 2016). Mu et al. (2011) 
showed that activation of ATM with PE resulted in reduced cardiac remodelling, fibrosis and 
cardiac dysfunction eight weeks following myocardial infarction. 
Long-term ATM deficiency, as seen in ATM knockout mice, resulted in structural cardiac 
changes. Foster et al. (2012) found that ATM knockout mice had smaller heart weights, reduced 
septal wall thickness, reduced left ventricular diameters, increased basal fibrosis and increased 
cross-sectional areas of cardiomyocytes compared to wild type mice. In response to chronic β-
adrenergic receptor stimulation, increased apoptosis, possibly due to decreased PKB/Akt 
activity, was observed in ATM knockout mice (Foster et al., 2012). 
In our study, KU-60019, administered prior to regional ischaemia, had no effect on cardiac 
function during reperfusion in either the control or HCD hearts. We observed no changes in CF, 
total work, aortic SP or heart rate (Tables 4.9, 4.11 to 4.13). When co-administered with insulin, 
KU-60019 reduced AO to vehicle control levels compared to when only insulin was administered 
in control hearts (Table 4.10). Based on these haemodynamic results, ATM inhibition therefore 
appeared to block the protective effect of insulin in control hearts, suggesting a role for ATM in 
the signalling network of insulin. 
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However, KU-60019 administration resulted in improved cardiac outcomes during reperfusion 
following global ischaemia according to our Langendorff balloon model perfusion studies. 
Improved RPP values and LVDevP were achieved in both the control and HCD hearts in 
response to KU-60019 treatment (Tables 4.3 and 4.4). Interestingly, KU-60019 increased 
insulin-stimulated LVDevP and RPP at both five and ten minutes of reperfusion. Additionally, 
KU-60019 treatment resulted in increased times to the onset of contracture during global 
ischaemia as well as lower peak developed pressures that were achieved during global 
ischaemia in both the control and HCD hearts (Table 4.7). Together, these data indicate that 
ATM inhibition prior to an ischaemic period resulted in improved cardiac function, at least during 
early reperfusion. These findings are in agreement with the studies of Foster et al. (2013) and 
Daniel et al. (2014) who also observed that ATM deficient hearts had reduced cardiac 
dysfunction early following myocardial infarction. 
During ischaemia, oxygen and nutrient supply is prevented, while waste products accumulate 
(Beauloye et al., 2001). It is possible that the increased CF observed in response to KU-60019 
treatment contributed to the improved cardiac function seen in KU-60019 treated hearts as 
accumulated waste products were cleared, and oxygen and nutrient supply was restored faster. 
When looking at cardiac function parameters measured with the Langendorff balloon model, the 
effect of KU-60019 treatment was smaller at 10 minutes versus at five minutes reperfusion 
(Table 4.3) or was no longer seen at 10 minutes reperfusion (Table 4.6). KU-60019 is a 
reversible inhibitor of ATM (Golding et al., 2012), which means its effect disappeared as it was 
washed out during reperfusion. It is possible that this is why we did not observe changes in 
cardiac function during our work heart studies as functional parameters were only measured 
after approximately 25 minutes of reperfusion. 
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ATM inhibition had no effect on IFS in control hearts. This is in agreement with other studies 
that also observed no differences in IFS between hearts from wild-type mice and hearts from 
ATM heterozygous knock-out mice at one, three, seven and 28 days post myocardial infarction 
(Foster et al., 2013; Daniel et al., 2014; Daniel et al., 2016). However, in contrast to findings in 
the ATM heterozygous KO animals, acute inhibition of ATM in hearts from HCD animals 
protected the hearts and infarcts were smaller compared to untreated HCD hearts as well as 
compared to KU-60019 treated control hearts (Figure 4.73). 
5.4 Insulin signalling in control and HCD hearts  
Langendorff perfused hearts were treated with insulin, KU-60019 and a combination of insulin 
and KU-60019 for 20 minutes following a stabilisation period. Proteins that participate in the 
insulin signalling network were analysed with Western blots to determine what the effects of the 
treatments are in the absence of IRI (before ischaemia) and following 10 minutes of reperfusion. 
5.4.1 Before ischaemia 
In control hearts, JNK expression and activation was not altered by insulin (Figure 4.14). 
However, insulin treatment did increase IRS-1 Ser307 phosphorylation (Figure 4.16). This is 
possibly due to inhibition in response to hyperinsulinaemia caused by the 1 U/L insulin 
treatment. In response to insulin, Ser307 phosphorylation of IRS-1 acts as a mechanism for 
negative feedback to down regulate insulin action (Rajan et al., 2013). PI3K (p85 subunit), 
which is downstream of IRS-1 in the insulin signalling network, was also down regulated in 
response to insulin treatment in control hearts (Figure 4.18). In spite of the apparent down 
regulation of insulin signalling, PKB/Akt activation was increased in response to insulin 
treatment, as expected in the insulin responsive control hearts (Figure 4.22). Furthermore, 
AS160, which is a downstream substrate of activated PKB/Akt (Kane et al., 2002), was also 
activated in response to insulin treatment and PKB/Akt activation (Figure 4.28). 
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Hirosumi et al. (2002) reported increased JNK activity in liver, adipose and muscle tissue in a 
diet-induced obesity animal model. JNK plays a central role in the stress-induced insulin 
resistance observed in obesity. JNK is activated by elevated TNF-α and FFA in obesity, which in 
turn inhibits IRS-1 through phosphorylation of its Ser307 residue (Hirosumi et al., 2002). 
Phosphorylation of Ser307 is associated with reduced insulin signalling (Aguirre et al., 2002). 
We did not see increased activity of JNK in hearts from our obese HCD model compared to the 
control diet (Figure 4.15). Insulin treatment caused reduced activation of JNK in HCD hearts 
compared to untreated HCD hearts, suggesting that insulin had a protective effect in the HCD 
hearts in spite of their insulin resistant state (Figures 4.15). Unfortunately, we were unable to 
determine IRS-1 Ser307 levels in HCD hearts, even after numerous attempts. It is therefore not 
known if insulin signalling was reduced in HCD hearts due to IRS-1 inhibition and insulin had no 
effect on p85 subunit of PI3K in HCD hearts. 
The phosphatase, PTEN, antagonises the effect of PI3K by dephosphorylating PIP3 to PIP2 and 
in doing so, PTEN inhibits insulin signalling (Maehama and Dixon, 1998). The phosphatase 
activity of PTEN is reduced upon phosphorylation at residues Ser380, Thr382 and Thr383 
(Yang et al., 2015). Compared to the control hearts, HCD hearts had decreased 
phosphorylation of PTEN and therefore increased phosphatase activity and increased inhibition 
of insulin signalling (Figure 4.21). Insulin treatment caused a further increase in PTEN 
phosphatase activity through a reduction in PTEN phosphorylation in HCD hearts. The 
increased activity of PTEN, together with reduced PI3K activity in HCD hearts, indicated by a 
reduced P/T ratio of its regulatory subunit (Figure 4.19), indicate that insulin signalling was 
ineffective in HCD hearts. Consistent with the insulin resistant state of the HCD hearts, PKB/Akt 
and AS160 were not phosphorylated in response to insulin treatment (Figures 4.23 and 4.29). 
Additionally, insulin did not increase GLUT4 expression in HCD hearts (Figure 4.30D) and HCD 
hearts had reduced GLUT4 levels compared to control hearts. 
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GSK-3β regulates metabolism by controlling glycogen and protein synthesis (Cross et al., 
1995). Insulin signalling inhibits GSK-3β by PKB/Akt-dependent phosphorylation, resulting in 
increased GS activity and consequently, increased conversion of glucose to glycogen. In 
contrast to this well-known effect of insulin on GSK-3β, we found that insulin treatment 
increased GSK-3β activity in control hearts, thereby reducing glucose conversion to glycogen 
(Figure 4.26). We are not certain why we observed increased GSK-3β activity after insulin 
treatment and would need to redo the analysis to confirm the results. Insulin had no effect on 
GSK-3β phosphorylation in the HCD hearts. 
Another protein downstream of PKB/Akt in the insulin signalling network is mTOR. Cell growth is 
regulated by mTOR according to the nutrient and energy status of the cell as well as in 
response to growth factors such as insulin (Chiang and Abraham, 2005). Although mTOR is 
activated by insulin signalling, it has been suggested that mTOR is also a negative modulator of 
insulin signalling (Khamzina et al., 2005). Insulin had no effect on mTOR in control hearts 
(Figure 4.24). We observed increased expression and phosphorylation of mTOR in hearts from 
HCD animals compared to hearts from control animals (Figure 4.25). Insulin treatment further 
increased mTOR phosphorylation in the HCD hearts (Figure 4.25 C). Our results correspond 
with the findings of Khamzina et al. (2005) who also found that mTOR was hyperphosphorylated 
in muscle of obese rats fed a diet high in sugar and fat. Chronic activation of mTOR has been 
associated with the promotion of insulin resistance in muscle as it leads to serine 
phosphorylation of IRS-1 (Haruta et al., 2000; Tremblay and Marette, 2001). 
AMPK acts as an energy sensor that activates ATP generating processes such as fatty acid 
oxidation and inhibits ATP consuming processes such as fatty acid synthesis (Ruderman et al., 
2013). Reduced activation of AMPK was seen in the insulin resistant HCD hearts compared to 
control hearts (Figure 4.32). This is consistent with previous studies (Gauthier et al., 2011; 
Steinberg et al., 2006). The increased TNF-α levels associated with obesity, increase the 
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transcription of the phosphatase PP2C. This in turn leads to the de-activation and suppression 
of AMPK (Steinberg et al., 2006). Insulin is able to inhibit AMPK through PKB/Akt-dependent 
phosphorylation of Ser485/491 (Valentine et al., 2014). Although we did not quantify the 
inhibitory phosphorylation site of AMPK (Ser485/491), we did quantify the activation 
phosphorylation site of AMPK (Thr172) (Hawley et al., 1996). Insulin treatment did not alter the 
Thr172 phosphorylation status significantly in control or HCD hearts in our study. The P/T ratio 
was however lower in both the control and HCD hearts in response to insulin administration 
(Figures 4.31 & 4.32). In control hearts, the reduced P/T ratio was due to increased AMPK 
expression in response to insulin. AMPK expression was however unchanged by insulin in HCD 
hearts. The reduced P/T ratio observed in HCD hearts was possibly due to altered AMPK 
phosphorylation as AMPK phosphorylation tended to be reduced by insulin in HCD hearts, 
although not significantly so (p=0.08). Reduced P/T AMPK ratios are an indication that AMPK 
activity was reduced with insulin treatment, however, a reduction in AMPK activity has been 
seen without an accompanying reduction in AMPK Thr172 phosphorylation (Valentine et al., 
2014). 
AMPK inactivates ACC by phosphorylation (Davies et al., 1990). In spite of reduced AMPK 
activity in HCD hearts compared to control hearts, we observed an increase in total ACC and 
ACC phosphorylation in HCD hearts, however, the P/T ACC ratio was reduced in HCD hearts 
compared to control hearts (Figure 4.34). It is believed that increased β-oxidation of fatty acids 
and reduced fatty acid synthesis resulting from inhibition of ACC activity could be protective 
against cardiovascular risk factors associated with the metabolic syndrome (Harwood, 2000). 
In response to insulin, AMPK activity is reduced, leading to activation of ACC due to reduced 
phosphorylation of ACC (Witters and Kemp, 1992). Our results in control hearts are consistent 
with this as the reduced P/T AMPK ratio in response to insulin led to reduced phosphorylation, 
and therefore increased activation, of ACC (Figure 4.33). ACC inhibits β-oxidation of fatty acids 
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and promotes fatty acid synthesis. This is consistent with the Randle cycle theory, where insulin 
treatment inhibits fatty acid oxidation while glucose oxidation is favoured (Randle et al., 1963). 
Taken together, our Western blot data confirms that hearts from animals on the control diet 
were insulin responsive while the insulin signalling network was not stimulated by insulin in the 
insulin resistant HCD hearts. 
5.4.2 During early reperfusion 
Hearts pre-treated with insulin underwent 20 minutes of global ischaemia. After 10 minutes of 
reperfusion in the absence of insulin, insulin signalling intermediates were analysed with 
Western blot analysis. Activation of PKB/Akt in response to insulin is inhibited during ischaemia 
due to reduced pH during ischaemia. Insulin signalling is however resumed quickly upon 
reperfusion (Beauloye et al., 2001). Activation of the insulin signalling network in reperfusion is 
associated with improved cardiac outcomes following IRI. 
Although ACC was activated during reperfusion in control hearts in response to insulin (Figure 
4.65), none of the other proteins analysed (JNK, IRS-1, p85 subunit of PI3K, PTEN, PKB/Akt, 
mTOR, GSK-3β, AS160, GLUT4 or AMPK) were affected by insulin in control or HCD hearts. 
This suggests that insulin signalling was not increased during reperfusion in response to insulin 
treatment before ischaemia and this could explain the increased IFS observed in insulin treated 
hearts. However, ACC activation during reperfusion is considered to have a protective effect on 
the heart as fatty acid β-oxidation is inhibited by the increase in malonyl coenzyme-A and the 
resultant stimulation of glucose oxidation (Lopaschuk, 1997).  
We did observe differences in proteins of the insulin signalling network in HCD hearts compared 
to control hearts. IRS-1 was inhibited in HCD hearts (Figure 4.41) and reduced activation of 
PI3K was seen (Figures 4.44 and 4.45). Interestingly, PKB/Akt was more active in HCD hearts 
during reperfusion (Figure 4.51), which led to increased phosphorylation of AS160 (Figure 4.60). 
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Increased phosphorylation of ACC was also observed in HCD hearts compared to control hearts 
during reperfusion (Figure 4.67). The decreased activity of ACC suggests that HCD hearts had 
increased oxidation of fatty acids during reperfusion compared to control hearts in spite of 
PKB/Akt activation and AS160 phosphorylation. The fact that insulin signalling was not 
completely blocked in HCD hearts during reperfusion is a possible explanation as to why we did 
not observe reduced cardiac function and increased IFS in HCD hearts compared to control 
hearts in our study. 
5.5 The role of ATM in the insulin signalling network  
ATM is suggested to participate in the insulin signalling network in skeletal muscle, but it is not 
yet clear if this is the case in cardiac muscle. In order to elucidate the role of ATM in the insulin 
signalling network in the heart, the effect of ATM inhibition on insulin signalling intermediates 
was determined in perfused hearts. Our basal Western blot analysis revealed that ATM 
expression was decreased in the insulin resistant HCD hearts compared to control hearts 
(Figure 4.1). In line with previous studies that showed increased ATM activity in response to 
insulin (Yang and Kastan, 2000), we observed increased expression and phosphorylation of 
ATM in the insulin-responsive control hearts following treatment with insulin. Treatment with KU-
60019 reduced ATM phosphorylation in control hearts, implying reduced ATM activity. KU-
60019 was able to block the ATM-stimulating effect of insulin (Figure 4.35). These results 
validate the use of insulin as an ATM activator and the use of KU-60019 as an ATM inhibitor in 
the study. Although ATM was expressed in HCD hearts, insulin had no effect on ATM 
expression or activation levels and KU-60019 treatment did not decrease ATM activity further 
(Figure 4.36). This suggests that the reduced ATM levels in HCD hearts are resistant to 
manipulation. 
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An inverse relationship was seen between the amount of ATM expressed and JNK activity by 
Schneider et al. (2006), while Halaby et al. (2008) detected no difference in JNK activity 
associated with ATM deficiency. In our study, JNK activity was not altered in control hearts while 
HCD hearts had reduced JNK activity when ATM was inhibited (Figures 4.14 and 4.15). ATM 
deficiency was therefore not likely to influence insulin signalling via JNK according to our 
results. 
ATM inhibition reduced IRS-1 expression levels and insulin-stimulated inhibition of IRS-1 in 
control hearts (Figure 4.16). Ching et al. (2013a) found that IRS-1 activation (Tyr612) was not 
affected by ATM deficiency and they therefore suggested that ATM participates in insulin 
signalling downstream of IRS-1. Our results support this notion as ATM inhibition did not 
increase IRS-1 inhibition. 
Reduced phosphorylation of the p85 subunit of PI3K (Figures 4.18 and 4.19) and increased 
phosphatase activity of PTEN (Figures 4.20 and 4.21) was seen when ATM was inhibited. 
Although this is suggestive of inhibition of the insulin signalling network, the effect was not seen 
in PKB/Akt as PKB/Akt activity was not affected by ATM inhibition (Figures 4.22 and 4.23). As 
previously mentioned, ATM has been shown to participate in activation of PKB/Akt in skeletal 
muscle and KU-60019 reduced basal phosphorylation of PKB/Akt (Ser473) in human glioma 
cells (Golding et al., 2009). It was proposed that ATM regulates a phosphatase, which in turn 
regulates PKB/Akt phosphorylation as PKB/Akt does not have an ATM recognition site. It was, 
however shown in other studies that PKB/Akt activation is not ATM-dependent and the 
involvement of ATM appears to be cell type dependent (Jeong et al., 2009). Our results indicate 
that ATM is not involved in PKB/Akt activation in the heart as PKB/Akt was not affected by ATM 
inhibition in either the control or HCD hearts (Figures 4.22 and 4.23). This is not entirely 
consistent with the results of Foster et al. (2012). They found that PKB/Akt activation tended to 
be reduced in ATM knock-out hearts, however this effect was not significant. Mu et al. (2011) 
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found increased phosphorylation of PKB/Akt in the areas surrounding infarcted tissue in 
response to treatment with PE, which is believed to activate ATM. This effect was only observed 
in response to PE in the presence of myocardial infarction and not in the absence of PE or in 
the absence of myocardial infarction. This suggests that ATM is only involved in PKB/Akt 
activation under very specific conditions, which is in agreement with the views of Ching et al. 
(2013a). This notion is further supported by the findings of Ching et al. (2013b). They found that, 
in response to insulin, ATM phosphorylates PKB/Akt in skeletal muscle comprised of fast 
glycolytic fibers, but that AS160, and not PKB/Akt, is phosphorylated by ATM in muscle 
comprised of slow and fast oxidative-glycolytic fibers. 
Although PKB/Akt activation was not affected when ATM was inhibited, AS160 phosphorylation 
was reduced with KU-60019 treatment in HCD hearts (Figure 4.29). This is an indication that 
ATM could function on the level of AS160 in HCD cardiomyocytes. AMPK has been shown to be 
an activator of AS160 and this effect is independent of insulin (Treebak et al., 2006). ATM 
inhibition resulted in AMPK inhibition in HCD hearts in our study (Figure 4.32) and it is possible 
that the reduced activity of AMPK also contributed to the reduced activation of AS160 in HCD 
hearts. ATM is a known activator of AMPK (Fu et al., 2008; Suzuki et al., 2004), which is 
consistent with our results in HCD hearts. ACC activity was not affected by KU-60019 treatment 
in HCD hearts (Figure 4.34). 
In control hearts, insulin-stimulated phosphorylation of AS160 was further increased by KU-
60019 treatment, and the P/T AS160 ratio was increased in hearts by KU-60019 treatment 
alone as well as in hearts co-treated with insulin and KU-60019 (Figure 4.28). This was an 
unexpected finding as ATM deficiency led to reduced AS160 phosphorylation in soleus muscle 
and L6 myotubes (Ching et al. 2010; Jeong et al., 2010). The effect of ATM on AS160 activation 
needs to be investigated further. Expression levels of GLUT4, which is downstream of AS160, 
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was unaffected by ATM manipulation (Figure 4.30). Future measurement of GLUT4 
translocation could shed more light on the effects elicited by ATM. 
KU-60019 treatment alone had no effect on AMPK or ACC phosphorylation in control hearts. 
The P/T AMPK ratio was higher in the insulin and KU-60019 co-treated hearts compared to 
hearts treated with insulin alone (Figure 4.31). This suggests that insulin is unable to inhibit 
AMPK activity in the absence of ATM. The increased activity of AMPK after insulin and KU-
60019 co-treatment caused increased phosphorylation of ACC, resulting in increased β-
oxidation of fatty acids in co-treated control hearts. These results indicate that insulin action on 
AMPK and ACC was blocked when ATM was inhibited in control hearts. 
According to Foster et al. (2012), activation of GSK-3β was not affected in ATM knockout hearts 
compared to wild type hearts, while Thornton et al. (2016) found that nuclear GSK-3β is 
inhibited by ATM in response to DSB. Our results are in agreement with Thornton et al. (2016) 
as we also observed that ATM inhibition resulted in reduced expression and phosphorylation of 
GSK-3β in both the control and HCD hearts. (Figures 4.26 and 4.27). This suggests that GSK-
3β phosphorylation is increased in the presence of active ATM and that ATM thus acts as a 
GSK-3β inhibitor in the heart. This is in line with the effect of insulin on GSK-3β and it is thus 
possible that ATM is involved in insulin mediated inhibition of GSK-3β. 
Very few of the analysed proteins were altered during reperfusion in response to ATM inhibition 
prior to ischaemia. We believe that this is due to the reversible nature of the ATM inhibitor used 
in this study. The inhibitor was washed out during reperfusion and ATM could thus be activated 
as normal during reperfusion. In spite of this, hearts in which ATM was inhibited prior to 
ischaemia had reduced activation of JNK during reperfusion (Figure 4.40). JNK is usually 
activated during reperfusion (Yin et al., 1997) and JNK-knockout mice have been shown to have 
better cardiac outcomes following IRI compared to wild-type mice (Kaiser et al., 2005). It is 
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possible that the reduced activation of JNK seen in KU-60019 treated hearts contributed to the 
improved cardiac function seen in hearts in which ATM was inhibited. 
5.6 The role of ATM in vasoconstriction 
The innermost layer of blood vessels, the endothelium, acts as an autocrine, paracrine and 
endocrine organ to maintain vasomotor balance and vascular-tissue homeostasis (Esper et al., 
2006). The endothelium achieves vasodilation and vasoconstriction by modulation of the 
vascular smooth muscle. One of the most potent endothelium-derived factors is NO, which is an 
effective vasodilator (Eliseyeva, 1013). 
In response to treatment with KU-60019, we observed an immediate increase in CF during 
Langendorff perfusions (Table 4.6). This effect of KU-60019 was also seen in the work heart 
perfusions during the treatment period (data not shown), but was lost by the time functional data 
was collected (~25 minutes into reperfusion; Table 4.9). The increased CF could not be due to 
increased pressure as Langendorff perfusions were performed at a constant preload pressure of 
100 cm H2O and we also did not observe an increase in LVDevP during the KU-60019 
administration period (Table 4.3). The increased CF was an interesting and unexpected 
observation. We therefore performed aortic ring isometric tension studies to determine if ATM 
inhibition has a vasodilatory effect. 
PE has been shown to increase ATM kinase activity (Mu et al., 2011). PE is commonly used to 
induce vasoconstriction of smooth muscle cells by acting on α1-adrenergic receptors. It is thus 
possible that ATM could participate in the vasoconstriction mechanism of PE. In our study, the 
ATM inhibitor, KU-60019 induced relaxation of aortic rings (Figure 4.75). Our results therefore 
suggest a vasoconstrictive role for ATM. The vasodilation induced by KU-60019 was dependent 
on NO, as vasodilation was inhibited by the non-specific NOS inhibitor, L-NAME. This suggests 
that NO production is increased when ATM activity is reduced. This is however not consistent 
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with the study of Oleson et al. (2014) that showed that ATM inhibition reduced NO-induced 
effects. They, however, looked at the ability of NO to induce DNA damage as a reactive nitrogen 
species and not at the vasodilative effect of NO. Nevertheless, our results are in agreement 
with, and can explain the telangiectasias seen especially in the vessels of the eyes of A-T 
patients.  
Together with the increase in CF, the temperature of the heart rose considerably in response to 
KU-60019 treatment during the Langendorff perfusion studies (data not shown). Heat production 
is a by-product of mitochondrial respiration, the rate of which increases with increased 
contractility of muscle (van Beek, 1996; Ricquier and Bouillaud, 2000). Although we did not 
observe an increase in heart rate or pressure development with the increase in temperature due 
to KU-60019 treatment, it would be interesting to analyse mitochondria after exposure to KU-
60019 to determine if mitochondrial respiration is affected or if there are differences in the 
expression of the uncoupling proteins induced by inhibition of ATM. 
It is however possible that the increased temperature was merely caused by the increased CF 
as the buffer had less time to cool down between the bubble trap and the heart. Increased 
temperature leads to increased activity of NOS and subsequently, an increase in NO production 
(Brown and Borutaite, 2007). In order to reduce the temperature, NO increases blood flow by 
vasodilation. NO also reduces heat production by reducing mitochondrial respiration through 
inhibition of complex IV of the electron transport chain (Sarti et al., 2003). 
5.7 The use of chloroquine as a pharmaceutical activator of ATM in the heart 
Chloroquine has been used as an antimalarial drug since World War II (Tönnesmann et al., 
2013). Since then, studies that show glucose lowering effects of chloroquine, specifically in the 
diabetic state, have emerged (Emami et al., 1999). This effect of chloroquine is mediated, at 
least in part, by an increase in insulin secretion (Asamoah et al., 1990). Another mechanism in 
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which chloroquine has been shown to increase glucose tolerance is via activation of ATM and 
subsequent activation of PKB/Akt (Halaby et al., 2013; Schneider et al., 2006; Zhou et al., 
2013). 
Chloroquine has been suggested as a therapeutic agent in the treatment of insulin resistance, 
glucose intolerance and diabetes (Asamoa et al., 1990; Schneider et al., 2006). We aimed to 
test the feasibility of the use of chloroquine, specifically in the cardiac context.  
Unlike the study in L6 muscle cells by Halaby et al. (2013), we did not observe an increase in 
glucose uptake in response to chloroquine treatment in isolated cardiomyocytes (Figure 4.4). 
Insulin treatment (100 nM) also did not increase glucose uptake which could imply a possible 
methodological problem. However, insulin treatment did tend to increase glucose uptake 
(p=0.09) and this effect could have become significant if the n-value was increased from three 
to six as in the insulin concentration experiments. In addition to not observing an effect of 
chloroquine on glucose uptake, we also did not observe an increase in ATM expression or 
activation in response to chloroquine treatment in Langendorff perfused hearts (Figure 4.7). This 
suggests that chloroquine does not activate ATM in cardiac tissue and, consequently, does not 
cause an increase in glucose uptake in cardiomyocytes as it does in skeletal muscle tissue. 
However, the possibility exists that chloroquine requires a longer treatment period to have its 
effect. In our study, the chloroquine treatment period was 45 minutes for the glucose uptake 
study and 10 minutes for the perfusion and ATM Western blot analysis, while Halaby et al. 
(2013) allowed a three-hour treatment period after which they observed chloroquine-dependent 
effects. Other studies suggest chronic chloroquine treatment (Asamoah et al., 1990; Schneider 
et al., 2006). Rats in which myocardial infarction had been induced, were administered low-dose 
chloroquine daily over 12 weeks following the myocardial infarction procedure. Chloroquine was 
found to significantly increase phosphorylation of PKB/Akt and reduce cardiomyocyte apoptosis 
(Zhou et al., 2013). 
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Chronic treatment with chloroquine is, however, problematic as cardiotoxic effects in the form of 
conduction disorders and cardiomyopathy have been reported (Teixeira et al., 2002; 
Tönnesmann et al., 2013). Our results are consistent with results where the cardiotoxic effect of 
chloroquine was observed. A cell viability assay using PI revealed that chloroquine 
concentrations of 10 μM and 50 μM significantly increased necrosis in isolated cardiomyocytes 
(Figure 4.5). Furthermore, chloroquine had a severely detrimental effect on cardiac function as 
observed in Langendorff balloon model perfusion studies. Following 10 minutes of chloroquine 
perfusion, a significant decrease in LVDevP and heart rate was observed (Figure 4.6). 
Interestingly, the highest chloroquine concentration, namely 100 μM, did not result in significant 
necrosis, suggesting a potential concentration-dependent cardiotoxic effect. 
Although glucose lowering effects were observed at a higher chloroquine concentration (100 
μM) and at a longer treatment period (three hours) in the study conducted by Halaby et al. 
(2013) in L6 myoblasts, this is not possible in the heart. We found that heart function was 
adversely affected almost instantaneously with chloroquine perfusion with concentrations as low 
as 10 μM (data not shown). These results should be followed up by an in vivo study where 
animals are orally treated with chloroquine to substantiate or negate the effects observed with 
ex vivo perfusions.  
Taken together, our results strongly argue that chloroquine is not a suitable pharmaceutical 
agent in the treatment of insulin resistance and glucose intolerance as it has proved to be 
ineffective in the heart with possible cardiotoxic effects. 
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Chapter 6: Concluding Chapter 
6.1 Conclusion 
In this study we made use of a diet with a high carbohydrate and fat content to induce obesity, 
glucose intolerance and insulin resistance in a rat model. This HCD resulted in reduced ATM 
and PKB/Akt expression, however, ATM and PKB/Akt activity was increased as seen by the 
increased P/T ratios. In spite of these effects, the HCD did not have a detrimental effect on 
cardiac function and IFS was not larger in the HCD hearts compared to control hearts. In 
response to insulin treatment, control hearts had increased cardiac haemodynamic function 
during reperfusion. Insulin treatment activated the insulin signalling pathway prior to ischaemia, 
but not during reperfusion. Furthermore, the insulin concentration used in this study was 
possibly too high as IFS was larger in insulin treated hearts compared to untreated hearts. 
Infarct size is considered the golden standard to evaluate cardioprotection. The increased IFS 
observed in response to insulin therefore indicate that insulin did not protect the control hearts in 
spite of the improved haemodynamic effect that insulin had on the control hearts. In line with 
their insulin resistant state, HCD hearts did not have improved cardiac haemodynamic function 
in response to insulin and insulin-stimulated cardiac function was less efficient in HCD hearts 
compared to control hearts. This is possibly due to the fact that the animals were insulin 
resistant, therefore, the insulin signalling pathway was not activated in response to insulin, 
either before ischaemia or during reperfusion in HCD hearts. Insulin also resulted in larger IFS 
in HCD hearts. 
The main aim of this study was to determine the effect of ATM in cardiac function and the role of 
ATM in the cardiac insulin signalling network. Insulin was used as an ATM activator and KU-
60019 was used to inhibit ATM. In control hearts, ATM activation was increased with insulin and 
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decreased with KU-60019, as expected. However, neither insulin nor KU-60019 altered ATM 
activation in HCD hearts. ATM inhibition resulted in increased cardiac function during early 
reperfusion (10 minutes) following global ischaemia in control and HCD hearts. Following 
regional ischaemia, later in reperfusion (~25 minutes), ATM inhibition attenuated the improved 
heamodynamic effect of insulin in control hearts while ATM inhibition had no effect in HCD 
hearts during later reperfusion. 
PKB/Akt activation is said to be ATM-dependent in some tissues while it is ATM-independent in 
other tissues. We found that ATM inhibition did not reduce insulin-stimulated PKB/Akt activation 
and we therefore conclude that PKB/Akt activation is not ATM-dependent in cardiac tissue. In 
both control and HCD hearts, ATM inhibition decreased PI3K activation and increased PTEN 
and GSK-3β activity. Although these effects are consistent with down-regulation of the insulin 
signalling pathway, it is still not completely clear how ATM fits into the insulin signalling 
pathway. 
Besides insulin, oxidative stress is another known activator of ATM which will inevitably affect 
cardiac ATM during IRI. The regulation of signalling networks is complex and elucidating the 
role of a master regulator such as ATM, which has been said to have close to 500 substrates 
(Matsuoka et al., 2007), is not a simple task. What complicates matters more is that it has been 
proposed that different tissues have different responses to ATM deficiency (Hammond and 
Muschel, 2014) and that the role of ATM in insulin signalling is dependent on the type of cell 
(Yang and Kastan, 2000). Moding et al. (2014) found that ATM-deficient proliferating endothelial 
cells of tumours were sensitive to radiation while ATM-deficient quiescent endothelial cells were 
not sensitive to radiation. This indicates that the state of a cell also influences the role of ATM. 
With this study we have only started to scratch at the surface of the cardiac function of ATM and 
many questions remain to be answered. More in depth and detailed studies would need to be 
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conducted before we will fully understand the importance of the ATM protein in the myocardial 
pathology associated with insulin resistance. 
6.2 Shortcomings and limitations of the study 
 Some of the drug dosage studies (ie. PI studies and KU-60019 concentration perfusions) 
had an n-value of 2. For statistical reasons, larger n-values should have been used. 
 We used hearts from animals on the HCD and age-matched control diet only. We did not 
include a young control group. Aging Wistar rats have been shown to have signs of the 
metabolic syndrome (Ghezzi et al., 2012) so our age-matched control group was 
possibly not completely healthy. 
 Western blot analysis to evaluate the insulin signalling intermediates during reperfusion 
was performed on animals that have been on the diet for 25 weeks. Although we 
determined that the longer feeding time had no effect on cardiac function, we did not 
determine if the longer feeding time affected basal protein expression levels. 
 Many of the hearts in the working heart studies did not regain cardiac function following 
regional ischaemia. This resulted in low n-values for the working heart data. Larger n-
values would have provided a clearer and more accurate picture of the effects of the 
treatments. However, because of the large amount of animals already used in the study, 
we were unable to further increase the n-values. 
 We did not look at the effect of the drugs when administered in the beginning of 
reperfusion. The drugs were washed out during reperfusion which potentially limited or 
reversed their effects. This especially applies to KU-60019. The reversible nature of the 
KU-60019 inhibitor meant that its effect was lost during the initial phase of reperfusion. 
More distinct results would have been obtained if KU-60019, and the other drugs used, 
could have remained in the perfusate during reperfusion. However, only small amounts 
of the inhibitor can be acquired which limited our use of it. We had to use KU-60019 in a 
re-circulating manner and since we reperfused for an hour during the work heart studies, 
it was not a viable option to have the inhibitor in the perfusate during reperfusion. 
 The fact that the treatments were re-circulated could potentially have influenced the 
effects observed. Webster et al. (2014) reported that different outcomes were observed 
in response to treatment with sanguinarine, depending on whether the drug was re-
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circulated or not. We did not test whether or not re-circulation had an effect on the drugs 
used in this study. 
 We only looked at the effect of acute ATM deficiency on cardiac function and insulin 
signalling. Insulin resistance, diabetes and CVD develop over time. In has been 
suggested that the insulin resistance and glucose intolerance observed in A-T patients is 
due to the accumulation of oxidative damage over time (Armata et al., 2010). Clearer 
results could possibly have been obtained if ATM was inhibited chronically by treating 
animals with KU-60019. 
 The aortic ring studies were only performed on aortas isolated from age-matched control 
animals. It would have been interesting to see what the effect would have been on 
aortas from the HCD animals. 
6.3 Future research 
 It was shown in several studies that different cell types have different functions for ATM. 
It could thus be informative to look at the different cardiac cells, namely cardiomyocytes, 
fibroblasts and endothelial cells separately. 
 Our Western blot analyses were done before ischaemia and during reperfusion, not 
during ischaemia. Hypoxia is a known ATM activator so it will be interesting to observe 
how ATM responds to hypoxia during cardiac ischaemia. 
 It has been proposed that accumulated oxidative stress experienced in ATM deficiency 
contributes to the disrupted glucose tolerance seen in the ATM deficient state. Oxidative 
stress is also an ATM activator. Future studies should thus look at the effect of oxidative 
stress caused specifically by ATM deficiency on insulin signalling. 
 KU-60019 treatment does not block ATM activation completely and residual ATM activity 
could make it difficult to observe effects of ATM deficiency. A-T heterozygotes do not 
display the debilitating symptoms seen in A-T patients, indicating that even with reduced 
ATM expression levels, ATM function could be normal. The use of ATM knockout 
animals will combat this problem. 
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 During treatment with KU-60019, the temperature of the heart was significantly higher. It 
will be interesting to further investigate the cause of the increased heat production in 
response to ATM inhibition. 
6.4 Research Outputs 
The following publications and conference contributions were produced during this study: 
Publication 
 Espach, Y., Lochner, A., Strijdom, H. and Huisamen, B. 2015. ATM protein kinase signaling, 
type 2 diabetes and cardiovascular disease. Cardiovascular Drugs and Therapy, 29(1), 51-
58. doi: 10.1007/s10557-015-6571-z 
Published abstracts 
 Huisamen, B., Strijdom, H., Collop, N., Espach, Y. 2014. A possible role for the ATM protein 
in the myocardial pathology associated with obesity and insulin resistance. Cardiovascular 
Research, 103 (Suppl 1), S118. doi: 10.1093/cvr/cvu098.75 
 Huisamen, B., van Vuuren, M.A., Espach, Y., Marais, E. and Lochner, A. 2016. Is low ATM 
protein responsible for myocardial insulin resistance associated with obesity? Cardiovascular 
Research. 111(Suppl 1), S88-S89. doi: 10.1093/cvr/cvw147 
International conference contributions 
 Huisamen, B., van Vuuren, M.A., Espach, Y., Marais, E. and Lochner, A. Is low ATM protein 
responsible for myocardial insulin resistance associated with obesity? 4th Meeting of the 
ESC Council on Basic Cardiovascular Science. Florence, Italy. July 8-10, 2016. (Oral 
presentation by Prof. Huisamen) 
 Espach, Y. and Huisamen, B. Myocardial functioning and response to ischemia/reperfusion 
injury following manipulation of the ATM protein kinase. 33rd Meeting of the European 
Section of the International Society for Heart Research. Bordeaux, France. July 1-4, 2015. 
(Poster presentation) 
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 Huisamen, B., Strijdom, H., Collop, N., Espach, Y. A possible role for the ATM protein in the 
myocardial pathology associated with obesity and insulin resistance. Third Congress of the 
ESC Council on Basic Cardiovascular Science. Barcelona, Spain. July 4-6, 2014. (Poster 
presented by Prof. Huisamen) 
Local conference contributions 
 Espach, Y. and Huisamen, B. The effect of ATM on myocardial function and cardiac 
signalling networks following ischemia/reperfusion injury. Diabetes Discovery Platform 
Research Symposium. MRC, South Africa. November 10, 2014. 
 Huisamen B, Strijdom H, Collop N, Espach Y. A possible role for the ATM protein in the 
myocardial pathology associated with obesity and insulin resistance. 15th Annual SA Heart 
congress in collaboration with the ESC. Durban, South Africa. October 16-19, 2014. SA 
Heart Journal 11(4):183-184. (Poster presented by Prof. Huisamen) 
 Espach, Y. and Huisamen, B. An investigation into the importance of the ATM protein in the 
myocardial pathology associated with insulin resistance and type 2 diabetes. Diabetes 
Discovery Platform Research Symposium. MRC, South Africa. June 23, 2014. 
 Espach, Y. and Huisamen, B. The importance of the ATM protein in the myocardial 
pathology associated with insulin resistance. 41st Conference of the Physiology Society of 
Southern Africa. Pretoria, South Africa. 15-18 September, 2013. (Poster presentation). 
Honours student co-supervised 
 Ascentia M. Seboko – Graduated December 2015 
 Project title: Elucidating the role of ATM in the insulin signalling pathway. 
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